GLP-1Approved 2017

Semaglutide

Last updated

GLP-1 receptor agonist. Once weekly (injectable); once daily (oral).

Ozempic, Wegovy, Wegovy HD, Rybelsus·Novo Nordisk

Semaglutide: lowest prices now

  • Lowest FDA-approved

    NovoCare (Novo Nordisk)

    $149/30 days · about $149 per 30 days

  • Lowest compounded on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Rybelsus tablets (3, 7 and 14 mg) are being discontinued in the US and replaced by Ozempic tablets (1.5, 4 and 9 mg), per Novo Nordisk's June 2026 notice to the FDA. The two tablets are not interchangeable milligram for milligram.

Average weight lost in its trials

  • 2.4 mg weekly (Wegovy)STEP 1 · 68 wks
    −14.9% (nejm.org/doi/full/10.1056/NEJMoa2032183) (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy))about 30 lb at 200 lb
  • 25 mg daily (Wegovy tablet)OASIS 4 · 64 wks
    −13.6% (nejm.org/doi/full/10.1056/NEJMoa2500969) (-13.6% at 64 wks · OASIS 4 · 25 mg daily (Wegovy tablet))about 27 lb at 200 lb
  • 7.2 mg weekly (Wegovy HD)STEP UP · 72 wks
    −18.7% (doi.org/10.1016/S2213-8587(25)00226-8) (-18.7% at 72 wks · STEP UP · 7.2 mg weekly (Wegovy HD))about 37 lb at 200 lb

Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.

What the FDA label says

  • Wegovy injectionWeight management in eligible adults and adolescents 12+ with obesity; cardiovascular risk reduction in eligible adults; noncirrhotic MASH with moderate to advanced liver fibrosis in adults (accelerated approval). FDA label (novo-pi.com)
  • Wegovy pillWeight management and cardiovascular risk reduction in eligible adults. The tablet is not labeled for MASH or pediatric use. FDA label (novo-pi.com)
  • Wegovy HD injectionWeight management in adults with obesity, or overweight with a weight-related condition. The 7.2 mg dose is for adults who tolerate 2.4 mg and need additional weight reduction. FDA label (novo-pi.com)
Information from FDA labels and published trials, not medical advice.

What to know about Semaglutide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Sourced starting quote

$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

30-day supply (pharmacy.amazon.com)

$149 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Wegovy pill via Amazon Pharmacy

Amazon Pharmacy · without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Quote at the cited trial dose

$349/28 days (pharmacy.amazon.com/Novo-Nordisk-WEGOVY-2-4-MG-0-75-ML-PEN-INJECTOR-Box-3-Milliliter/dp/B09BHXXL2R)

28-day supply (pharmacy.amazon.com)

≈ $373.93 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Wegovy pen via Amazon Pharmacy · 2.4 mg

Amazon Pharmacy · without insurance, 0.25 mg; includes the manufacturer coupon if eligible (list price $1,349.02), which Novo Nordisk limits to a new patient's first two 28-day fills, filled by 12/31/2026; prescription required

Price conditions

without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01)

Amazon fills a prescription you already have and delivers in all 50 states. Its $199 for 0.25 mg "Includes $100.00 off with manufacturer coupon if eligible": Novo Nordisk's coupon, which its terms limit to a new patient's first two 28-day fills, filled by Dec 31, 2026. FDA-approved product.

28-day supply

FDA-approved offers only in this summary. Starting and trial-dose quotes may cover different products. Every cash quote was checked on or after . Confirm eligibility, dose, fees, and supply length with the provider.

Mean weight change in the cited trial
−14.9% (nejm.org/doi/full/10.1056/NEJMoa2032183) (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy))

STEP 1 · 2.4 mg weekly (Wegovy)

A1c reduction in the cited trial
−1.6 pp (thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract) (-1.6% at 68 wks · STEP 2 · HbA1c change in percentage points)

STEP 2

Stopped treatment for adverse events
7% (nejm.org/doi/full/10.1056/NEJMoa2032183) (7.0% vs 3.1% placebo · STEP 1 (2.4 mg, 68 wks, obesity))

STEP 1 (2.4 mg, 68 wks, obesity)

FDA shortage report
No shortage reported

No shortage is listed in the latest complete FDA check. The FDA does list discontinuation notices for specific presentations.

Route & frequency
Once weekly (injectable); once daily (oral)

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

How to read the trial results
  • The oral Wegovy pill (once-daily oral semaglutide 25 mg, FDA-approved Dec 2025) is a distinct product: it showed -16.6% mean weight loss at 64 wks (efficacy estimand) vs -2.7% placebo. The doses are from different trials and estimands, so read them side by side with care. OASIS-4 (prnewswire.com)
Where to get it

Ways to get Semaglutide

Compare sourced starting and maintenance-dose prices. Compounded products and membership fees are labeled separately.

669 current prices

  • View
    $59/mo + $199/yr membership (collective.org)

    about $76 a month over a year with the membership

    Checked on collective.org

    Top dose: same price at 2.4 mg

    Terms & source

    Advertised price: medication billed monthly, cancel anytime, the same price at any dose, plus a required $199 annual membership after a 21-day free trial

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 2.4 mg.

    Collective says "Same price, any dose" and "Cancel anytime". Its membership is required for every medication: "$199 /year, billed annually", after a 21-day free trial. Run by Health for Everyone Inc. d/b/a CollectiveOS; not sold in AL, CA, LA, MA, MS or WA. Compounded products are not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (collective.org)
  • View
    $99/mo (eden.health/glp-1/semaglutide)

    Checked on eden.health

    Top dose: same price at 2.4 mg

    Terms & source

    Advertised price: one price at every dose ("Monthly pricing at every dose"); no membership fee ("No membership fees"); no introductory rate ("Semaglutide $99 $99 $99 $99" for month one, two, three and every month)

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 2.4 mg.

    One flat monthly price at every dose, including doctor-guided care and free expedited shipping; its page: "One monthly price, guaranteed for life." and "no annual or long term plans required". Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (eden.health)
  • View
    from $69/mo (galaglp1.com/weight-loss/compounded-semaglutide)

    12-month plan

    Checked on galaglp1.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: annual plan, billed once a year ("From $69/month Annual plan, billed once a year"); "Your exact price depends on your state, your dose and the plan you choose, and you see it before you pay."

    The monthly figure of a 12-month plan; days of supply not on record, so ordered as four weekly doses.

    Gala's semaglutide page: "compounded semaglutide starts at $69 per month on the annual plan, billed once a year" (read 11 Nov 2026; it said from $129 a month on 9 Nov). Its weight-loss page: "Semaglutide from $69/mo". No month-to-month price is published. Its weight-loss page and homepage say a higher dose costs nothing more, while both product pages (read 12 Nov 2026) say the price depends on the dose, so no price at the full dose is stated here. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (galaglp1.com)
  • View
    $79/mo (joinem.co/pages/terms-conditions)

    Checked on joinem.co

    Top dose: same price at 2.4 mg

    Terms & source

    Advertised price: its terms page, "Semaglutide Injections": "Monthly: $79/month", "3-month bundle: $76/month", "6-month bundle: $73/month", "12-month bundle: $49/month"; "Includes all doses, shipping and provider visits."; "Charges will continue until you cancel your subscription"; its FAQ: "Your price does not increase if your dose changes within the same medication."

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Other plan lengths

    • $76/mo on 3 months
    • $73/mo on 6 months
    • $49/mo on 12 months

    Top-dose terms: The seller states one price at every dose, so this is also its price at 2.4 mg.

    Its homepage shows "flat rate at" "$49/month" under "Pre-Black Friday Sale Promo Applied. Save $200 instantly" without naming a plan; that figure equals the 12-month bundle price on its terms page, which is why the monthly price is quoted here. Its homepage says "No membership or hidden fees". Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (joinem.co)
  • View
    $99/mo (lttl.com/weight-loss)

    ≈ $106.07 per 30 days

    Checked on lttl.com

    Top dose: same price at 2.4 mg

    Terms & source

    Advertised price: "Monthly Auto-Refill", "4-Week Supply · Cancel anytime", "$99/mo every month" (its plans page), pay as you go; the 3, 6 and 12-month plans are 12, 24 and 52-week supplies: $96 a month on a 3-month plan ($288 quarterly), $93 on 6 months ($558 every 6 months), $89 on 12 months ($1,068 annually); the same price at every dose, shipping free

    28-day supply (lttl.com)

    ≈ $106.07 per 30 days at this quoted rate

    Other plan lengths

    • $96/28 days on 3 months ($288 up front)
    • $93/28 days on 6 months ($558 up front)
    • $89/28 days on 12 months ($1,068 up front)

    Top-dose terms: The seller states one price at every dose, so this is also its price at 2.4 mg.

    Lttl says "Same price at every dose" and "One flat price for every dose"; it advertises "Up to $140 off your first month" with a code applied automatically and no end date. Cancel by emailing its care team; orders already processed by the pharmacy cannot be canceled or refunded. Plans sold in U.S. states where its partner providers are licensed. Compounded products are not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (lttl.com)
  • View
    $89/mo (maxlife.com/compounded-semaglutide)

    Checked on maxlife.com

    Top dose: same price at 2.4 mg

    Terms & source

    Advertised price: "Flat $89/mo*" ("*All-inclusive, same price at every dose"); its FAQ says "MaxLife programs do not require a long-term contract. Cancel anytime with notice before your next billing period."; "Your prescription ships every 3 months (90 days)."; prescription, supplies, medical support and expedited shipping, no membership fee

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 2.4 mg.

    The order page itself says only "Flat $89/mo*"; the monthly billing is from MaxLife's comparison page (maxlife.com/compare/maxlife-vs-hims, read 2026-11-13), which counts a first year as $1,068 (twelve times $89) and states no longer plan. Shipping is every 3 months while the price is a month. Its FAQ says to cancel with notice before the next billing period; its terms (2024) ask for 30 days by email to cs@maxlife.com. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (maxlife.com)
  • View
    $87/mo (mondae.com/treatments/compounded-semaglutide)

    Checked on mondae.com

    Top dose: same price at 2.4 mg

    Terms & source

    Advertised price: per month on the 1-month plan ("Plan length: 1 month 3 months 6 months", the 1-month plan selected), the same price at every dose, no membership fees

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 2.4 mg.

    Mondae says "No membership fees" and "Same price every dose". Its product page shows this price with its 1-month plan selected, beside tabs for 3 and 6 months; its homepage says from $69 and from $114, the longer plans' prices. Compounded products are not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (mondae.com)
  • View
    from $89/mo (nuimagemedical.com/semaglutide)

    6-month plan

    Checked on nuimagemedical.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: "Semaglutide Injections As low as $89/mo 6-month supply"; also "weekly injection from $89/month"

    The monthly figure of a 6-month plan; days of supply not on record, so ordered as four weekly doses.

    The figure is a starting price on a 6-month supply; the dose it covers is not stated. Rapid-dissolve semaglutide tablets are also sold from $89/mo on a 5-month supply (not listed). Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (nuimagemedical.com)
  • View
    from $89/mo (nuimagemedical.com/semaglutide)

    5-month plan

    Checked on nuimagemedical.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: "Semaglutide RDT Rapid-dissolve tablets As low as $89/mo 5-month supply"; also "a daily rapid-dissolve tablet"

    The monthly figure of a 5-month plan; days of supply not on record, so ordered as four weekly doses.

    The figure is a starting price on a 5-month supply; the dose it covers is not stated, so treat it as a floor. The page says "compounded semaglutide is not FDA-approved". Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (nuimagemedical.com)
  • View
    $99/30 days (struthealth.com/weight-loss/semaglutide/oral)

    Checked on struthealth.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: daily buccal lozenge, "30-DAY SUPPLY $99 Monthly supply" and "As low as $99/mo" with auto-refill on its own page; Strut's semaglutide page lists the lozenge at "$199 30-day supply" and its injection at $129/mo

    30-day supply (struthealth.com)

    $99 per 30 days at this quoted rate

    A lozenge dissolved between cheek and gum once a day, not an injection. Strut now prescribes compounded GLP-1s only for patients who cannot use a commercially available GLP-1 (medical necessity required). Physician consultations and shipping included; final pricing is set after the consultation. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (struthealth.com)
  • View
    $99/mo (snagrx.com/terms-conditions)

    Checked on snagrx.com

    Top dose: same price at 2.4 mg

    Terms & source

    Advertised price: billed monthly; multi-month plans billed once up front for the full plan and renewed for the same length: $267 for 3 months ($89/mo), $474 for 6 months ($79/mo), $828 for 12 months ($69/mo); the same price at every dose; medication, supplies, doctor review and shipping included, no membership fee

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Other plan lengths

    • $89/mo on 3 months ($267 up front)
    • $79/mo on 6 months ($474 up front)
    • $69/mo on 12 months ($828 up front)

    Top-dose terms: SnagRx states the same price at every dose.

    Weekly injection. SnagRx's homepage advertises semaglutide for $69/month, the 12-month rate in its Terms. Payment is taken before the intake and is non-refundable unless a provider declines to prescribe. Not available in Louisiana. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (snagrx.com)
  • View
    $78/mo (sunlight.com/lp_05)

    ≈ $83.57 per 30 days

    Checked on sunlight.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: fall promotion, flat monthly rate locked in at enrollment, month to month; a 4-week supply each month; prescription, unlimited telehealth visits and shipping included

    28-day supply (sunlight.com)

    ≈ $83.57 per 30 days at this quoted rate

    Sunlight's homepage shows the $78 promotion and, in its menu, semaglutide "Starting at $179" (read Nov 7, 2026; its weight-loss medications page, sunlight.com/weight-loss-medications, says "Sunlight semaglutide starts at $78 per month and tirzepatide at $139 per month."). The promotion states no end date. Compounded; not FDA-approved.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (sunlight.com)

Read prices in context. Compare the same product, dose and payment terms; missing prices are not estimated. Compounded medicines are not FDA-approved.

How this list is ordered. Lowest price first, with partners moved up: sellers that may pay us a referral fee, as each one's terms say. A partner is moved up, not put first: a much cheaper seller still comes before it. This never changes what you pay; sort by lowest cost to see price order alone.

How prices are compared, what FDA says about compounding and how we earn

A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes, converted to 30 days: by the supply a price buys where the seller states it in days, otherwise a monthly price with its plan length on record read as four weekly doses, a yearly membership in the price spread over twelve months. Introductory prices, ranges, prices with no plan length on record and separately billed fees are unranked references. Dose changes and added fees affect what you pay.

A listed maintenance dose is not a dosing recommendation.

FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved (fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize). Its conditions for a pharmacy compounding them now include "The drug product is compounded for an individual patient based on receipt of a prescription" and "The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product." (fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) In May 2026 FDA proposed leaving semaglutide, tirzepatide and liraglutide off the 503B Bulks List (federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal), the ingredients outsourcing facilities may compound from; comments closed Jul 30, 2026 (govinfo.gov/content/pkg/FR-2026-06-26/html/2026-12937.htm), and we found no final notice when we last read the Federal Register (Nov 6, 2026). FDA's newest warning letter to a pharmacy over compounded semaglutide or tirzepatide went to Empower Clinic Services, LLC dba Empower Pharmacy (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026) on Sep 18, 2026 (every GLP-1 warning letter). FDA's newest recall report of a compounded semaglutide or tirzepatide product is Houston Rx LLC's tirzepatide (api.fda.gov/drug/enforcement.json), reported Oct 21, 2026: "Lack of assurance of sterility." (every tirzepatide recall). Liraglutide is different: FDA's shortage database (accessdata.fda.gov/scripts/drugshortages) still lists it in shortage (updated at source Oct 14, 2026; every GLP-1 shortage). FDA: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." (fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) A low price is not a low-risk signal; confirm current terms with the provider.

GLPcompare links out only to sellers with a referral program: if you sign up or buy through one of those links, we may earn a commission at no extra cost to you. For other sellers we show the price and the seller's address, and suggest sellers we can link to. It never changes the price you pay or the underlying data. Our default order is lowest price first, with sellers that pay us moved up, and the note under each list says which order it shows; every lowest-cost sort uses the price alone. In a price table, a partner's offer says so in its terms. The order is not a medical recommendation; a higher-placed offer is not necessarily the lowest price or the right product for you.

Prices are self-pay cash figures a person pays, not pharmacy acquisition costs. They change often; each names its source. Every cash quote was checked on or after Nov 6, 2026. Compounded semaglutide and tirzepatide are prepared by pharmacies and are not FDA-approved. This is information, not medical advice.

Indications

Brands, formulations & approved uses

Ozempic

  • InjectionOnce weekly

    Adults with type 2 diabetes: glucose control; cardiovascular risk reduction with established cardiovascular disease; kidney and cardiovascular protection with chronic kidney disease.

    Prescribing information (novo-pi.com) · Reviewed Nov 4, 2026

  • TabletOnce daily, on an empty stomach

    Adults with type 2 diabetes: glucose control and cardiovascular risk reduction in those at high risk. The tablet label does not include the injection's kidney indication.

    Prescribing information (novo-pi.com) · Reviewed Nov 4, 2026

Wegovy

  • InjectionOnce weekly

    Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular risk reduction in eligible adults; noncirrhotic MASH with moderate to advanced liver fibrosis in adults (accelerated approval).

    Prescribing information (novo-pi.com) · Reviewed Nov 4, 2026

  • TabletOnce daily, on an empty stomach

    Weight management and cardiovascular risk reduction in eligible adults. The tablet is not labeled for MASH or pediatric use.

    Prescribing information (novo-pi.com) · Reviewed Nov 4, 2026

Wegovy HD

  • 7.2 mg injectionOnce weekly

    Weight management in adults with obesity, or overweight with a weight-related condition. The 7.2 mg dose is for adults who tolerate 2.4 mg and need additional weight reduction.

    Prescribing information (novo-pi.com) · Reviewed Nov 4, 2026

Rybelsus

  • TabletOnce daily, on an empty stomach

    Adults with type 2 diabetes: glucose control and cardiovascular risk reduction in those at high risk. Rybelsus and Ozempic tablets are not substitutable milligram for milligram.

    Prescribing information (novo-pi.com) · Reviewed Nov 4, 2026

A GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and increases satiety.

Under review, not yet FDA-approved

  • Peripheral artery disease (PAD): the STRIDE trial showed improved walking distance in type 2 diabetes with symptomatic PAD. Approved in the EU (2025) and filed for a US label expansion, but as of the May 2026 Ozempic label revision PAD is not among the FDA-approved indications. STRIDE · US label (May 2026) (dailymed.nlm.nih.gov)
  • MASH for the Wegovy pill (oral semaglutide 25 mg): the FDA has accepted Novo Nordisk's filing to add the ESSENCE liver-disease data to the pill's label, with a decision expected in Q1 2027. Today the MASH indication covers the Wegovy injection, not the pill. Novo Nordisk H1 2026 report (Aug 2026) (sec.gov)
  • A 25 mg dose of the Ozempic pill for type 2 diabetes: submitted to the FDA in 2026, with a decision expected in Q4 2026 (still pending in Novo Nordisk's November 2026 report). Novo Nordisk Q3 2026 report (Nov 2026) (sec.gov)
  • Children and adolescents with type 2 diabetes: in Q3 2026 Novo Nordisk submitted pediatric label updates for the Ozempic pill and Ozempic to the FDA, based on the PIONEER TEENS trial. Today neither Ozempic form is labeled for patients under 18. Novo Nordisk Q3 2026 report (Nov 2026) (sec.gov)
Availability

Shortage status

No shortage reported

No shortage is listed in the latest complete FDA check. The FDA does list discontinuation notices for specific presentations. Check the FDA database (accessdata.fda.gov).

Last complete check: Nov 17, 2026

View FDA presentations (3)

These notices concern specific presentations, not every product containing this ingredient. A current shortage and a planned discontinuation can be reported together. FDA availability notes do not confirm local pharmacy stock.

  • Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)

    Planned discontinuation
    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      Posted by FDA: Jun 4, 2026

      Updated at source: Jun 4, 2026

  • Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)

    Planned discontinuation
    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      Posted by FDA: Jun 4, 2026

      Updated at source: Jun 4, 2026

  • Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)

    Planned discontinuation
    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      Posted by FDA: Jun 4, 2026

      Updated at source: Jun 4, 2026

Pricing

Pharmacy acquisition-cost reference

NADAC measures pharmacy acquisition costs per unit, not what you pay. Different strengths and concentrations are not equivalent monthly supplies.

View pharmacy and policy price references
  • Ozempic 0.25-0.5 Mg/dose (2 MG/3 Ml) Pen
    NDC 00169418103
    Acquisition
    $332.02169/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic 0.25-0.5 Mg/dose (2 MG/3 Ml) Pen
    NDC 00169418113
    Acquisition
    $332.02169/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic 1 Mg/dose (4 MG/3 Ml) Pen
    NDC 00169413001
    Acquisition
    $331.93928/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic 1 Mg/dose (4 MG/3 Ml) Pen
    NDC 00169413013
    Acquisition
    $331.93928/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic 2 Mg/dose (8 MG/3 Ml) Pen
    NDC 00169477211
    Acquisition
    $332.00349/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic 2 Mg/dose (8 MG/3 Ml) Pen
    NDC 00169477212
    Acquisition
    $332.00349/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic Pen, Federal Direct
    Cash
    $199.00/month (trumprx.gov/p/ozempic)
    Checked Nov 17, 2026
  • Wegovy 0.25 MG/0.5 ML Pen
    NDC 00169452514
    Acquisition
    $653.32515/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 0.5 MG/0.5 ML Pen
    NDC 00169450514
    Acquisition
    $653.29947/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 1 MG/0.5 ML Pen
    NDC 00169450114
    Acquisition
    $653.06615/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 1.7 MG/0.75 ML Pen
    NDC 00169451714
    Acquisition
    $435.56833/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 2.4 MG/0.75 ML Pen
    NDC 00169452414
    Acquisition
    $435.57199/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy Hd 7.2 MG/0.75 ML Pen
    NDC 00169457214
    Acquisition
    $434.94/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy Pen, Federal Direct
    Cash
    $199.00/month (trumprx.gov/p/wegovy)
    Checked Nov 17, 2026
  • Ozempic 1.5 MG Tablet
    NDC 00169171530
    Acquisition
    $33.15291/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic 4 MG Tablet
    NDC 00169170430
    Acquisition
    $33.18905/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic 9 MG Tablet
    NDC 00169170930
    Acquisition
    $33.18941/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Ozempic Pill (oral Semaglutide), Federal Direct
    Cash
    $149.00/month (trumprx.gov/p/ozempic-pill)
    Checked Nov 17, 2026
  • Rybelsus 14 MG Tablet
    NDC 00169431430
    Acquisition
    $33.18894/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Rybelsus 3 MG Tablet
    NDC 00169430330
    Acquisition
    $33.19006/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Rybelsus 7 MG Tablet
    NDC 00169430730
    Acquisition
    $33.19466/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 1.5 MG Tablet
    NDC 00169441531
    Acquisition
    $43.52712/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 25 MG Tablet
    NDC 00169442531
    Acquisition
    $43.46306/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 4 MG Tablet
    NDC 00169440431
    Acquisition
    $43.49305/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy 9 MG Tablet
    NDC 00169440931
    Acquisition
    $43.48426/ea (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Wegovy Pill (oral Semaglutide), Federal Direct
    Cash
    $149.00/month (trumprx.gov/p/wegovy-pill)
    Checked Nov 17, 2026

Source: NADAC (Data.Medicaid.gov) (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d) · as of Nov 16, 2026

The ingredient index tracks pharmacy acquisition costs over windows up to 53 days long, not patient cash prices or just the presentation listed above. Each NDC starts at 100; we average its percentage change with the same NDCs at every point, so per-tablet and per-mL dollar prices are never averaged together. Incomplete days are omitted. “Flat” means a change smaller than 0.5%. Insufficient or truncated history shows no index.

NADAC is the average price pharmacies pay to acquire a drug, not the cash price at the counter. Compounded and cash prices, where shown, are labeled and are not FDA-approved list prices.

Patient copay

Medicare GLP-1 Bridge

For eligible Part D enrollees using a covered product for weight management, with prior authorization. Bridge operates outside the Part D benefit. Its copay does not count toward Part D out-of-pocket spending, and the Part D deductible does not apply.

Published effective dates: to

Check Medicare eligibility and coverage (medicare.gov)Who qualifies and how to get it
  • Wegovy

    Injection and tablets

    $50 (cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge) (Patient copay for Wegovy; per 28- or 30-day fill)

    per 28- or 30-day fill

  • Wegovy HD

    7.2 mg pen (NDC 0169-4572-14), listed by CMS among the covered Wegovy products

    $50 (cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge) (Patient copay for Wegovy HD; per 28- or 30-day fill)

    per 28- or 30-day fill

CMS program details (cms.gov)Covered products (CMS PDF) (cms.gov)Source reviewed

Negotiated drug price

Medicare negotiated prices for 2027

CMS maximum fair prices for these exact packages, for eligible Medicare coverage. These are drug prices, not patient copays. Your out-of-pocket cost depends on your plan and coverage. Semaglutide's price applies to every Ozempic, Rybelsus and Wegovy package CMS lists, including packages added after its announcement.

Scheduled: to

  • Ozempic

    One 4 mg/3 mL pen

    NDC 00169-4130-13

    $276.78 (cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf) (Negotiated drug price for Ozempic; per package)

    per package

  • Rybelsus

    30 tablets, 7 mg each. The FDA lists this package as to be discontinued, replaced by Ozempic tablets

    NDC 00169-4307-30

    $276.78 (cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf) (Negotiated drug price for Rybelsus; per package)

    per package

  • Wegovy

    Four 2.4 mg/0.75 mL pens

    NDC 00169-4524-14

    $385.63 (cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf) (Negotiated drug price for Wegovy; per package)

    per package

  • Wegovy HD

    Four 7.2 mg/0.75 mL pens, added by CMS in September 2026

    NDC 00169-4572-14

    $385.63 (cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices) (Negotiated drug price for Wegovy HD; per package)

    per package

  • Ozempic tablets

    30 tablets, 4 mg each (the 1.5 mg and 9 mg bottles have the same price), added by CMS in September 2026

    NDC 00169-1704-30

    $276.78 (cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices) (Negotiated drug price for Ozempic tablets; per package)

    per package

CMS package-price examples (PDF) (cms.gov)Source reviewed

Manufacturer list price

Novo Nordisk list-price announcement

Announced US wholesale acquisition cost for Wegovy injection (including Wegovy HD 7.2 mg) and tablets, Ozempic injection, and the 7 and 14 mg semaglutide tablets (Rybelsus, which Novo now calls the Ozempic pill). This is a list price, not a patient quote. Novo says the change does not affect its direct-to-patient self-pay prices.

Scheduled:

  • Wegovy / Ozempic / Rybelsus

    Products named in Novo's February 2026 announcement; see source for doses.

    $675 (prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html) (Manufacturer list price for Wegovy / Ozempic / Rybelsus; per month)

    per month

Novo Nordisk announcement (prnewswire.com)Source reviewed
From FDA and CMS records

Semaglutide: timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455

How long each takes · Generics and patents · Who covers what

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

Showing the most recently effective indexed record for each brand and route combination. Alternate submissions and older records are linked below.

Ozempic

SUBCUTANEOUS · Novo Nordisk Pharmaceutical Industries, LP

Label effective · version 20Retrieved · Nov 11, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)
Read indexed warnings and label text

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)]. OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC [see Contraindications (4), Warnings and Precautions (5.1)].

Contraindications

4 CONTRAINDICATIONS OZEMPIC is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)] . A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.8 )] .

Indications and uses

1 INDICATIONS AND USAGE OZEMPIC is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.

Dosing and administration

2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions Inspect OZEMPIC visually before use. It should appear clear and colorless. Do not use OZEMPIC if particulate matter and coloration is seen. Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals. Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region. When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never mix the products. It is acceptable to inject OZEMPIC and insulin in the same body region, but the injections should not be adjacent to each other. The day of weekly administration can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours). If a dose is missed, administer OZEMPIC as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-weekly dosing schedule. 2.2 Recommended Dosage Recommended Initiation Dosage Initiate OZEMPIC with a dosage of 0.25 mg injected subcutaneously once weekly for 4 weeks. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.7), Adverse Reactions (6.1)]. After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg once weekly. Recommended Maintenance and Maximum Dosages for Glycemic Control The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg, injected subcutaneously once weekly, based on glycemic control. If additional glycemic control is needed after at least 4 weeks on the: 0.5 mg dosage, the dosage may be increased to 1 mg once weekly. 1 mg dosage, the dosage may be increased to 2 mg once weekly. The maximum recommended dosage is 2 mg once weekly. Recommended Maintenance Dosage in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Increase the dosage to the maintenance dosage, 1 mg once weekly, after at least 4 weeks on the 0.5 mg dosage.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS 5.1 Risk of Thyroid C-Cell Tumors In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures [see Nonclinical Toxicology (13.1)] . It is unknown whether OZEMPIC causes thyroid C-cell tumors, including MTC, in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans. OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC. Such monitoring may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin value may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated. 5.2 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC [see Adverse Reactions (6)]. After initiation of OZEMPIC, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue OZEMPIC and initiate appropriate management. 5.3 Diabetic Retinopathy Complications In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with OZEMPIC (3.0%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (OZEMPIC 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (OZEMPIC 0.7%, placebo 0.4%). Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. 5.4 Never Share an OZEMPIC Pen Between Patients OZEMPIC pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens. 5.5 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving OZEMPIC in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1), Drug Interactions (7)]. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. 5.6 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6.1)]. Monitor renal function in patients reporting adverse reactions to OZEMPIC that could lead to volume depletion, especially during dosage initiation and escalation of OZEMPIC. 5.7 Severe Gastrointestinal Adverse Reactions Use of OZEMPIC has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions ( 6 )] . In OZEMPIC clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving OZEMPIC (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. OZEMPIC is not recommended in patients with severe gastroparesis. 5.8 Hypersensitivity Reactions Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with OZEMPIC. If hypersensitivity reactions occur, discontinue use of OZEMPIC; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity to OZEMPIC [see Contraindications (4), Adverse Reactions (6.2)] . Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with OZEMPIC. 5.9 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively. Cholelithiasis was not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. 5.10 Pulmonary Aspiration During General Anesthesia or Deep Sedation OZEMPIC delays gastric emptying [see Clinical Pharmacology (12.2)] . There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking OZEMPIC, including whether modifying preoperative fasting recommendations or temporarily discontinuing OZEMPIC could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking OZEMPIC.

Drug interactions

7 DRUG INTERACTIONS 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving OZEMPIC in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.5), Adverse Reactions (6)] . 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree [see Clinical Pharmacology (12.3)] . Nonetheless, caution should be exercised when oral medications are concomitantly administered with OZEMPIC.

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)] Acute Pancreatitis [see Warnings and Precautions (5.2)] Diabetic Retinopathy Complications [see Warnings and Precautions (5.3)] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.5)] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.6)] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.7)] Hypersensitivity Reactions [see Warnings and Precautions ( 5.8 )] Acute Gallbladder Disease [see Warnings and Precautions (5.9)] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.10)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Pool of Placebo-Controlled Trials The data in Table 1 are derived from 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin) in patients with type 2 diabetes [see Clinical Studies (14)] . These data reflect exposure of 521 patients to OZEMPIC and a mean duration of exposure to OZEMPIC of 32.9 weeks. Across the treatment arms, the mean age of patients was 56 years, 3.4% were 75 years or older and 55% were male. In these trials 71% were White, 7% were Black or African American, and 19% were Asian; 21% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes for an average of 8.8 years and had a mean HbA 1c of 8.2%. At baseline, 8.9% of the population reported retinopathy. Baseline estimated renal function was normal (eGFR ≥90 mL/min/1.73m² ) in 57.2%, mildly impaired (eGFR 60 to 90 mL/min/1.73m² ) in 35.9% and moderately impaired (eGFR 30 to 60 mL/min/1.73m² ) in 6.9% of patients. Pool of Placebo- and Active-Controlled Trials The occurrence of adverse reactions was also evaluated in a larger pool of patients with type 2 diabetes participating in 7 placebo- and active-controlled glycemic control trials [see Clinical Studies (14)] including two trials in Japanese patients evaluating the use of OZEMPIC as monotherapy and add-on therapy to oral medications or insulin. In this pool, a total of 3150 patients with type 2 diabetes were treated with OZEMPIC for a mean duration of 44.9 weeks. Across the treatment arms, the mean age of patients was 57 years, 3.2% were 75 years or older and 57% were male. In these trials, 60% were White, 6% were Black or African American, and 31% were Asian; 16% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes for an average of 8.2 years and had a mean HbA 1c of 8.2%. At baseline, 7.8% of the population reported retinopathy. Baseline estimated renal function was normal (eGFR ≥90 mL/min/1.73m² ) in 63.1%, mildly impaired (eGFR 60 to 90 mL/min/1.73m² ) in 34.3%, and moderately impaired (eGFR 30 to 60 mL/min/1.73m² ) in 2.5% of the patients. Common Adverse Reactions Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of OZEMPIC in the pool of placebo-controlled trials. These adverse reactions occurred more commonly on OZEMPIC than on placebo and occurred in at least 5% of patients treated with OZEMPIC. Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated Patients with Type 2 Diabetes Mellitus Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated Patients with Type 2 Diabetes Mellitus Adverse Reaction Placebo (N=262) % OZEMPIC 0.5 mg (N=260) % OZEMPIC 1 mg (N=261) % Nausea 6.1 15.8 20.3 Vomiting 2.3 5 9.2 Diarrhea 1.9 8.5 8.8 Abdominal pain 4.6 7.3 5.7 Constipation 1.5 5 3.1 In the pool of placebo- and active-controlled trials and in the 2-year cardiovascular outcomes trial, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1 . In a clinical trial with 959 patients treated with OZEMPIC 1 mg or OZEMPIC 2 mg as add-on to metformin with or without sulfonylurea treatment for 40 weeks, no new safety signals were identified. In the FLOW trial [see Clinical Studies (14.3)] in patients with type 2 diabetes mellitus and chronic kidney disease, safety data collection was limited to serious adverse events and selected predefined categories of adverse events regardless of seriousness. There were no new serious or severe adverse reactions identified in this trial. Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC than placebo (placebo 15.3%, OZEMPIC 0.5 mg 32.7%, OZEMPIC 1 mg 36.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving OZEMPIC 0.5 mg (3.1%) and OZEMPIC 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). In the trial with OZEMPIC 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC 2 mg (34%) vs OZEMPIC 1 mg (30.8%). In addition to the reactions in Table 1 , the following gastrointestinal adverse reactions with a frequency of <5% were associated with OZEMPIC (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%). Other Adverse Reactions Hypoglycemia Table 2 summarizes the incidence of events related to hypoglycemia by various definitions in the placebo-controlled trials. Table 2. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus Table 2. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus Placebo OZEMPIC 0.5 mg OZEMPIC 1 mg Monotherapy Monotherapy Monotherapy Monotherapy (30 weeks) N=129 N=127 N=130 Severe 0% 0% 0% Documented symptomatic (≤70 mg/dL glucose threshold) 0% 1.6% 3.8% Severe or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold) 1.6% 0% 0% Add-on to Basal Insulin with or without Metformin Add-on to Basal Insulin with or without Metformin Add-on to Basal Insulin with or without Metformin Add-on to Basal Insulin with or without Metformin (30 weeks) N=132 N=132 N=131 Severe 0% 0% 1.5% Documented symptomatic (≤70 mg/dL glucose threshold) 15.2% 16.7% 29.8% Severe or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold) 5.3% 8.3% 10.7% “Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person. “Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person. “Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person. “Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person. Hypoglycemia was more frequent when OZEMPIC was used in combination with a sulfonylurea [see Warnings and Precautions (5.5), Clinical Studies (14)]. Severe hypoglycemia occurred in 0.8% and 1.2% of patients when OZEMPIC 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea. Documented symptomatic hypoglycemia occurred in 17.3% and 24.4% of patients when OZEMPIC 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea. Severe or blood glucose confirmed symptomatic hypoglycemia occurred in 6.5% and 10.4% of patients when OZEMPIC 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea. Injection Site Reactions In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC-treated patients. Increases in Amylase and Lipase In placebo-controlled trials, patients exposed to OZEMPIC had a mean increase from baseline in amylase of 13% and lipase of 22%. These changes were not observed in placebo-treated patients. Acute Pancreatitis In glycemic control trials, acute pancreatitis was confirmed by adjudication in 7 OZEMPIC-treated patients (0.3 cases per 100 patient years) versus 3 in comparator-treated patients (0.2 cases per 100 patient years). Cholelithiasis In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively. Cholelithiasis was not reported in placebo-treated patients. Increases in Heart Rate In placebo-controlled trials, OZEMPIC 0.5 mg and 1 mg resulted in a mean increase in heart rate of 2 to 3 beats per minute. There was a mean decrease in heart rate of 0.3 beats per minute in placebo-treated patients. Fatigue, Dysgeusia and Dizziness Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC include fatigue, dysgeusia and dizziness. 6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of OZEMPIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal : acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction Hypersensitivity : anaphylaxis, angioedema, rash, urticaria Hepatobiliary : cholecystitis, cholecystectomy Neurologic : dysesthesia, headache Pulmonary : Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation. Renal : acute kidney injury Skin and Subcutaneous Tissue : alopecia

Clinical studies

14 CLINICAL STUDIES 14.1 Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus OZEMPIC has been studied as monotherapy and in combination with metformin, metformin and sulfonylureas, metformin and/or thiazolidinedione, and basal insulin in patients with type 2 diabetes mellitus. The efficacy of OZEMPIC was compared with placebo, sitagliptin, exenatide extended-release (ER), and insulin glargine. Most trials evaluated the use of OZEMPIC 0.5 mg, and 1 mg, with the exception of the trial comparing OZEMPIC and exenatide ER where only the 1 mg dose was studied. One trial evaluated the use of OZEMPIC 2 mg once weekly. In patients with type 2 diabetes mellitus, OZEMPIC produced clinically relevant reduction from baseline in HbA 1c compared with placebo. The efficacy of OZEMPIC was not impacted by age, gender, race, ethnicity, BMI at baseline, body weight (kg) at baseline, diabetes duration and level of renal function impairment. Monotherapy Use of OZEMPIC in Adults with Type 2 Diabetes Mellitus In a 30-week double-blind trial (NCT02054897), 388 patients with type 2 diabetes mellitus inadequately controlled with diet and exercise were randomized to OZEMPIC 0.5 mg or OZEMPIC 1 mg once weekly or placebo. Patients had a mean age of 54 years and 54% were men. The mean duration of type 2 diabetes was 4.2 years, and the mean BMI was 33 kg/m² . Overall, 64% were White, 8% were Black or African American, and 21% were Asian; 30% identified as Hispanic or Latino ethnicity. Monotherapy with OZEMPIC 0.5 mg and 1 mg once weekly for 30 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see Table 3 ). Table 3. Results at Week 30 in a Trial of OZEMPIC as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Table 3. Results at Week 30 in a Trial of OZEMPIC as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Placebo OZEMPIC 0.5 mg OZEMPIC 1 mg Intent-to-Treat (ITT) Population (N) 129 128 130 HbA 1c (%) Baseline (mean) 8 8.1 8.1 Change at week 30 -0.1 -1.4 -1.6 Difference from placebo [95% CI] -1.2 [-1.5, -0.9] -1.4 [-1.7, -1.1] Patients (%) achieving HbA 1c <7% 28 73 70 FPG (mg/dL) Baseline (mean) 174 174 179 Change at week 30 -15 -41 -44 a The intent-to-treat population includes all randomized and exposed patients. At week 30 the primary HbA 1c endpoint was missing for 10%, 7% and 7% of patients and during the trial rescue medication was initiated by 20%, 5% and 4% of patients randomized to placebo, OZEMPIC 0.5 mg and OZEMPIC 1 mg, respectively. Missing data were imputed using multiple imputation based on retrieved dropouts. b Intent-to-treat analysis using ANCOVA adjusted for baseline value and country. c p <0.0001 (2-sided) for superiority, adjusted for multiplicity. The mean baseline body weight was 89.1 kg, 89.8 kg, 96.9 kg in the placebo, OZEMPIC 0.5 mg, and OZEMPIC 1 mg arms, respectively. The mean changes from baseline to week 30 were -1.2 kg, -3.8 kg and -4.7 kg in the placebo, OZEMPIC 0.5 mg, and OZEMPIC 1 mg arms, respectively. The difference from placebo (95% CI) for OZEMPIC 0.5 mg was -2.6 kg (-3.8, -1.5), and for OZEMPIC 1 mg was -3.5 kg (-4.8, -2.2). Combination Therapy Use of OZEMPIC in Adults with Type 2 Diabetes Mellitus Combination with metformin and/or thiazolidinediones In a 56-week, double-blind trial (NCT01930188), 1231 patients with type 2 diabetes mellitus were randomized to OZEMPIC 0.5 mg once weekly, OZEMPIC 1 mg once weekly, or sitagliptin 100 mg once daily, all in combination with metformin (94%) and/or thiazolidinediones (6%). Patients had a mean age of 55 years and 51% were men. The mean duration of type 2 diabetes was 6.6 years, and the mean BMI was 32 kg/m² . Overall, 68% were White, 5% were Black or African American, and 25% were Asian; 17% identified as Hispanic or Latino ethnicity. Treatment with OZEMPIC 0.5 mg and 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA1c compared to sitagliptin (see Table 4 and Figure 5 ). Table 4. Results at Week 56 in a Trial of OZEMPIC Compared to Sitagliptin in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin and/or Thiazolidinediones Table 4. Results at Week 56 in a Trial of OZEMPIC Compared to Sitagliptin in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin and/or Thiazolidinediones OZEMPIC 0.5 mg OZEMPIC 1 mg Sitagliptin Intent-to-Treat (ITT) Population (N) 409 409 407 HbA 1c (%) Baseline (mean) 8 8 8.2 Change at week 56 -1.3 -1.5 -0.7 Difference from sitagliptin [95% CI] -0.6 [-0.7, -0.4] -0.8 [-0.9, -0.6] Patients (%) achieving HbA 1c <7% 66 73 40 FPG (mg/dL) Baseline (mean) 168 167 173 Change at week 56 -35 -43 -23 a The intent-to-treat population includes all randomized and exposed patients. At week 56 the primary HbA 1c endpoint was missing for 7%, 5% and 6% of patients and during the trial rescue medication was initiated by 5%, 2% and 19% of patients randomized to OZEMPIC 0.5 mg, OZEMPIC 1 mg and sitagliptin, respectively. Missing data were imputed using multiple imputation based on retrieved dropouts. b Intent-to-treat analysis using ANCOVA adjusted for baseline value and country. c p <0.0001 (2-sided) for superiority, adjusted for multiplicity. The mean baseline body weight was 89.9 kg, 89.2 kg, 89.3 kg in the OZEMPIC 0.5 mg, OZEMPIC 1 mg, and sitagliptin arms, respectively. The mean changes from baseline to week 56 were -4.2 kg, -5.5 kg, and -1.7 kg for the OZEMPIC 0.5 mg, OZEMPIC 1 mg, and sitagliptin arms, respectively. The difference from sitagliptin (95% CI) for OZEMPIC 0.5 mg was -2.5 kg (-3.2, -1.8), and for OZEMPIC 1 mg was -3.8 kg (-4.5, -3.1). Figure 5. Mean HbA1c (%) Over Time - Baseline to Week 56 Combination with metformin or metformin with sulfonylurea In a 56-week, open-label trial (NCT01885208), 813 patients with type 2 diabetes mellitus on metformin alone (49%), metformin with sulfonylurea (45%), or other (6%) were randomized to OZEMPIC 1 mg once weekly or exenatide 2 mg once weekly. Patients had a mean age of 57 years and 55% were men. The mean duration of type 2 diabetes was 9 years, and the mean BMI was 34 kg/m² . Overall, 84% were White, 7% were Black or African American, and 2% were Asian; 24% identified as Hispanic or Latino ethnicity. Treatment with OZEMPIC 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA1c compared to exenatide 2 mg once weekly (see Table 5 ). Table 5. Results at Week 56 in a Trial of OZEMPIC Compared to Exenatide 2 mg Once Weekly in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin or Metformin with Sulfonylurea Table 5. Results at Week 56 in a Trial of OZEMPIC Compared to Exenatide 2 mg Once Weekly in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin or Metformin with Sulfonylurea OZEMPIC 1 mg Exenatide ER 2 mg Intent-to-Treat (ITT) Population (N) 404 405 HbA 1c (%) Baseline (mean) 8.4 8.3 Change at week 56 -1.4 -0.9 Difference from exenatide [95% CI] -0.5 [-0.7, -0.3] Patients (%) achieving HbA 1c <7% 62 40 FPG (mg/dL) Baseline (mean) 191 188 Change at week 56 -44 -34 a The intent-to-treat population includes all randomized and exposed patients. At week 56 the primary HbA 1c endpoint was missing for 9% and 11% of patients and during the trial rescue medication was initiated by 5% and 10% of patients randomized to OZEMPIC 1 mg and exenatide ER 2 mg, respectively. Missing data were imputed using multiple imputation based on retrieved dropouts. b Intent-to-treat analysis using ANCOVA adjusted for baseline value and country. c p <0.0001 (2-sided) for superiority, adjusted for multiplicity. The mean baseline body weight was 96.2 kg and 95.4 kg in the OZEMPIC 1 mg and exenatide ER arms, respectively. The mean changes from baseline to week 56 were -4.8 kg and -2 kg in the OZEMPIC 1 mg and exenatide ER arms, respectively. The difference from exenatide ER (95% CI) for OZEMPIC 1 mg was -2.9 kg (-3.6, -2.1). Combination with metformin or metformin with sulfonylurea In a 30-week, open-label trial (NCT02128932), 1089 patients with type 2 diabetes mellitus were randomized to OZEMPIC 0.5 mg once weekly, OZEMPIC 1 mg once weekly, or insulin glargine once daily on a background of metformin (48%) or metformin and sulfonylurea (51%). Patients had a mean age of 57 years and 53% were men. The mean duration of type 2 diabetes was 8.6 years, and the mean BMI was 33 kg/m² . Overall, 77% were White, 9% were Black or African American, and 11% were Asian; 20% identified as Hispanic or Latino ethnicity. Patients assigned to insulin glargine had a baseline mean HbA1c of 8.1% and were started on a dose of 10 U once daily. Insulin glargine dose adjustments occurred throughout the trial period based on self-measured fasting plasma glucose before breakfast, targeting 71 to <100 mg/dL. In addition, investigators could titrate insulin glargine at their discretion between study visits. Only 26% of patients had been titrated to goal by the primary endpoint at week 30, at which time the mean daily insulin dose was 29 U per day. Treatment with OZEMPIC 0.5 mg and 1 mg once weekly for 30 weeks resulted in a statistically significant reduction in HbA1c compared with the insulin glargine titration implemented in this study protocol (see Table 6 ). Table 6. Results at Week 30 in a Trial of OZEMPIC Compared to Insulin Glargine in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin or Metformin with Sulfonylurea Table 6. Results at Week 30 in a Trial of OZEMPIC Compared to Insulin Glargine in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin or Metformin with Sulfonylurea OZEMPIC 0.5 mg OZEMPIC 1 mg Insulin Glargine Intent-to-Treat (ITT) Population (N) 362 360 360 HbA 1c (%) Baseline (mean) 8.1 8.2 8.1 Change at week 30 -1.2 -1.5 -0.9 Difference from insulin glargine [95% CI] -0.3 [-0.5, -0.1] -0.6 [-0.8, -0.4] Patients (%) achieving HbA 1c <7% 55 66 40 FPG (mg/dL) Baseline (mean) 172 179 174 Change at week 30 -35 -46 -37 a The intent-to-treat population includes all randomized and exposed patients. At week 30 the primary HbA 1c endpoint was missing for 8%, 6% and 6% of patients and during the trial rescue medication was initiated by 4%, 3% and 1% of patients randomized to OZEMPIC 0.5 mg, OZEMPIC 1 mg and insulin glargine, respectively. Missing data were imputed using multiple imputation based on retrieved dropouts. b Intent-to-treat analysis using ANCOVA adjusted for baseline value, country and stratification factors. c p <0.0001 (2-sided) for superiority, adjusted for multiplicity. The mean baseline body weight was 93.7 kg, 94 kg, 92.6 kg in the OZEMPIC 0.5 mg, OZEMPIC 1 mg, and insulin glargine arms, respectively. The mean changes from baseline to week 30 were -3.2 kg, -4.7 kg and 0.9 kg in the OZEMPIC 0.5 mg, OZEMPIC 1 mg, and insulin glargine arms, respectively. The difference from insulin glargine (95% CI) for OZEMPIC 0.5 mg was -4.1 kg (-4.9, -3.3) and for OZEMPIC 1 mg was -5.6 kg (-6.4, -4.8). Combination with metformin or metformin with sulfonylurea In a 40-week, double-blind trial (NCT03989232), 961 patients with type 2 diabetes currently treated with metformin with or without sulfonylurea treatment were randomized to OZEMPIC 2 mg or OZEMPIC 1 mg once weekly. Patients had a mean age of 58 years and 58.6% were men. The mean duration of type 2 diabetes was 9.5 years and the mean BMI was 34.6 kg/m 2 . At randomization, 53.3% of patients were treated with sulfonylurea and metformin. Overall, 88.1% were White, 4.5% were Black or African American, and 7.2% were Asian; 11.6% identified as Hispanic or Latino ethnicity. Treatment with OZEMPIC 2 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA 1c compared with OZEMPIC 1 mg (see Table 7 ). Patients were stratified by region (Japan/outside Japan) at randomization. Table 7. Results at Week 40 in a Trial of OZEMPIC 2 mg Compared to OZEMPIC 1 mg in Adult Patients with Type 2 Diabetes Mellitus in Combination With Metformin or Metformin with Sulfonylurea Table 7. Results at Week 40 in a Trial of OZEMPIC 2 mg Compared to OZEMPIC 1 mg in Adult Patients with Type 2 Diabetes Mellitus in Combination With Metformin or Metformin with Sulfonylurea OZEMPIC 1 mg OZEMPIC 2 mg Intent-to-Treat (ITT) Population (N) 481 480 HbA 1c (%) Baseline (mean) 8.8 8.9 Change at week 40 -1.9 -2.1 Difference from OZEMPIC 1 mg [95% CI] -0.2 [-0.31 ; -0.04] Patients (%) achieving HbA 1c <7% 56 64 FPG (mg/dL) Baseline (mean) 196 193 Change at week 40 -55 -59 a The intent-to-treat population includes all randomized subjects. At week 40 the primary HbA 1c endpoint was missing for 3% and 5% of patients randomized to OZEMPIC 1 mg and OZEMPIC 2 mg, respectively. Missing data were imputed using multiple imputation based on retrieved dropouts. For calculation of proportions, imputed values are dichotomized and the denominator is the number of all randomized subjects. b Intent-to-treat analysis using ANCOVA adjusted for baseline value and stratification factor. c p <0.01 (2-sided) for superiority, adjusted for multiplicity. The mean baseline body weight was 98.6 kg and 100.1 kg in the OZEMPIC 1 mg and OZEMPIC 2 mg arms, respectively. The mean changes from baseline to week 40 were -5.6 kg and -6.4 kg in the OZEMPIC 1 mg and OZEMPIC 2 mg arms, respectively. The difference between treatment arms in body weight change from baseline at week 40 was not statistically significant. Combination with basal insulin In a 30-week, double-blind trial (NCT02305381), 397 patients with type 2 diabetes mellitus inadequately controlled with basal insulin, with or without metformin, were randomized to OZEMPIC 0.5 mg once weekly, OZEMPIC 1 mg once weekly, or placebo. Patients with HbA 1c ≤8.0% at screening reduced their insulin dose by 20% at start of the trial to reduce the risk of hypoglycemia. Patients had a mean age of 59 years and 56% were men. The mean duration of type 2 diabetes was 13 years, and the mean BMI was 32 kg/m² . Overall, 78% were White, 5% were Black or African American, and 17% were Asian; 12% identified as Hispanic or Latino ethnicity. Treatment with OZEMPIC resulted in a statistically significant reduction in HbA 1c after 30 weeks of treatment compared to placebo (see Table 8 ). Table 8. Results at Week 30 in a Trial of OZEMPIC in Adult Patients with Type 2 Diabetes Mellitus in Combination with Basal Insulin with or without Metformin Table 8. Results at Week 30 in a Trial of OZEMPIC in Adult Patients with Type 2 Diabetes Mellitus in Combination with Basal Insulin with or without Metformin Placebo OZEMPIC 0.5 mg OZEMPIC 1 mg Intent-to-Treat (ITT) Population (N) 133 132 131 HbA 1c (%) Baseline (mean) 8.4 8.4 8.3 Change at week 30 -0.2 -1.3 -1.7 Difference from placebo [95% CI] -1.1 [-1.4, -0.8] -1.6 [-1.8, -1.3] Patients (%) achieving HbA 1c <7% 13 56 73 FPG (mg/dL) Baseline (mean) 154 161 153 Change at week 30 -8 -28 -39 a The intent-to-treat population includes all randomized and exposed patients. At week 30 the primary HbA 1c endpoint was missing for 7%, 5% and 5% of patients and during the trial rescue medication was initiated by 14%, 2% and 1% of patients randomized to placebo, OZEMPIC 0.5 mg and OZEMPIC 1 mg, respectively. Missing data were imputed using multiple imputation based on retrieved dropouts. b Intent-to-treat analysis using ANCOVA adjusted for baseline value, country and stratification factors. c p <0.0001 (2-sided) for superiority, adjusted for multiplicity. The mean baseline body weight was 89.9 kg, 92.7 kg, and 92.5 kg in the placebo, OZEMPIC 0.5 mg, and OZEMPIC 1 mg arms, respectively. The mean changes from baseline to week 30 were -1.2 kg, -3.5 kg, and -6 kg in the placebo, OZEMPIC 0.5 mg, and OZEMPIC 1 mg arms, respectively. The difference from placebo (95% CI) for OZEMPIC 0.5 mg was -2.2 kg (-3.4, -1.1), and for OZEMPIC 1 mg was -4.7 kg (-5.8, -3.6). 14.2 Cardiovascular Outcomes Trial of OZEMPIC in Adults with Type 2 Diabetes Mellitus and Cardiovascular Disease SUSTAIN 6 (NCT01720446) was a multi-center, multi-national, placebo-controlled, double-blind cardiovascular outcomes trial. In this trial, 3,297 patients with inadequately controlled type 2 diabetes and atherosclerotic cardiovascular disease were randomized to OZEMPIC (0.5 mg or 1 mg) once weekly or placebo for a minimum observation time of 2 years. The trial compared the risk of Major Adverse Cardiovascular Event (MACE) between semaglutide and placebo when these were added to and used concomitantly with standard of care treatments for diabetes and cardiovascular disease. The primary endpoint, MACE, was the time to first occurrence of a three-part composite outcome which included cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. Patients eligible to enter the trial were 50 years of age or older and had established, stable, cardiovascular, cerebrovascular, peripheral artery disease, chronic kidney disease or NYHA class II and III heart failure or were 60 years of age or older and had other specified risk factors for cardiovascular disease. In total, 1,940 patients (58.8%) had established cardiovascular disease without chronic kidney disease, 353 (10.7%) had chronic kidney disease only, and 442 (13.4%) had both cardiovascular disease and kidney disease; 562 patients (17%) had cardiovascular risk factors without established cardiovascular disease or chronic kidney disease. In the trial 453 patients (13.7%) had peripheral artery disease. The mean age at baseline was 65 years, and 61% were men. The mean duration of diabetes was 13.9 years, and mean BMI was 33 kg/m² . Overall, 83% were White, 7% were Black or African American, and 8% were Asian; 16% identified as Hispanic or Latino ethnicity. Concomitant diseases of patients in this trial included, but were not limited to, heart failure (24%), hypertension (93%), history of ischemic stroke (12%) and history of a myocardial infarction (33%). In total, 98.0% of the patients completed the trial and the vital status was known at the end of the trial for 99.6%. For the primary analysis, a Cox proportional hazards model was used to test for non-inferiority of OZEMPIC to placebo for time to first MACE using a risk margin of 1.3. The statistical analysis plan pre specified that the 0.5 mg and 1 mg doses would be combined. Type-1 error was controlled across multiple tests using a hierarchical testing strategy. OZEMPIC significantly reduced the occurrence of MACE. The estimated hazard ratio for time to first MACE was 0.74 (95% CI: 0.58, 0.95). Refer to Figure 6 and Table 9 . Figure 6. Kaplan-Meier: Time to First Occurrence of a MACE in the SUSTAIN 6 Trial The treatment effect for the primary composite endpoint and its components in the SUSTAIN 6 trial is shown in Table 9 . Table 9. Treatment Effect for MACE and its Components, Median Study Observation Time of 2.1 Years Table 9. Treatment Effect for MACE and its Components, Median Study Observation Time of 2.1 Years Placebo N=1649 (%) OZEMPIC N=1648 (%) Hazard ratio vs Placebo (95% CI) Composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke (time to first occurrence) 146 (8.9) 108 (6.6) 0.74 (0.58, 0.95) Non-fatal Myocardial Infarction 64 (3.9) 47 (2.9) 0.74 (0.51, 1.08) Non-fatal Stroke 44 (2.7) 27 (1.6) 0.61 (0.38, 0.99) Cardiovascular Death 46 (2.8) 44 (2.7) 0.98 (0.65, 1.48) Fatal or Non-fatal Myocardial Infarction 67 (4.1) 54 (3.3) 0.81 (0.57, 1.16) Fatal or Non-fatal Stroke 46 (2.8) 30 (1.8) 0.65 (0.41, 1.03) a Cox-proportional hazards models with treatment as factor and stratified by evidence of cardiovascular disease, insulin treatment and renal impairment. 14.3 Kidney Outcomes Trial of OZEMPIC in Adults with Type 2 Diabetes Mellitus and Chronic Kidney Disease FLOW (NCT03819153) was a randomized, double-blind, placebo-controlled, event driven trial in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR 25 to 75 mL/min/1.73m² with urine albumin-to- creatinine ratio [UACR] >100 mg/g and <5000 mg/g). All patients needed to have an HbA 1c ≤10% at screening and be receiving standard of care background therapy, including a maximum tolerated labeled dose of a renin- angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment was contraindicated or not tolerated. The trial excluded patients with congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations. A total of 3,533 patients were randomized to receive OZEMPIC 1 mg once weekly or placebo and were followed for a median of 41 months. The mean age of the study population was 67 years, and 70% of patients were male. Approximately 66% of the trial population was White, 24% Asian, and 5% Black or African American. At baseline, the mean eGFR was 47 mL/min/1.73m² , with 11% of patients having an eGFR <30 mL/min/1.73m² . Median baseline UACR was 568 mg/g with 69% of patients with a UACR >300 mg/g. At baseline, 95% of patients were treated with an ACE inhibitor or ARB, 16% were on sodium-glucose cotransporter 2 (SGLT2) inhibitors, 76% were on a statin, and 50% were on an antiplatelet agent. OZEMPIC was superior to placebo in reducing the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥50%, sustained eGFR <15 mL/min/1.73m² , chronic renal replacement therapy, renal death, CV death (HR 0.76 [95% CI 0.66, 0.88], p=0.0003) as shown in Table 10 and Figure 7 . The treatment effect reflected a reduction in a sustained decline in eGFR of ≥50%, progression to kidney failure and CV death. There were few renal deaths during the trial. OZEMPIC also reduced the annual rate of change in eGFR ( Figure 9 ), the incidence of a composite cardiovascular endpoint, consisting of non-fatal myocardial infarction (MI), non-fatal stroke, and cardiovascular death, and the incidence of all-cause death ( Table 10 and Figure 8 ). The treatment effect on the primary composite endpoint was generally consistent across the pre-specified subgroups examined, including age, biological sex, eGFR and UACR. The treatment benefit on the primary composite endpoint was not evident in patients taking SGLT2 inhibitors at baseline, but there were few events in these patients. Table 10: Analyses of the Primary and Secondary Endpoints and their Individual Components in FLOW Trial Table 10: Analyses of the Primary and Secondary Endpoints and their Individual Components in FLOW Trial Placebo N=1766 (%) OZEMPIC 1 mg N=1767 (%) Hazard Ratio vs Placebo (95% CI) p-value Number of Patients (%) Composite Endpoint (≥50% sustained eGFR decline, sustained eGFR <15 mL/min/1.73m² , chronic renal replacement therapy, or renal or cardiovascular death (time to first occurrence) 410 (23.2) 331 (18.7) 0.76 (0.66, 0.88) 0.0003 ≥50% sustained eGFR decline 213 (12.1) 165 (9.3) 0.73 (0.59, 0.89) Sustained eGFR <15mL/min/1.73m 110 (6.2) 92 (5.2) 0.8 (0.61, 1.06) Chronic renal replacement therapy 100 (5.7) 87 (4.9) 0.84 (0.63, 1.12) Renal death 5 (0.3) 5 (0.3) 0.97 (0.27, 3.49) Cardiovascular death 169 (9.6) 123 (7) 0.71 (0.56, 0.89) Composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke (time to first occurrence) 254 (14.4) 212 (12) 0.82 (0.68, 0.98) 0.0289 All-cause death 279 (15.8) 227 (12.8) 0.8 (0.67, 0.95) 0.0104 1 Cox proportional hazards model with treatment as factor and stratified by baseline use of SGLT2-inhibitor at baseline (yes or no). 2 Two-sided p-value for the test of no difference. The significance level was 0.03224. 3 Sustained was defined as having 2 consecutive measurements ≥28 days apart fulfilling the criteria. Figure 7. Cumulative Incidence: Time to First Occurrence of the Primary Composite Endpoint - Sustained Decline in eGFR ≥50%, Sustained eGFR<15 mL/min/1.73m², Chronic Renal Replacement Therapy, Renal Death or CV Death Cumulative incidence estimates are based on time from randomization to first composite renal event with non-CV and non-renal death modelled as competing risk. The x-axis is truncated at 52 months where approximately 5% of the population was in the trial. Sustained was defined as having 2 consecutive measurements ≥28 days apart fulfilling the criteria. Figure 8. Cumulative incidence: Time to First Occurrence of MACE in FLOW Trial Cumulative incidence estimates are based on time from randomization to first EAC-confirmed MACE with non-CV death modelled as competing risk. The x-axis is truncated at 52 months where approximately 5% of the population was in the trial. Figure 9. Observed Mean Plot: eGFR (mL/min/1.73m²) by Week in FLOW Trial Observed data from the in-trial period until week 104. Error bars are +/- 1.96 *standard error of the mean eGFR, which was calculated using the CKD-EPI 2009 formula. CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration, eGFR: estimated glomerular filtration rate.

OZEMPIC / RYBELSUS

ORAL · Novo Nordisk Pharmaceutical Industries, LP

Label effective · version 14Retrieved · Nov 17, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)Indexed source record (api.fda.gov)
Read indexed warnings and label text

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS or OZEMPIC tablets [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )]. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). • RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ).

Contraindications

4 CONTRAINDICATIONS RYBELSUS and OZEMPIC tablets are contraindicated in patients with: • A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )] . • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets [see Warnings and Precautions ( 5.7 )] . • Personal or family history of MTC or in patients with MEN 2 syndrome type 2 ( 4 ) • Prior serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC ( 4 )

Indications and uses

1 INDICATIONS AND USAGE RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )

Dosing and administration

2 DOSAGE AND ADMINISTRATION • RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis. • Take RYBELSUS or OZEMPIC tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces of water); do not take with other liquids besides water. ( 2.1 ) • Swallow tablets whole. Do not split, crush, chew or dissolve in any solution. ( 2.1 ) • After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. ( 2.1 ) • See the Full Prescribing Information for instructions on switching between RYBELSUS and OZEMPIC tablets ( 2.3 ) and from OZEMPIC injections to RYBELSUS or OZEMPIC tablets. ( 2.4 ) Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS and OZEMPIC Tablets ( 2.2 ) RYBELSUS ( 2.2 ) • Day 1 to 30: Recommended starting dosage is 3 mg orally once daily for 30 days (this dosage is not effective for glycemic control) • Days 31 to 60: Increase the dosage to 7 mg orally once daily. • On Day 61 or thereafter, if: ( 2.2 ) o No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily. o Additional glycemic control is needed, increase the dosage to 14 mg orally once daily. OZEMPIC Tablets ( 2.2 ) • Day 1 to 30: Recommended starting dosage is 1.5 mg orally once daily for 30 days (this dosage is not effective for glycemic control). • Days 31 to 60: Increase the dosage to 4 mg orally once daily. • On Day 61 or thereafter, if: ( 2.2 ) o No additional glycemic control is needed, maintain the dosage at 4 mg orally once daily. o Additional glycemic control is needed, increase the dosage to 9 mg orally once daily. 2.1 Important Administration Instructions • RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis. • Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water [see Clinical Pharmacology ( 12.3 )] . • Do not take more than one tablet per day. • Swallow tablets whole. Do not split, crush, chew or dissolve in any solution. • After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [see Clinical Pharmacology ( 12.3 )] . • If a dose is missed, skip the missed dose and take the next dose the following day. 2.2 Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS and OZEMPIC Tablets RYBELSUS: Recommended Dosage Follow the RYBELSUS starting, escalation, and maintenance dosage described below to reduce the risk of gastrointestinal (GI) adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] : • Starting Dosage (Initiation Phase) (Days 1 to 30) : The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control). • Escalation and Maintenance Dosage (Days 31 and beyond) : o Days 31 to 60: Increase the dosage to 7 mg orally once daily. o On Day 61 or thereafter, if: ▪ No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily. ▪ Additional glycemic control is needed, increase the dosage to 14 mg orally once daily. OZEMPIC Tablets: Recommended Dosage Follow the OZEMPIC tablets starting, escalation, and maintenance dosage described below to reduce the risk of GI adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] : • Starting Dosage (Initiation Phase) (Days 1 through 30) : The recommended starting dosage is 1.5 mg orally once daily (this dosage is not effective for glycemic control). • Escalation and Maintenance Dosage (Days 31 and beyond) : o Days 31 to 60: Increase the dosage to 4 mg orally once daily. o On Day 61 or thereafter, if: ▪ No additional glycemic control is needed, maintain the dosage at 4 mg orally once daily. ▪ Additional glycemic control is needed, increase the dosage to 9 mg orally once daily. 2.3 Switching Between RYBELSUS and OZEMPIC Tablets • Do not switch between RYBELSUS and OZEMPIC tablets during the initiation phase (Days 1 to 30) [see Dosage and Administration ( 2.2 )] . • After 30 days of RYBELSUS or OZEMPIC tablet treatment (after the initiation phase) [see Dosage and Administration ( 2.2 )] , patients may switch between RYBELSUS and OZEMPIC tablet products (see Table 1 ). • When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product. Table 1. Switching Between Escalation or Maintenance Dosage of RYBELSUS and OZEMPIC Tablets RYBELSUS OZEMPIC Tablets 7 mg orally once daily 4 mg orally once daily 14 mg orally once daily 9 mg orally once daily 2.4 Switching from OZEMPIC Injection to RYBELSUS or OZEMPIC Tablets Switching from OZEMPIC Injection to RYBELSUS Tablets • Patients taking the 0.5 mg dose of OZEMPIC injection may switch to RYBELSUS tablets. • One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 7 mg or 14 mg of RYBELSUS orally once daily. Switching from OZEMPIC Injection to OZEMPIC Tablets • Patients taking the 0.5 mg dose of OZEMPIC injection may switch to OZEMPIC tablets. • One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 4 mg or 9 mg of OZEMPIC tablets orally once daily.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS or OZEMPIC tablets. Discontinue if pancreatitis is suspected. ( 5.2 ) • Diabetic Retinopathy Complications : Has been reported in a cardiovascular outcomes trial with semaglutide injection. Patients with a history of diabetic retinopathy should be monitored. ( 5.3 ) • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : May increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin secretagogue or insulin may be necessary. ( 5.4 ) • Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.5 ) • Severe Gastrointestinal Adverse Reactions : Use of RYBELSUS or OZEMPIC tablets has been associated with gastrointestinal adverse reactions, sometimes severe. RYBELSUS and OZEMPIC tablets are not recommended in patients with severe gastroparesis. ( 5.6 ) • Hypersensitivity Reactions : Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue RYBELSUS or OZEMPIC tablets if hypersensitivity reactions occur and monitor until signs and symptoms resolve. ( 5.7 ) • Acute Gallbladder Disease : If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. ( 5.8 ) • Pulmonary Aspiration During General Anesthesia or Deep Sedation : Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures. ( 5.9 ) 5.1 Risk of Thyroid C-Cell Tumors In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures [see Nonclinical Toxicology ( 13.1 )] . It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans. RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS or OZEMPIC tablets. Such monitoring may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin value may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated. 5.2 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide tablets [see Adverse Reactions ( 6 )] . After initiation of RYBELSUS or OZEMPIC tablets, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue RYBELSUS or OZEMPIC tablets and initiate appropriate management. 5.3 Diabetic Retinopathy Complications In a pooled analysis of glycemic control trials, patients reported diabetic retinopathy related adverse reactions during the trial (4.2% with semaglutide tablets and 3.8% with comparator) [see Adverse Reactions ( 6.1 )] . In a 2-year CV outcomes trial with semaglutide injection involving patients with type 2 diabetes mellitus and high CV risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (semaglutide injection 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide injection 0.7%, placebo 0.4%). Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with RYBELSUS and OZEMPIC tablets on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. 5.4 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving RYBELSUS or OZEMPIC tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions ( 6.1 ), Drug Interactions ( 7 )] . The risk of hypoglycemia may be lowered by a reduction in the dosage of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. 5.5 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions ( 6 )] . Monitor renal function in patients reporting adverse reactions to RYBELSUS or OZEMPIC tablets that could lead to volume depletion, especially during dosage initiation and escalation of RYBELSUS or OZEMPIC tablets. 5.6 Severe Gastrointestinal Adverse Reactions Use of semaglutide tablets has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions ( 6.1 )] . In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients who received semaglutide tablets (7 mg 0.6%, 14 mg 2%) than placebo (0.3%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. RYBELSUS and OZEMPIC tablets are not recommended in patients with severe gastroparesis. 5.7 Hypersensitivity Reactions Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with semaglutide tablets. If hypersensitivity reactions occur, discontinue use of RYBELSUS or OZEMPIC tablets; treat promptly per standard of care and monitor until signs and symptoms resolve. RYBELSUS and OZEMPIC tablets are contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets [see Adverse Reactions ( 6.2 )] . Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with RYBELSUS or OZEMPIC tablets. 5.8 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials to improve glycemic control, cholelithiasis was reported in 1% of patients treated with semaglutide tablets (7 mg once daily). In a 4-year CV outcomes trial (Trial 7), cholelithiasis was reported in 1.1% of patients treated with semaglutide tablets (14 mg once daily) and in 0.9% of placebo-treated patients. In Trial 7, cholecystitis was reported in 1.1% of patients treated with semaglutide tablets (14 mg once daily) and in 0.7% of placebo-treated patients [see Adverse Reactions ( 6.1 )] . If cholelithiasis or cholecystitis is suspected, gallbladder studies and appropriate clinical follow-up are indicated [see Adverse Reactions ( 6.2 )] . 5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation RYBELSUS and OZEMPIC tablets delay gastric emptying [see Clinical Pharmacology ( 12.2 )] . There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking RYBELSUS or OZEMPIC tablets, including whether modifying preoperative fasting recommendations or temporarily discontinuing RYBELSUS or OZEMPIC tablets could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking RYBELSUS or OZEMPIC tablets.

Drug interactions

7 DRUG INTERACTIONS Other Oral Drugs : RYBELSUS and OZEMPIC tablets delay gastric emptying. Consider increased clinical or laboratory monitoring when co-administered with other oral medications that have a narrow therapeutic index or that require clinical monitoring. ( 7.2 ) 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin Semaglutide stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving RYBELSUS or OZEMPIC tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. When initiating RYBELSUS or OZEMPIC tablets, consider reducing the dosage of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6.1 )] . 7.2 Other Oral Drugs Semaglutide cause a delay of gastric emptying and thereby has the potential to impact the absorption of other oral drugs. Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study [see Clinical Pharmacology ( 12.3 )] . When using RYBELSUS or OZEMPIC tablets concomitantly with other oral drugs that have a narrow therapeutic index or that require clinical monitoring, consider increased clinical or laboratory monitoring [see Dosage and Administration ( 2 )] .

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: • Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] • Acute Pancreatitis [see Warnings and Precautions ( 5.2 )] • Diabetic Retinopathy Complications [see Warnings and Precautions ( 5.3 )] • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions ( 5.4 )] • Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.5 )] • Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.6 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.7 )] • Acute Gallbladder Disease [see Warnings and Precautions ( 5.8 )] • Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (incidence ≥5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-833-457-7455 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of OZEMPIC tablets (1.5 mg, 4 mg and 9 mg strengths) [see Dosage and Administration ( 2.2 )] and RYBELSUS (3 mg, 7, mg and 14 mg strengths) [see Dosage and Administration ( 2.2 )] has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus [see Clinical Pharmacology ( 12.3 ), Clinical Studies ( 14 )] . Below is a display of the safety results of the adequate and well-controlled studies of RYBELSUS (referred to below as semaglutide tablets) in adult patients with type 2 diabetes mellitus. Pool of Placebo-Controlled Trials The data in Table 2 are derived from 2 placebo-controlled trials in adult patients with type 2 diabetes mellitus [see Clinical Studies ( 14 )] . These data reflect exposure of 1,071 patients to semaglutide tablets (3 mg, 7, mg or 14 mg orally once daily) with a mean duration of exposure of 41.8 weeks. The mean age of patients was 58 years, 3.9% were 75 years or older and 52% were male. In these trials, 63% were White, 6% were Black or African American and 27% were Asian; 19% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 mellitus diabetes for an average of 9.4 years and had a mean HbA 1c of 8.1%. At baseline, 20.1% of the population reported retinopathy. Baseline estimated renal function was normal (eGFR ≥90 mL/min/1.73m 2 ) in 66.2%, mildly impaired (eGFR 60 to 90 mL/min/1.73m 2 ) in 32.4% and moderately impaired (eGFR 30 to 60 mL/min/1.73m 2 ) in 1.4% of patients. Pool of Placebo- and Active-Controlled Trials The occurrence of adverse reactions was also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in 9 placebo- and active-controlled trials [see Clinical Studies ( 14 )] . In this pool, 4,116 patients with type 2 diabetes mellitus were treated with semaglutide tablets for a mean duration of 59.8 weeks. The mean age of patients was 58 years, 5% were 75 years or older and 55% were male. In these trials, 65% were White, 6% were Black or African American and 24% were Asian; 15% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 8.8 years and had a mean HbA 1c of 8.2%. At baseline, 16.6% of the population reported retinopathy. Baseline estimated renal function was normal (eGFR ≥90 mL/min/1.73m 2 ) in 65.9%, mildly impaired (eGFR 60 to 90 mL/min/1.73m 2 ) in 28.5% and moderately impaired (eGFR 30 to 60 mL/min/1.73m 2 ) in 5.4% of the patients. Common Adverse Reactions Table 2 shows common adverse reactions, excluding hypoglycemia, associated with the use of semaglutide tablets in adult patients with type 2 diabetes mellitus in the pool of placebo-controlled trials. These adverse reactions occurred more commonly on semaglutide tablets than on placebo and occurred in at least 5% of patients treated with semaglutide tablets. Table 2. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of Semaglutide Tablets-Treated Patients with Type 2 Diabetes Mellitus Adverse Reaction Placebo (N=362) % Semaglutide Tablets 7 mg (N=356) % Semaglutide Tablets 14 mg (N=356) % Nausea 6 11 20 Abdominal Pain 4 10 11 Diarrhea 4 9 10 Decreased appetite 1 6 9 Vomiting 3 6 8 Constipation 2 6 5 In the pool of placebo- and active-controlled trials, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 2 . In a 4-year CV outcomes trial (Trial 7), 4,825 patients were randomized to semaglutide tablets for a median follow-up of 49.6 months and 4,825 patients were randomized to placebo for a median follow-up of 49.4 months [see Clinical Studies ( 14.4 )] . Safety data collection was limited to serious adverse events (including death), adverse events leading to discontinuation, and adverse events of special interest. Study drug was permanently discontinued due to an adverse event in 15.5% of semaglutide tablets-treated patients and 11.6% of placebo-treated patients. Additional information from this trial is included in subsequent sections below, when relevant. Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received semaglutide tablets than placebo: semaglutide tablets 14 mg once daily (41%), semaglutide tablets 7 mg once daily (32%) and placebo (21%), including severe reactions (semaglutide tablets 14 mg 2.0%, semaglutide tablets 7 mg 0.6%, placebo 0.3%). The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation. A greater percentage of patients who received semaglutide tablets 14 mg once daily (8%) and semaglutide tablets 7 mg once daily (4%) discontinued treatment due to gastrointestinal adverse reactions than patients who received placebo (1%). In addition to the reactions in Table 2 , the following gastrointestinal adverse reactions with a frequency of <5% occurred in semaglutide tablets -treated patients (frequencies listed, respectively, as 14 mg once daily, 7 mg once daily and placebo): abdominal distension (3%, 2% and 1%), dyspepsia (0.6%, 3%, 0.6%), eructation (2%, 0.6%, 0%,), flatulence (1%, 2%, 0%), gastroesophageal reflux disease (2%, 2%, 0.3%) and gastritis (2%, 2%, 0.8%). Other Adverse Reactions Pancreatitis : In the pool of placebo- and active-controlled trials with semaglutide tablets, pancreatitis was reported as a serious adverse event in 6 semaglutide tablets -treated patients (0.1 events per 100 patient years) versus 1 in comparator-treated patients (<0.1 events per 100 patient years). Diabetic Retinopathy Complications : In the pool of placebo- and active-controlled trials with semaglutide tablets, patients reported diabetic retinopathy related adverse reactions during the trial (4.2% with semaglutide tablets and 3.8% with comparator). Hypoglycemia : Table 3 summarizes the incidence of hypoglycemia by various definitions in the placebo-controlled trials. Table 3. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus Placebo Semaglutide Tablets 7 mg Semaglutide Tablets 14 mg Monotherapy (26 weeks) N=178 N=175 N=175 Severe* 0% 1% 0% Plasma glucose <54 mg/dL 1% 0% 0% Add-on to metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin in patients with moderate renal impairment (26 weeks) N=161 - N=163 Severe* 0% - 0% Plasma glucose <54 mg/dL 3% - 6% Add-on to insulin with or without metformin (52 weeks) N=184 N=181 N=181 Severe* 1% 0% 1% Plasma glucose <54 mg/dL 32% 26% 30% * “Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person. Hypoglycemia was more frequent when semaglutide tablets were used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. Increases in Amylase and Lipase : In placebo-controlled trials, patients exposed to semaglutide tablets 7 mg and 14 mg tablets had a mean increase from baseline in amylase of 10% and 13%, respectively and lipase of 30% and 34%, respectively. These changes were not observed in placebo-treated patients. Cholelithiasis : In placebo-controlled trials to improve glycemic control, cholelithiasis was reported in 1% of patients treated with semaglutide tablets 7 mg. In a 4-year CV outcomes trial (Trial 7), cholelithiasis was reported in 1.1% of patients treated with semaglutide 14 mg tablets and in 0.9% of placebo-treated patients. In Trial 7, cholecystitis was reported in 1.1% of patients treated with semaglutide14 mg tablets and in 0.7% of placebo-treated patients. Increases in Heart Rate : In placebo-controlled trials, semaglutide tablets 7 mg and 14 mg tablets resulted in a mean increase in heart rate of 1 to 3 beats per minute. There was no change in heart rate in placebo-treated patients. 6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient in RYBELSUS and OZEMPIC tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Gastrointestinal : acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction • Hypersensitivity : anaphylaxis, angioedema, rash, urticaria • Hepatobiliary : cholecystitis, cholelithiasis requiring cholecystectomy • Nervous system disorders : dizziness, dysesthesia, dysgeusia, headache • Pulmonary : Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation • Renal : acute kidney injury • Skin and Subcutaneous Tissue : alopecia

Clinical studies

14 CLINICAL STUDIES 14.1 Overview of Clinical Studies The effectiveness of OZEMPIC tablets (1.5 mg, 4 mg and 9 mg strengths) [see Dosage and Administration ( 2.2 )] and RYBELSUS (3 mg, 7, mg and 14 mg strengths) [see Dosage and Administration ( 2.3 )] has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus [see Clinical Pharmacology ( 12.3 )] . Below is a display of the efficacy results of the adequate and well-controlled studies of RYBELSUS, referred to below as semaglutide tablets, in adult patients with type 2 diabetes mellitus. Semaglutide tablets have been studied as monotherapy and in combination with metformin, sulfonylureas, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, insulins, and thiazolidinediones in patients with type 2 diabetes mellitus. The efficacy of semaglutide tablets was compared with placebo, empagliflozin, sitagliptin and liraglutide. Semaglutide tablets have also been studied in patients with type 2 diabetes mellitus with mild and moderate renal impairment. In patients with type 2 diabetes mellitus, semaglutide tablets produced clinically significant reduction from baseline in HbA 1c compared with placebo. The efficacy of semaglutide tablets was not impacted by baseline age, sex, race, ethnicity, BMI, body weight, duration of diabetes and degree of renal impairment. 14.2 Monotherapy Use of Semaglutide Tablets in Patients with Type 2 Diabetes Mellitus In a 26-week double-blind trial (Trial 1, NCT02906930), 703 adult patients with type 2 diabetes mellitus inadequately controlled with diet and exercise were randomized to semaglutide tablets 3 mg, semaglutide tablets 7 mg or semaglutide tablets14 mg orally once daily or placebo. Patients had a mean age of 55 years and 51% were men. The mean duration of type 2 diabetes mellitus was 3.5 years, and the mean BMI was 32 kg/m 2 . Overall, 75% were White, 5% were Black or African American and 17% were Asian; 26% identified as Hispanic or Latino ethnicity. Monotherapy with semaglutide tablets7 mg and semaglutide tablets 14 mg tablets once daily for 26 weeks resulted in a statistically significant reduction in HbA 1c compared with placebo (see Table 4 ). Table 4. Trial 1 Results at Week 26 in a Monotherapy Trial of Semaglutide Tablets in Adult Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Placebo Semaglutide Tablets 7 mg Semaglutide Tablets 14 mg Intent-to-Treat (ITT) Population (N) a 178 175 175 HbA 1c (%) Baseline (mean) 7.9 8 8 Change at Week 26 b -0.3 -1.2 -1.4 Difference from placebo b [95% CI] -0.9 [-1.1; -0.6] c -1.1 [-1.3; -0.9] c Patients (%) achieving HbA 1c <7% 31 69 77 FPG (mg/dL) Baseline (mean) 160 162 158 Change at Week 26 b -3 -28 -33 a The intent-to-treat population includes all randomized patients. At Week 26, the primary HbA 1c endpoint was missing for 5.6%, 8.6% and 8.6% of patients randomized to placebo, semaglutide tablets 7 mg and semaglutide tablets14 mg, respectively. Missing data were imputed by a pattern mixture model using multiple imputation (MI). Pattern was defined by randomized treatment and treatment status at Week 26. During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 15%, 2% and 1% of patients randomized to placebo, semaglutide tablets 7 mg and semaglutide tablets 14 mg, respectively. b Estimated using an ANCOVA model based on data irrespectively of discontinuation of trial product or initiation of rescue medication adjusted for baseline value and region. c p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. The mean baseline body weight was 88.6 kg, 89 kg and 88.1 kg in the placebo, semaglutide tablets 7 mg, and semaglutide tablets 14 mg arms, respectively. The mean changes from baseline to week 26 were -1.4 kg, -2.3 kg and -3.7 kg in the placebo, semaglutide tablets7 mg and semaglutide tablets 14 mg arms, respectively. The difference from placebo (95% CI) for semaglutide tablets 7 mg was -0.9 kg (-1.9, 0.1) and for semaglutide tablets 14 mg was -2.3 kg (-3.1, -1.5). 14.3 Combination Therapy Use of Semaglutide Tablets in Patients with Type 2 Diabetes Mellitus Combination with Metformin In a 26-week trial (Trial 2, NCT02863328), 822 adult patients with type 2 mellitus diabetes were randomized to semaglutide tablets 14 mg orally once daily or empagliflozin 25 mg orally once daily, all in combination with metformin. Patients had a mean age of 58 years and 50% were men. The mean duration of type 2 diabetes mellitus was 7.4 years and the mean BMI was 33 kg/m 2 . Overall, 86% were White, 7% were Black or African American and 6% were Asian; 24% identified as Hispanic or Latino ethnicity. Treatment with semaglutide tablets 14 mg once daily for 26 weeks resulted in a statistically significant reduction in HbA 1c compared to empagliflozin 25 mg once daily (see Table 5 ). Table 5. Trial 2 Results at Week 26 in a Trial of Semaglutide Tablets Compared to Empagliflozin in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin Semaglutide Tablets 14 mg Empagliflozin 25 mg Intent-to-Treat (ITT) Population (N) a 411 410 HbA 1c (%) Baseline (mean) 8.1 8.1 Change at Week 26 b -1.3 -0.9 Difference from empagliflozin b [95% CI] -0.4 [-0.6, -0.3] c Patients (%) achieving HbA 1c <7% 67 40 FPG (mg/dL) Baseline (mean) 172 174 Change at Week 26 b -36 -36 a The intent-to-treat population includes all randomized patients. At Week 26, the primary HbA 1c endpoint was missing for 4.6% and 3.7% of patients randomized to semaglutide tablets 14 mg and empagliflozin 25 mg, respectively. Missing data were imputed by a pattern mixture model using multiple imputation (MI). Pattern was defined by randomized treatment and treatment status at Week 26. During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 1.9% and 1.2% of patients randomized to semaglutide tablets 14 mg and empagliflozin 25 mg, respectively. b Estimated using an ANCOVA based on data irrespectively of discontinuation of trial product or initiation of rescue medication adjusted for baseline value and region. c p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. The mean baseline body weight was 91.9 kg and 91.3 kg in the semaglutide tablets 14 mg and empagliflozin 25 mg arms, respectively. The mean changes from baseline to Week 26 were -3.8 kg and -3.7 kg in the semaglutide tablets 14 mg and empagliflozin 25 mg arms, respectively. The difference from empagliflozin (95% CI) for semaglutide tablets 14 mg was -0.1 kg (-0.7, 0.5). Combination with Metformin or Metformin with Sulfonylurea In a 26-week, double-blind trial (Trial 3, NCT02607865), 1864 adult patients with type 2 mellitus diabetes on metformin alone or metformin with sulfonylurea were randomized to semaglutide tablets 3 mg, semaglutide tablets 7 mg, semaglutide tablets 14 mg orally once daily or sitagliptin 100 mg once daily. Patients had a mean age of 58 years and 53% were men. The mean duration of type 2 diabetes mellitus was 8.6 years, and the mean BMI was 32 kg/m 2 . Overall, 71% were White, 9% were Black or African American and 13% were Asian; 17% identified as Hispanic or Latino ethnicity. Treatment with semaglutide tablets 7 mg and semaglutide tablets 14 mg once daily for 26 weeks resulted in a statistically significant reduction in HbA 1c compared to sitagliptin 100 mg once daily (see Table 6 ). Table 6. Trial 3 Results at Week 26 in a Trial of Semaglutide Tablets Compared to Sitagliptin 100 mg Once Daily in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin or Metformin with Sulfonylurea Semaglutide Tablets 7 mg Semaglutide Tablets 14 mg Sitagliptin 100 mg Intent-to-Treat (ITT) Population (N) a 465 465 467 HbA 1c (%) Baseline (mean) 8.4 8.3 8.3 Change at Week 26 b -1 -1.3 -0.8 Difference from sitagliptin b [95% CI] -0.3 [-0.4; -0.1] c -0.5 [-0.6; -0.4] c Patients (%) achieving HbA 1c <7% 44 56 32 FPG (mg/dL) Baseline (mean) 170 168 172 Change at Week 26 b -21 -31 -15 a The intent-to-treat population includes all randomized patients. At Week 26, the primary HbA 1c endpoint was missing for 5.8%, 6.2% and 4.5% of patients randomized to semaglutide tablets 7 mg, semaglutide tablets 14 mg and sitagliptin 100 mg, respectively. Missing values were imputed by a pattern mixture model using multiple imputation (MI). Pattern was defined by randomized treatment and treatment status at Week 26. During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 2.4%, 1.1% and 2.8% of patients randomized to semaglutide tablets 7 mg, semaglutide tablets 14 mg and sitagliptin 100 mg, respectively. b Estimated using an ANCOVA based on data irrespectively of discontinuation of trial product or initiation of rescue medication adjusted for baseline value, background medication and region. c p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. The mean baseline body weight was 91.3 kg, 91.2 kg and 90.9 kg in the semaglutide tablets 7 mg, semaglutide tablets 14 mg and sitagliptin 100 mg arms, respectively. The mean changes from baseline to Week 26 were -2.2 kg, -3.1 kg and -0.6 kg in the semaglutide tablets 7 mg, semaglutide tablets 14 mg and sitagliptin 100 mg arms, respectively. The difference from sitagliptin (95% CI) for semaglutide tablets 7 mg was -1.6 kg (-2.0, -1.1) and semaglutide tablets 14 mg was -2.5 kg (-3.0, -2.0). Combination with Metformin or Metformin with SGLT-2 Inhibitors In a 26-week, double-blind, double-dummy trial (Trial 4, NCT02863419), 711 adult patients with type 2 diabetes mellitus on metformin alone or metformin with SGLT-2 inhibitors were randomized to semaglutide tablets 14 mg orally once daily, liraglutide 1.8 mg subcutaneous injection once daily or placebo. Patients had a mean age of 56 years and 52% were men. The mean duration of type 2 diabetes mellitus was 7.6 years and the mean BMI was 33 kg/m 2 . Overall, 73% were White, 4% were Black or African American and 13% were Asian; 6% identified as Hispanic or Latino ethnicity. Treatment with semaglutide tablets 14 mg once daily for 26 weeks resulted in statistically significant reductions in HbA 1c compared to placebo. Treatment with semaglutide tablets 14 mg once daily for 26 weeks resulted in non-inferior reductions in HbA 1c compared to liraglutide 1.8 mg (see Table 7 ). Table 7. Trial 4 Results at Week 26 in a Trial of Semaglutide Tablets Compared to Liraglutide and Placebo in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin or Metformin with SGLT-2i Placebo Semaglutide Tablets 14 mg Liraglutide 1.8 mg Intent-to-Treat (ITT) Population (N) a 142 285 284 HbA 1c (%) Baseline (mean) 7.9 8 8 Change at Week 26 b -0.2 -1.2 -1.1 Difference from placebo b [95% CI] -1.1 [-1.2; -0.9] c Difference from liraglutide b [95% CI] -0.1 [-0.3; 0] Patients (%) achieving HbA 1c <7% 14 68 62 FPG (mg/dL) Baseline (mean) 167 167 168 Change at Week 26 b -7 -36 -34 a The intent-to-treat population includes all randomized patients. At Week 26, the primary HbA 1c endpoint was missing for 5.6%, 4.2% and 2.5% of patients randomized to placebo, liraglutide 1.8 mg and semaglutide tablets 14 mg, respectively. Missing values were imputed by a pattern mixture model using multiple imputation (MI). Pattern was defined by randomized treatment and treatment status at Week 26. During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 7.7%, 3.2% and 3.5% of patients randomized to placebo, liraglutide 1.8 mg and semaglutide tablets 14 mg respectively. b Estimated using an ANCOVA based on data irrespectively of discontinuation of trial product or initiation of rescue medication adjusted for baseline value, background medication and region. c p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. The mean baseline body weight was 93.2 kg, 95.5 kg and 92.9 kg in the placebo, liraglutide 1.8 mg and semaglutide tablets 14 mg arms, respectively. The mean changes from baseline to Week 26 were -0.5 kg, -3.1 kg and -4.4 kg in the placebo, liraglutide 1.8 mg and semaglutide tablets 14 mg arms, respectively. The difference from placebo (95% CI) for semaglutide tablets 14 mg was -3.8 kg (-4.7, -3). The difference from liraglutide 1.8 mg for semaglutide tablets 14 mg was -1.2 (-1.9, -0.6). Combination in patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment with Metformin alone, Sulfonylurea alone, Basal Insulin alone or Metformin in Combination with either Sulfonylurea or Basal Insulin In a 26-week, double-blind trial (Trial 5, NCT02827708), 324 adult patients with moderate renal impairment (eGFR CKD-EPI 30 to 59 mL/min/1.73 m 2 ) were randomized to semaglutide tablets 14 mg orally once daily or placebo once daily. Semaglutide tablets were added to the patient’s stable pre-trial antidiabetic regimen. The insulin dose was reduced by 20% at randomization for patients on basal insulin. Dose reduction of insulin and sulfonylurea was allowed in case of hypoglycemia; up titration of insulin was allowed but not beyond the pre-trial dose. Patients had a mean age of 70 years and 48% were men. The mean duration of type 2 diabetes mellitus was 14 years and the mean BMI was 32 kg/m 2 . Overall, 96% were White, 4% were Black or African American and 0.3% were Asian; 6.5% identified as Hispanic or Latino ethnicity. 39.5% of patients had an eGFR value of 30 to 44 mL/min/1.73 m 2 . Treatment with semaglutide tablets 14 mg once daily for 26 weeks resulted in a statistically significant reduction in HbA 1c from baseline compared to placebo (see Table 8 ). Table 8. Trial 5 Results at Week 26 in a Trial of Semaglutide Tablets Compared to Placebo in Patients with Moderate Renal Impairment Placebo Semaglutide Tablets 14 mg Intent-to-Treat (ITT) Population (N) a 161 163 HbA 1c (%) Baseline (mean) 7.9 8 Change at Week 26 b -0.2 -1 Difference from placebo b [95% CI] -0.8 [-1.0; -0.6] c Patients (%) achieving HbA 1c <7% 23 58 FPG (mg/dL) Baseline (mean) 164 164 Change at Week 26 b -7 -28 a The intent-to-treat population includes all randomized patients including patients on rescue medication. At Week 26, the primary HbA 1c endpoint was missing for 3.7% and 5.5% of patients randomized to placebo and semaglutide tablets 14 mg, respectively. Missing values were imputed by a pattern mixture model using multiple imputation (MI). Pattern was defined by randomized treatment and treatment status at Week 26. During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 10% and 4.3% of patients randomized to placebo and semaglutide tablets 14 mg, respectively. b Estimated using an ANCOVA based on data irrespectively of discontinuation of trial product or initiation of rescue medication adjusted for baseline value, background medication, renal status and region. c p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. The mean baseline body weight was 90.4 kg and 91.3 kg in the placebo and semaglutide tablets 14 mg arms, respectively. The mean changes from baseline to Week 26 were -0.9 kg and -3.4 kg in the placebo and semaglutide tablets 14 mg arms, respectively. The difference from placebo (95% CI) for semaglutide tablets 14 mg was -2.5 kg (-3.2, -1.8). Combination with Insulin with or without Metformin In a 26-week double blind trial (Trial 6, NCT03021187), 731 adult patients with type 2 diabetes mellitus inadequately controlled on insulin (basal, basal/bolus or premixed) with or without metformin, were randomized to semaglutide tablets 3 mg, 7 mg and 14 mg orally once daily or placebo once daily. All patients reduced their insulin dose by 20% at randomization to reduce the risk of hypoglycemia. Patients were allowed to increase the insulin dose only up to the starting insulin dose prior to randomization. Patients had a mean age of 61 years and 54% were men. The mean duration of type 2 diabetes mellitus was 15 years and the mean BMI was 31 kg/m 2 . Overall, 51% were White, 7% were Black or African American and 36% were Asian; 13% identified as Hispanic or Latino ethnicity. Treatment with semaglutide tablets 7 mg and 14 mg once daily for 26 weeks resulted in a statistically significant reduction in HbA 1c from baseline compared to placebo once daily (see Table 9 ). Table 9. Trial 6 Results at Week 26 in a Trial of Semaglutide Tablets Compared to Placebo in Adult Patients with Type 2 Diabetes Mellitus in Combination with Insulin alone or with Metformin Placebo Semaglutide Tablets 7 mg Semaglutide Tablets 14 mg Intent-to-Treat (ITT) Population (N) a 184 182 181 HbA 1c (%) Baseline (mean) 8.2 8.2 8.2 Change at Week 26 b -0.1 -0.9 -1.3 Difference from placebo b [95% CI] -0.9 [-1.1; -0.7] c -1.2 [-1.4; -1] c Patients (%) achieving HbA 1c <7% 7 43 58 FPG (mg/dL) Baseline (mean) 150 153 150 Change at Week 26 b 5 -20 -24 a The intent-to-treat population includes all randomized patients. At Week 26, the primary HbA 1c endpoint was missing for 4.3%, 4.4% and 4.4% of patients randomized to placebo, semaglutide tablets 7 mg and semaglutide tablets 14 mg, respectively. Missing values were imputed by a pattern mixture model using multiple imputation (MI). Pattern was defined by randomized treatment and treatment status at Week 26. During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 4.9%, 1.1 % and 2.2% of patients randomized to placebo, semaglutide tablets 7 mg and semaglutide tablets 14 mg, respectively. b Estimated using an ANCOVA based on data irrespectively of discontinuation of trial product or initiation of rescue medication adjusted for baseline value, background medication and region. c p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. The mean baseline body weight was 86 kg, 87.1 kg and 84.6 kg in the placebo, semaglutide tablets7 mg and semaglutide tablets 14 mg arms, respectively. The mean changes from baseline to Week 26 were -0.4 kg, -2.4 kg and -3.7 kg in the placebo, semaglutide tablets 7 mg and semaglutide tablets 14 mg arms, respectively. The difference from placebo (95% CI) for semaglutide tablets 7 mg was -2 kg (-3, -1) and for semaglutide tablets 14 mg was -3.3 kg (-4.2, -2.3). 14.4 Cardiovascular Outcomes Trial of Semaglutide Tablets in Adult Patients with Type 2 Diabetes Mellitus and High Risk of Having a Cardiovascular Event Trial 7 (NCT03914326) was a randomized, double-blind, parallel-group, placebo-controlled trial. In this trial, 9,650 patients with type 2 diabetes mellitus and established cardiovascular (CV) disease and/or chronic kidney disease (CKD) (defined as eGFR <60 mL/min/1.73 m 2 ), were randomized to either once daily semaglutide tablets 14 mg or placebo, in addition to standard of care. The primary endpoint, major adverse cardiovascular events (MACE), was the time to first occurrence of a three-part composite outcome which included CV death, non-fatal myocardial infarction (MI) and non-fatal stroke. Patients eligible to enter the trial were: 50 years of age or older and with established CV disease or CKD. In total, 5,468 patients (56.7%) had established CV disease without CKD, 1,241 (13%) had CKD only, and 2,620 (27%) had both CV disease and CKD. Most patients (97%) were treated with one or more glucose lowering medications at baseline: metformin (76%), insulin (51%), SGLT-2 inhibitor (27%), sulfonylurea (29%), and DPP-4 inhibitor (23%). At baseline, CV disease and risk factors were managed with lipid-lowering medications (89%), platelet-aggregation inhibitors including aspirin (77%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (79%), and beta blockers (64%). The mean age at baseline was 66.1 years, and 71% of the patients were men. Overall, 69% were White, 3% were Black or African American, and 23% were Asian; 14% identified as Hispanic or Latino ethnicity. The mean duration of diabetes was 15.4 years, the mean BMI was 31.1 kg/m 2 , the mean HbA 1c was 8%, and the mean eGFR was 73.8 mL/min/1.73 m 2 . Concomitant diseases included heart failure (23%), hypertension (91%), previous ischemic stroke (12%), previous MI (40%), and peripheral artery disease (16%). In total, 98.4% patients completed the trial, and the vital status was known at the end of the trial for 99.5%. Semaglutide tablets significantly reduced the occurrence of MACE. The estimated hazard ratio for time to first MACE was 0.86 (95% CI: 0.77, 0.96) over the median follow-up duration of 49.6 months and 49.4 months for patients randomized to RYBELSUS and placebo, respectively. Refer to Table 10 and Figure 1 . The treatment effect for the primary composite endpoint and its components in Trial 7 are shown in Table 10 . Table 10. Trial 7 Treatment Effect for MACE and its Components Placebo N=4,825 Semaglutide Tablets 14 mg N=4,825 Hazard Ratio vs Placebo (95% CI) Primary composite endpoint MACE: Composite of CV death, non-fatal MI, non-fatal stroke (time to first occurrence) 668 (13.8%) 579 (12%) 0.86 (0.77, 0.96) CV death 320 (6.6%) 301 (6.2%) 0.93 (0.8, 1.09) Non-fatal MI 253 (5.2%) 191 (4%) 0.74 (0.61, 0.89) Non-fatal stroke 161 (3.3%) 144 (3%) 0.88 (0.7, 1.11) Note: Data from the in-trial period based on full analysis set defined as all randomized patients. Time from randomization to each endpoint was analyzed using a Cox proportional hazards model with treatment as categorical fixed factor. Subjects without events of interest were censored at the end of their in-trial period. For the primary endpoint the hazard ratio and CI were adjusted for the group sequential design using likelihood ratio ordering. CV death, non-fatal MI and non-fatal stroke are listed descriptively for supportive purpose. CV death includes both CV death and undetermined cause of death. N=number of patients; %: percentage of participants in the full analysis set with at least one event; CI: confidence interval Figure 1: Time to First Occurrence of a MACE in Trial 7 Data from the in-trial period based on full analysis set defined as all randomized patients. Cumulative incidence estimates are based on time from randomization to first EAC-confirmed MACE with non-CV death modeled as competing risk using the Aalen-Johansen estimator. Patients without events of interest were censored at the end of their in-trial observation period. Time from randomization to first MACE was analyzed using a Cox proportional hazards model with treatment as categorical fixed factor. The hazard ratio and confidence interval are adjusted for the group sequential design using the likelihood ratio ordering. HR: Hazard ratio; CI: confidence interval. Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Trial 8 (NCT02692716) was a multi-center, multi-national, placebo-controlled, double-blind trial. In this trial, 3,183 adult patients with inadequately controlled type 2 diabetes mellitus and atherosclerotic CV disease were randomized to semaglutide tablets 14 mg orally once daily or placebo for a median observation time of 16 months. The trial compared the risk of a MACE between semaglutide tablets 14 mg and placebo when added to current standard of care treatments for diabetes and cardiovascular CV disease. The primary endpoint, MACE, was the time to first occurrence of a three-part composite outcome which included cardiovascular death, non-fatal MI and non-fatal stroke. Patients eligible to enter the trial were 50 years of age or older and had established, stable, CV, cerebrovascular, peripheral artery disease, CKD or NYHA class II and III heart failure or were 60 years of age or older and had other specified risk factors for CV disease. In total, 1,797 patients (56.5%) had established CV disease without CKD, 354 patients (11.1%) had CKD only, and 544 patients (17.1%) had both CV disease and CKD; 488 patients (15.3%) had CV risk factors without established CV disease or CKD. The mean age at baseline was 66 years and 68% were men. The mean duration of diabetes was 14.9 years and mean BMI was 32 kg/m 2 . Overall, 72% were White, 6% were Black or African American and 20% were Asian; 16% identified as Hispanic or Latino ethnicity. Concomitant diseases of patients in this trial included, but were not limited to, heart failure (12%), history of ischemic stroke (8%) and history of a MI (36%). In total, 99.7% of the patients completed the trial and the vital status was known at the end of the trial for 100%. For the primary analysis, a Cox proportional hazards model was used to test for non-inferiority of semaglutide tablets 14 mg to placebo for time to first MACE using a risk margin of 1.3. Type-1 error was controlled across multiple tests using a hierarchical testing strategy. Non‑inferiority to placebo was established, with a hazard ratio equal to 0.79 (95% CI: 0.57, 1.11) over the median observation time of 16-months. The proportion of patients who experienced at least one MACE was 3.8% (61/1591) for semaglutide tablets14 mg and 4.8% (76/1592) for placebo. figure_1

Wegovy

SUBCUTANEOUS / ORAL · Novo Nordisk Pharmaceutical Industries, LP

Label effective · version 19Retrieved · Nov 11, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)
Read indexed warnings and label text

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )]. WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )]. Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )].

Contraindications

4 CONTRAINDICATIONS WEGOVY is contraindicated in the following conditions: a personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY [see Warnings and Precautions (5.7)] .

Indications and uses

1 INDICATIONS AND USAGE WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. o adults with overweight in the presence of at least one weight-related comorbid condition. for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14.4)]. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

Dosing and administration

2 DOSAGE AND ADMINISTRATION 2.1 Important Monitoring and Administration Instructions In patients with diabetes mellitus, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment [see Warnings and Precautions (5.4)]. Administer WEGOVY in combination with a reduced-calorie diet and increased physical activity. WEGOVY Injection Inform patients and their caregiver(s) which WEGOVY presentation (e.g., single-dose pen or syringe, or WEGOVY FlexTouch single-patient-use pen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed WEGOVY presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation. Prior to initiation, train patients and their caregiver(s) on proper injection technique for the prescribed WEGOVY presentation [see Instructions for Use ] . After training, a patient may self-inject WEGOVY if the healthcare provider determines that it can be properly administered, except for the following: o WEGOVY FlexTouch is not recommended for self-administration by those who are visually impaired. Visually inspect the WEGOVY injection prior to each administration. Only use if the solution is clear, colorless, and contains no particles. Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals. Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification. Rotate injection sites with each dose. WEGOVY Tablets Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water [see Clinical Pharmacology (12.3)]. Swallow tablets whole. Do not split, crush, chew or dissolve in any solution. Do not take more than one tablet per day. After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [see Clinical Pharmacology (12.3)]. 2.2 Recommended Dosage for WEGOVY Injection Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly. Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)]. If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. Table 1. Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications in Adults and Pediatric Patients Aged 12 Years and Older Table 1. Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications in Adults and Pediatric Patients Aged 12 Years and Older Weeks Once-weekly Subcutaneous Injection Dosage Starting Dosage 1 through 4 0.25 mg Dosage Escalation 5 through 8 0.5 mg Dosage Escalation 9 through 12 1 mg Dosage Escalation 13 through 16 1.7 mg Maintenance Dosage 17 and onward See the indication below for the recommended maintenance dosage(s) Recommended Maintenance Dosage of WEGOVY Injection for All Approved Indications Cardiovascular Risk Reduction in Adults The maintenance dosage of WEGOVY injection for cardiovascular risk reduction in adults is either 2.4 mg (recommended) or 1.7 mg once weekly. Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1), Clinical Studies (14.1)]. Weight Reduction in Adults The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly. For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly. Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions ( 6.1 ), Clinical Studies ( 14.2 )]. Weight Reduction in Pediatric Patients Aged 12 Years and Older The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), or 1.7 mg once weekly. Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions ( 6.1 ), Clinical Studies ( 14.3 )] . Noncirrhotic MASH with Moderate to Advanced Liver Fibrosis in Adults The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly. If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly. Consider reescalation to 2.4 mg once weekly [see Adverse Reactions ( 6.1 ), Clinical Studies ( 14.4 )] . 2.3 Recommended Dosage of WEGOVY Tablets Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults The recommended starting dosage of WEGOVY tablets is 1.5 mg taken orally once daily. Follow the dosage escalation in Table 2 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)]. If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation. The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily. If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly [see Dosage and Administration (2.5)]. Table 2. Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults Table 2. Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults Days Once Daily Tablet Dosage Starting Dosage 1 through 30 1.5 mg Dosage Escalation 31 through 60 4 mg Dosage Escalation 61 through 90 9 mg Maintenance Dosage 91 and onward 25 mg 2.4 Recommendations Regarding Missed Dose(s) WEGOVY Injection If one dose of WEGOVY injection is missed and the next scheduled dose is: more than 2 days away, administer WEGOVY injection as soon as possible. less than 2 days away, do not administer the WEGOVY injection dose. Resume dosing on the regularly scheduled day of the week. If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.2), Warnings and Precautions ( 5.6 ), Adverse Reactions (6.1)]. WEGOVY Tablets If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day. 2.5 Switching Between WEGOVY Injection and WEGOVY Tablets Switching from WEGOVY Injection to WEGOVY Tablets Patients taking WEGOVY 2.4 mg injection for cardiovascular risk reduction or weight reduction in adults may switch to WEGOVY 25 mg tablets. One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily. Switching from WEGOVY Tablets to WEGOVY Injection Patients may switch from WEGOVY 25 mg tablets to WEGOVY injection. The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly. For patients who do not tolerate WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection. If additional weight reduction is needed in patients with type 2 diabetes mellitus treated with WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection and follow the recommended dosage escalation for WEGOVY injection [see Dosage and Administration (2.2), Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

Warnings and precautions

5 WARNINGS AND PRECAUTIONS 5.1 Risk of Thyroid C-Cell Tumors In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures [see Nonclinical Toxicology ( 13.1 )] . It is unknown whether WEGOVY causes thyroid C-cell tumors, including MTC, in humans, as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans. WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY. Such monitoring may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin value may indicate MTC and patients with MTC usually have calcitonin values greater than 50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated. 5.2 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY [see Adverse Reactions (6)] . After initiation of WEGOVY, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue WEGOVY and initiate appropriate management. 5.3 Acute Gallbladder Disease Treatment with WEGOVY is associated with an increased occurrence of cholelithiasis and cholecystitis. The incidence of cholelithiasis and cholecystitis was higher in WEGOVY injection-treated pediatric patients aged 12 years and older than in WEGOVY injection-treated adults. In randomized clinical trials in adults for weight reduction, cholelithiasis was reported by 1.6% of WEGOVY injection-treated patients and 0.7% of placebo injection-treated patients, and by 2.5% of WEGOVY tablet-treated patients and 1% of placebo tablet-treated patients. Cholecystitis was reported by 0.6% of WEGOVY injection-treated adult patients and 0.2% of placebo- treated patients. In a clinical trial in pediatric patients aged 12 years and older for weight reduction, cholelithiasis was reported by 3.8% of WEGOVY injection-treated patients and 0% placebo-treated patients. Cholecystitis was reported by 0.8% of WEGOVY injection-treated pediatric patients and 0% placebo-treated patients [see Adverse Reactions ( 6.1)] . Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in WEGOVY-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. 5.4 Hypoglycemia WEGOVY lowers blood glucose and can cause hypoglycemia. In a trial of WEGOVY injection in adult patients with type 2 diabetes and body mass index (BMI) greater than or equal to 27 kg/m² for weight reduction (Study 3), hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in more patients treated with WEGOVY versus placebo [see Adverse Reactions (6.1)] . One episode of severe hypoglycemia (requiring the assistance of another person) was reported in one WEGOVY treated patient versus no placebo-treated patients [see Clinical Studies (14.2)] . In glycemic control clinical trials, the risk of hypoglycemia was increased when semaglutide injection or tablet was used concomitantly with insulin or an insulin secretagogue (e.g., sulfonylurea). Patients with diabetes mellitus taking WEGOVY in combination with insulin or an insulin secretagogue may have an increased risk of hypoglycemia, including severe hypoglycemia. The use of WEGOVY in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment. When initiating WEGOVY, consider reducing the dose of concomitantly administered insulin or insulin secretagogue to reduce the risk of hypoglycemia [see Drug Interactions (7.1)] . 5.5 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide [see Adverse Reactions ( 6)]. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6)]. Monitor renal function in patients reporting adverse reactions to WEGOVY that could lead to volume depletion, especially during dosage initiation and escalation of WEGOVY. 5.6 Severe Gastrointestinal Adverse Reactions Use of WEGOVY has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]. In clinical trials for adults for weight reduction, severe gastrointestinal adverse reactions were reported more frequently among patients receiving WEGOVY than placebo. Severe gastrointestinal adverse reactions were reported in 4.1% and 0.9% of WEGOVY injection and placebo-treated patients, respectively, and in 2% of WEGOVY tablet-treated and 0% of placebo-treated patients, respectively. Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. WEGOVY is not recommended in patients with severe gastroparesis. 5.7 Hypersensitivity Reactions Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with WEGOVY. If hypersensitivity reactions occur, discontinue use of WEGOVY, treat promptly per standard of care, and monitor until signs and symptoms resolve. WEGOVY is contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY [see Adverse Reactions (6.2)] . Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with WEGOVY. 5.8 Diabetic Retinopathy Complications in Patients with Type 2 Diabetes In a 2-year trial with semaglutide 0.5 mg and 1 mg once-weekly injection in adult patients with type 2 diabetes and high CV risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (semaglutide injection 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide injection 0.7%, placebo 0.4%). In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m² for weight reduction (Study 3), diabetic retinopathy was reported by 4% of WEGOVY injection-treated patients and 2.7% placebo-treated patients [see Clinical Studies (14.2)] . In a glycemic control trial evaluating a dose comparable to the 9 mg dose and the 25 mg semaglutide tablet dose in patients with type 2 diabetes, a similar proportion of patients in each dose group reported diabetic retinopathy related adverse reactions during the trial; 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. 5.9 Heart Rate Increase Treatment with WEGOVY was associated with increases in resting heart rate. Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in WEGOVY injection-treated adult patients compared to placebo in clinical trials for weight reduction. More adult patients treated with WEGOVY injection compared with placebo had maximum changes from baseline at any visit of 10 to 19 bpm (41% versus 34%, respectively) and 20 bpm or more (26% versus 16%, respectively). In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with WEGOVY injection compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%) [see Adverse Reactions ( 6.1)] . Findings were similar in a trial with the WEGOVY tablets. Monitor heart rate at regular intervals consistent with usual clinical practice. Instruct patients to inform their healthcare providers of palpitations or feelings of a racing heartbeat while at rest during WEGOVY treatment. If patients experience a sustained increase in resting heart rate, discontinue WEGOVY. 5.10 Pulmonary Aspiration During General Anesthesia or Deep Sedation WEGOVY delays gastric emptying [see Clinical Pharmacology ( 12.2 )] . There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking WEGOVY, including whether modifying preoperative fasting recommendations or temporarily discontinuing WEGOVY could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking WEGOVY. 5.11 Never Share WEGOVY FlexTouch Between Patients WEGOVY FlexTouch must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.

Drug interactions

7 DRUG INTERACTIONS 7.1 Concomitant Use with Insulin or an Insulin Secretagogue (e.g., Sulfonylurea) WEGOVY lowers blood glucose and can cause hypoglycemia. The risk of hypoglycemia is increased when WEGOVY is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas). The addition of WEGOVY in patients treated with insulin has not been evaluated. When initiating WEGOVY, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.4), Adverse Reactions (6.1)] . 7.2 Oral Medications WEGOVY causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials with semaglutide 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered medications [see Clinical Pharmacology (12.3)] . In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42). Monitor the effects of oral medications concomitantly administered with WEGOVY. Consider increased clinical or laboratory monitoring for medications that have a narrow therapeutic index or that require clinical monitoring.

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)] Acute Pancreatitis [see Warnings and Precautions (5.2)] Acute Gallbladder Disease [see Warnings and Precautions (5.3)] Hypoglycemia [see Warnings and Precautions (5.4)] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.5)] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Diabetic Retinopathy Complications in Patients with Type 2 Diabetes [see Warnings and Precautions (5.8)] Heart Rate Increase [see Warnings and Precautions (5.9)] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.10 )] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in Clinical Trials in Adults with Obesity or Overweight for Weight Reduction WEGOVY 2.4 mg Subcutaneous Injection Weekly Dosage WEGOVY was evaluated for safety in 3 randomized, double-blind, placebo-controlled trials that included 2,116 adult patients with obesity or overweight treated with 2.4 mg WEGOVY injection for up to 68 weeks and a 7-week off-drug follow-up period [see Clinical Studies ( 14.2 )] . Baseline characteristics included a mean age of 48 years, 71% female, 72% White, 14% Asian, 9% Black or African American, and 5% reported as other or unknown; and 85% were not Hispanic or Latino ethnicity, 13% were Hispanic or Latino ethnicity, and 2% reported as unknown. The baseline characteristics were 42% with hypertension, 19% with type 2 diabetes, 43% with dyslipidemia, 28% with a BMI greater than 40 kg/m² and 4% with CV disease. In these clinical trials, 6.8% of patients treated with 2.4 mg WEGOVY injection and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions. The most common adverse reactions leading to discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%), and diarrhea (0.7% versus 0.1%) for WEGOVY and placebo, respectively. Table 3 shows adverse reactions reported in greater than or equal to 2% of WEGOVY 2.4 mg injection-treated adult patients and more frequently than in the placebo group from these trials. Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction Placebo N=1,261 % WEGOVY Injection (2.4 mg Once Weekly) N=2,116 % Nausea 16 44 Diarrhea 16 30 Vomiting 6 24 Constipation 11 24 Abdominal Pain 10 20 Headache 10 14 Fatigue 5 11 Dyspepsia 3 9 Dizziness 4 8 Abdominal Distension 5 7 Eructation <1 7 Hypoglycemia in T2DM 2 6 Flatulence 4 6 Gastroenteritis 4 6 Gastroesophageal Reflux Disease 3 5 Gastritis 1 4 Gastroenteritis Viral 3 4 Hair Loss 1 3 Dysesthesia 1 2 a Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort and epigastric discomfort. b Includes fatigue and asthenia. c Defined as blood glucose <54 mg/dL with or without symptoms of hypoglycemia or severe hypoglycemia (requiring the assistance of another person) in patients with type 2 diabetes not on concomitant insulin (Study 3, WEGOVY N=403, Placebo N=402). See text below for further information regarding hypoglycemia in patients with and without type 2 diabetes. T2DM = type 2 diabetes mellitus. d Includes chronic gastritis, gastritis, gastritis erosive, and reflux gastritis. e Includes paresthesia, hyperesthesia, burning sensation, allodynia, dysesthesia, skin burning sensation, pain of skin, and sensitive skin. CV Outcomes Trial In a CV outcomes trial, 8,803 patients were exposed to WEGOVY injection for a median of 37.3 months and 8,801 patients were exposed to placebo for a median of 38.6 months [see Clinical Studies (14.1)] . Safety data collection was limited to serious adverse events (including death), adverse events leading to discontinuation, and adverse events of special interest. Sixteen percent (16%) of WEGOVY injection-treated patients and 8% of placebo-treated patients, respectively, discontinued study drug due to an adverse event. Additional information from this trial is included in subsequent sections below when relevant. WEGOVY 7.2 mg Subcutaneous Injection Weekly Dosage The safety of WEGOVY 7.2 mg injection was evaluated in two 72-week double-blinded randomized placebo-controlled 3-armed trials (Study 8 and Study 9), including 1,311 patients with obesity (BMI ≥30 kg/m² ) exposed in the treatment arm with WEGOVY 7.2 mg injection, 304 patients exposed in the treatment arm with WEGOVY 2.4 mg injection, and 303 patients exposed to placebo [see Clinical Studies (14.2)] . After dosage escalation, 1,149 patients received at least one dose of WEGOVY 7.2 mg injection, and 578 patients received 7.2 mg for at least 1 year. Baseline characteristics in the WEGOVY 7.2 mg injection arm included a mean age of 49 years, 70% female, 85% White, 5% Asian, 8% Black or African American, and 2% reported as other or unknown; and 5% were Hispanic or Latino ethnicity. At baseline, mean BMI was 39.5 kg/m² , 52% with hypertension, 38% with dyslipidemia, 40% with a BMI greater than 40 kg/m² , and 14% with CV disease. In these clinical trials, 5% of patients treated with 7.2 mg WEGOVY injection, 5% of patients treated with 2.4 mg of WEGOVY injection and 2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions. The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3%, 3%, and 0.3%, for WEGOVY 7.2 mg injection, WEGOVY 2.4 mg injection, and placebo, respectively. Table 4 shows adverse reactions reported in greater than or equal to 2% of WEGOVY 7.2 mg injection and more frequently than 2.4 mg injection-treated and placebo-treated patients from these studies. Table 4. Adverse Reactions (2% and Greater Than WEGOVY 2.4 mg and Placebo) in WEGOVY 7.2 mg Injection-treated Adults with Obesity for Weight Reduction Table 4. Adverse Reactions (2% and Greater Than WEGOVY 2.4 mg and Placebo) in WEGOVY 7.2 mg Injection-treated Adults with Obesity for Weight Reduction Placebo N=303 % WEGOVY Injection (2.4 mg Once Weekly) N=304 % WEGOVY Injection (7.2 mg Once Weekly) N=1,311 % Nausea 13 35 39 Vomiting 6 16 22 Dysesthesia 0 6 22 Constipation 8 19 20 Abdominal pain 7 9 12 Fatigue 5 9 11 Headache 7 8 9 Dizziness 1 5 6 Hair loss 1 3 6 Flatulence 2 2 4 a Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization. b Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort and epigastric discomfort. c Includes fatigue and asthenia. d Includes dizziness and dizziness postural. WEGOVY Tablet 25 mg Oral Daily Dosage WEGOVY tablet was evaluated for safety in a randomized, double-blind, placebo-controlled trial that included 204 adult patients with obesity or overweight and at least one weight-related comorbidity, treated with WEGOVY 25 mg tablets for up to 64 weeks and a 7-week off drug follow-up period (Study 7) [see Clinical Studies (14.2)] . Patients with type 2 diabetes mellitus were excluded. Baseline characteristics included a mean age of 48 years, 76% were female, 93% were White, 0.5% were Asian, 6% were Black or African American, and 8% were Hispanic or Latino ethnicity. Mean baseline body weight was 106.4 kg and mean BMI was 37.5 kg/m² . The baseline characteristics were 44% with hypertension, 31% with dyslipidemia, 27% with a BMI greater than 40 kg/m² and 1.5% with coronary artery disease. In the clinical trial, 6.9% of patients treated with WEGOVY 25 mg tablets and 5.9% patients treated with placebo permanently discontinued treatment as a result of adverse reactions. The most common event type leading to discontinuation was gastrointestinal adverse reactions reported in 3.4% with WEGOVY tablets and 2% with placebo. In the clinical trial with WEGOVY 25 mg tablets, the types and frequency of common adverse reactions were similar to those listed in Table 3 . Adverse Reactions in a Clinical Trial of Pediatric Patients Aged 12 Years and Older with Obesity Treated with WEGOVY 2.4 mg Injection for Weight Reduction WEGOVY injection was evaluated in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pediatric patients aged 12 years and older with obesity [see Clinical Studies (14.3)] . Baseline characteristics included a mean age of 15.4 years; 38% of patients were male; 79% were White, 8% were Black or African American, 2% were Asian, and 11% were of other or unknown race; and 11% were of Hispanic or Latino ethnicity. The mean baseline body weight was 107.5 kg, and mean BMI was 37 kg/m² . Table 5 shows adverse reactions reported in greater than or equal to 3% of WEGOVY injection-treated pediatric patients and more frequently than in the placebo group from a trial in pediatric patients aged 12 years and older. Table 5. Adverse Reactions (≥3% and Greater than Placebo) in WEGOVY 2.4 mg Injection-treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction Table 5. Adverse Reactions (≥3% and Greater than Placebo) in WEGOVY 2.4 mg Injection-treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction Placebo N=67 % WEGOVY Injection (2.4 mg Once Weekly) N=133 % Nausea 18 42 Vomiting 10 36 Diarrhea 19 22 Headache 16 17 Abdominal Pain 6 15 Nasopharyngitis 10 12 Dizziness 3 8 Gastroenteritis 3 7 Constipation 2 6 Gastroesophageal Reflux Disease 2 4 Sinusitis 2 4 Urinary tract infection 2 4 Ligament sprain 2 4 Anxiety 2 4 Hair Loss 0 4 Cholelithiasis 0 4 Eructation 0 4 Influenza 0 3 Rash 0 3 Urticaria 0 3 Adverse Reactions in Clinical Trials in Adults with MASH Treated with WEGOVY Injection The safety of WEGOVY injection was evaluated in a randomized, double-blind, placebo-controlled trial (Study 11) that included 1,195 adult patients with MASH, including 800 patients who were exposed to WEGOVY for a median of 95.3 weeks and 395 patients who were exposed to placebo for a median of 83.1 weeks [see Clinical Studies (14.4)]. The most commonly reported adverse reactions were consistent with the other approved WEGOVY indications (see Table 3 ). There is limited information in patients with MASH and a BMI <25 kg/m² . Additional information from the MASH trial is included in subsequent sections when notable. Unless indicated, the incidence of the adverse reactions in MASH patients was similar to other approved indications. Other Adverse Reactions in Adults and/or Pediatric Patients Treated with WEGOVY Injection or WEGOVY Tablets The safety of WEGOVY tablets and WEGOVY 7.2 mg injection have not been established in pediatric patients or patients with MASH. Acute Gallbladder Disease In WEGOVY clinical trials in adults for weight reduction, cholelithiasis was reported by 1.6% of WEGOVY injection-treated patients and 0.7% of placebo-treated patients and by 2.5% of WEGOVY tablet-treated patients and 1% of placebo tablet-treated patients. Cholecystitis was reported by 0.6% of WEGOVY injection-treated adult patients and 0.2% of placebo-treated patients. In a clinical trial in pediatric patients aged 12 years and older for weight reduction [see Clinical Studies ( 14.3)] , cholelithiasis was reported by 3.8% of WEGOVY injection-treated patients and 0% placebo-treated patients. Cholecystitis was reported by 0.8% of WEGOVY injection-treated pediatric patients and 0% placebo-treated patients. Hypoglycemia Patients with Type 2 Diabetes In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m² for weight reduction, clinically significant hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in 6.2% of WEGOVY injection-treated patients versus 2.5% of placebo-treated patients. A higher rate of clinically significant hypoglycemic episodes was reported with WEGOVY injection (semaglutide 2.4 mg) versus semaglutide 1 mg injection (10.7 vs. 7.2 episodes per 100 patient years of exposure, respectively); the rate in the placebo-treated group was 3.2 episodes per 100 patient years of exposure. In addition, one episode of severe hypoglycemia requiring intravenous glucose was reported in a WEGOVY injection-treated patient versus none in placebo-treated patients. The risk of hypoglycemia was increased when WEGOVY was used with a sulfonylurea. In a glycemic control trial evaluating a dose comparable to the 9 mg and 25 mg semaglutide tablet dose in patients with type 2 diabetes not on insulin, clinically significant hypoglycemia was reported in similar proportions of subjects in both treatment groups. Patients without Type 2 Diabetes Episodes of hypoglycemia have been reported with GLP-1 receptor agonists in adult patients without type 2 diabetes mellitus. In WEGOVY clinical trials in adult patients without type 2 diabetes mellitus for weight reduction, there was no systematic capturing or reporting of hypoglycemia. In a CV outcomes trial in adult patients without type 2 diabetes, 3 episodes of serious hypoglycemia were reported in WEGOVY injection-treated patients versus 1 episode in placebo. Patients with a history of bariatric surgery (a risk factor for hypoglycemia) had more events of serious hypoglycemia while taking WEGOVY injection (2.3%, 2/87) than placebo (0%, 0/97). Retinal Disorders in Patients with Type 2 Diabetes In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m² for weight reduction, retinal disorders were reported by 6.9% of patients treated with WEGOVY injection (semaglutide 2.4 mg), 6.2% of patients treated with semaglutide 1 mg, and 4.2% of patients treated with placebo. The majority of events were reported as diabetic retinopathy (4%, 2.7%, and 2.7%, respectively) and non-proliferative retinopathy (0.7%, 0%, and 0%, respectively). In a glycemic control trial evaluating the 9 mg and 25 mg semaglutide tablet doses in patients with type 2 diabetes, a similar proportion of patients in each dose group reported diabetic retinopathy related adverse reactions during the trial; 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively. In a 2-year trial with semaglutide 0.5 mg and 1 mg once-weekly injection in adult patients with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (semaglutide injection 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide injection 0.7%, placebo 0.4%). Gastrointestinal Adverse Reactions In clinical trials in adults for weight reduction, 73% of WEGOVY injection-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving WEGOVY injection (4.1%) than placebo (0.9%). The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%), and diarrhea (30% vs. 16%). Other reactions that occurred at a higher incidence among WEGOVY injection-treated adult patients included dyspepsia, abdominal pain, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, gastritis, hemorrhoids, and hiccups. These reactions were most frequently reported during dosage escalation. Severe gastrointestinal adverse reactions were reported in 2% of WEGOVY tablet-treated and 0% of placebo-treated patients, respectively. In the pediatric clinical trial for weight reduction, 62% of WEGOVY injection-treated patients and 42% of placebo-treated patients reported gastrointestinal adverse reactions. The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%). Other gastrointestinal-related reactions that occurred at a higher incidence than placebo among WEGOVY injection-treated pediatric patients included abdominal pain, constipation, eructation, gastroesophageal reflux disease, dyspepsia, and flatulence. Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of WEGOVY injection-treated adult patients versus 0.7% of placebo-treated patients. In a pediatric clinical trial for weight reduction, 2.3% of patients treated with WEGOVY injection versus 1.5% of patients who received placebo discontinued treatment as a result of gastrointestinal adverse reactions. Dysesthesia Dysesthesia, and related events of altered skin sensations including paresthesia, pain of skin, sensitive skin, and burning skin sensation, occurred in clinical trials with WEGOVY injection and tablet. The incidence of dysesthesia with WEGOVY increased with increasing dosage and drug levels in the blood. In clinical trials evaluating patients with and without type 2 diabetes mellitus, WEGOVY 7.2 mg injection dysesthesia was reported at a higher rate in the WEGOVY 7.2 mg injection group (22%), compared to WEGOVY 2.4 mg injection (6%) and placebo (0.3%). Among 288 patients who experienced dysesthesia with WEGOVY 7.2 mg injection, 2% permanently discontinued treatment, 8% had temporary interruption, and 23% had dose reduction; most subjects with these actions taken to WEGOVY 7.2 mg injection (permanent discontinuation, temporary interruption, or dose reduction) recovered from the event. When an action was taken with WEGOVY, events resolved faster than the events where no action was taken with WEGOVY. Among patients who experienced dysesthesia with WEGOVY 7.2 mg injection, 18% did not report recovering during the trial duration; in most of the patients who did not recover, the WEGOVY dosage was unchanged and not discontinued. Of the patients who recovered after action taken with WEGOVY, 38 patients were re-escalated to 7.2 mg. Of these 38 patients, 17 (45%) subsequently reported recurrence of dysesthesia. In a clinical trial with WEGOVY 25 mg tablets, 5% of WEGOVY-treated patients and no placebo-treated patients reported dysesthesia adverse reactions. Other Adverse Reactions in Adults and/or Pediatric Patients The below adverse reactions were reported in WEGOVY injection clinical trials and are applicable to both WEGOVY injection and WEGOVY tablets. The safety of WEGOVY tablets have not been established in pediatric patients or patients with MASH. Acute Pancreatitis In WEGOVY clinical trials in adults for weight reduction, acute pancreatitis was confirmed by adjudication in 4 WEGOVY-treated patients (0.2 cases per 100 patient years) and 1 in placebo-treated patients (less than 0.1 cases per 100 patient years). One additional case of acute pancreatitis was confirmed in a patient treated with WEGOVY in another clinical trial. Acute Kidney Injury Acute kidney injury occurred in clinical trials for weight reduction in 7 adult patients (0.4 cases per 100 patient years) receiving WEGOVY versus 4 patients (0.2 cases per 100 patient years of exposure) receiving placebo. Some of these adverse reactions occurred in association with gastrointestinal adverse reactions or dehydration. In addition, 2 patients treated with WEGOVY had acute kidney injury with dehydration in other clinical trials. The risk of renal adverse reactions with WEGOVY was increased in adult patients with a history of renal impairment (trials included 65 patients with a history of moderate or severe renal impairment at baseline), and occurred more frequently during dose titration. Increase in Heart Rate Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed with routine clinical monitoring in WEGOVY-treated adult patients compared to placebo in clinical trials for weight reduction. In weight reduction trials in which adult patients were randomized prior to dose-escalation, more patients treated with WEGOVY, compared with placebo, had maximum changes from baseline at any visit of 10 to 19 bpm (41% versus 34%, respectively) and 20 bpm or more (26% versus 16%, respectively). In a clinical trial for weight reduction in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with WEGOVY compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%). Hypotension and Syncope Adverse reactions related to hypotension (hypotension, orthostatic hypotension, and decreased blood pressure) were reported in 1.3% of WEGOVY-treated adult patients versus 0.4% of placebo-treated patients and syncope was reported in 0.8% of WEGOVY-treated patients versus 0.2% of placebo-treated patients in clinical trials for weight reduction. Some reactions were related to gastrointestinal adverse reactions and volume loss associated with WEGOVY. Hypotension and orthostatic hypotension were more frequently seen in patients on concomitant antihypertensive therapy. In a clinical trial in pediatric patients aged 12 years and older for weight reduction, hypotension was reported in 2.3% of WEGOVY-treated patients versus 0% in placebo-treated patients. Appendicitis Appendicitis (including perforated appendicitis) occurred in 10 (0.5%) WEGOVY-treated adult patients and 2 (0.2%) patients receiving placebo in clinical trials for weight reduction. Injection Site Reactions In clinical trials in adults for weight reduction, 1.4% of WEGOVY-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation). Hypersensitivity Reactions Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with WEGOVY. In a pediatric clinical trial for weight reduction, rash was reported in 3% of WEGOVY-treated patients and 0% of placebo-treated patients, and urticaria was reported in 3% of WEGOVY-treated patients and 0% of placebo-treated patients . In adult clinical trials for weight reduction, allergic reactions occurred in 16% (8/50) of WEGOVY-treated patients with anti-semaglutide antibodies and in 7% (114/1659) of WEGOVY-treated patients who did not develop anti-semaglutide antibodies [see Clinical Pharmacology (12.6)]. Fractures In the CV outcomes trial in adults, more fractures of the hip and pelvis were reported on WEGOVY than on placebo in female patients: 1% (24/2,448) vs. 0.2% (5/2,424), and in patients ages 75 years and older: 2.4% (17/703) vs. 0.6% (4/663), respectively. In a clinical trial in adults with MASH, fractures occurred in 4.4% of WEGOVY-treated patients (2.6 cases per 100 patient years) compared to 3.3% of placebo-treated patients (2 cases per 100 patient years). Fractures were reported in both males and females with a median age of 61 years (range, 44 to 75). Urolithiasis In a CV outcomes trial, 1.2% of WEGOVY-treated patients and 0.8% of patients receiving placebo reported urolithiasis, including serious reactions that were reported more frequently among patients receiving WEGOVY (0.6%) than placebo (0.4%). Dysgeusia In clinical trials in adults for weight reduction, 1.7% of WEGOVY-treated patients and 0.5% of placebo-treated patients reported dysgeusia. Hair Loss Hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction. In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male). In a pediatric trial, hair loss was reported in 4% of patients treated with 2.4 mg of WEGOVY and no placebo-treated patients. In clinical trials with WEGOVY 7.2 mg injection, hair loss was reported in 5.8% of patients treated with WEGOVY 7.2 mg (8.4% female, 0.2% male), 3.3% of patients treated with WEGOVY 2.4 mg (5.4% female, 0 male), and 1.0% of patients on placebo (1.5% female, 0 male). In the WEGOVY 7.2 mg group, 1 event led to permanent treatment discontinuation, 1 event led to temporary interruption, and 5 events led to dose reduction, versus none of these actions in the WEGOVY 2.4 mg or placebo groups. Laboratory Abnormalities in Adults and/or Pediatric Patients Treated with WEGOVY Injection The below laboratory abnormalities are applicable for both WEGOVY injection and WEGOVY tablets and include descriptions of WEGOVY injection clinical trial data, where relevant. The safety and effectiveness of WEGOVY tablets have not been established in pediatric patients or patients with MASH. Amylase and Lipase Adult and pediatric patients treated with WEGOVY had a mean increase from baseline in amylase of 15% to 16% and lipase of 39% in clinical trials for weight reduction. These changes were not observed in the placebo group. In a clinical trial in adults with MASH, increases in lipase greater than 3 times the upper limit of normal (ULN) occurred in 4.7% (35/750) of WEGOVY-treated patients compared with 1.3% (5/374) of placebo-treated patients. The clinical significance of elevations in lipase or amylase with WEGOVY is unknown in the absence of other signs and symptoms of pancreatitis. Liver Tests In a pediatric clinical trial for weight reduction, increases in alanine aminotransferase (ALT) greater than or equal to 5 times the ULN were observed in 4 (3%) WEGOVY-treated patients compared with 0% of placebo-treated patients. In some patients, increases in ALT and AST were associated with other confounding factors (such as gallstones). In the CV outcomes trial in adults, increases in total bilirubin greater than or equal to 3 times the ULN were observed in 0.3% (30/8,585) of WEGOVY-treated patients versus 0.2% (14/8,579) of placebo-treated patients. 6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of WEGOVY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal Disorders: acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction Hypersensitivity: anaphylaxis, angioedema, rash, urticaria Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation Renal and Urinary Disorders: acute kidney injury

Clinical studies

14 CLINICAL STUDIES 14.1 Cardiovascular Outcomes Trial in Adult Patients with Cardiovascular Disease and Either Obesity or Overweight Overview of Clinical Trial Study 1 (NCT03574597) was a multi-national, multi-center, placebo-controlled, double-blind trial to determine the effect of WEGOVY injection relative to placebo on major adverse CV events (MACE) when added to current standard of care, which included management of CV risk factors and individualized healthy lifestyle counseling (including diet and physical activity) in adults with established CV disease and either obesity or overweight. The primary endpoint, MACE, was the time to first occurrence of a three-part composite outcome which included CV death, non-fatal myocardial infarction, and non-fatal stroke. During the 16-week dose escalation period, patients were titrated to WEGOVY 2.4 mg injected subcutaneously once weekly or placebo. Patients who could not tolerate the recommended escalation dosage could stay at a lower dose level. All patients were 45 years or older, with an initial BMI of 27 kg/m² or greater and established CV disease (prior myocardial infarction, prior stroke, or peripheral arterial disease). Patients with a history of type 1 or type 2 diabetes were excluded. Concomitant CV therapies could be adjusted, at the discretion of the investigator, to ensure participants were treated according to the current standard of care for patients with established CV disease. In this trial, 17,604 patients were randomized to WEGOVY injection or placebo. At baseline, the mean age was 62 years (range 45 to 93), 72% were male, 84% were White, 4% were Black or African American, and 8% were Asian, and 10% were Hispanic or Latino. Mean baseline body weight was 97 kg and mean BMI was 33 kg/m² . At baseline, prior myocardial infarction was reported in 76% of randomized individuals, prior stroke in 23%, and peripheral arterial disease in 9%. Heart failure was reported in 24% of patients. At baseline, CV disease and risk factors were managed with lipid-lowering therapy (90%), platelet aggregation inhibitors (86%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (74%), and beta blockers (70%). A total of 10% had moderate renal impairment (eGFR 30 to <60 mL/min/1.73m² ) and 0.4% had severe renal impairment eGFR <30 mL/min/1.73m² . Results In total, 96.9% of patients completed the trial, and vital status was available for 99.4% of patients. The median follow-up duration was 41.8 months. A total of 31% of WEGOVY injection-treated patients and 27% of placebo-treated patients permanently discontinued study drug. Of those patients on treatment at 1 year, 76% were on the 2.4 mg dose, 8% were on the 1.7 mg dose, and 16% were on lower doses. Of those patients on treatment at 2 years, 77% were on the 2.4 mg dose, 7% were on the 1.7 mg dose, and 17% were on lower doses. For the primary analysis, a Cox proportional hazards model was used to test for superiority. Type 1 error was controlled across multiple tests. WEGOVY injection significantly reduced the risk for first occurrence of MACE. The estimated hazard ratio (95% CI) was 0.80 (0.72, 0.90) (see Figure 2 and Table 6 ). Figure 2. Cumulative Incidence Function: Time to First Occurrence of MACE in Study 1 with WEGOVY Injection Data from the in-trial period. Cumulative incidence estimates are based on time from randomization to first EAC-confirmed cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke with non-CV death modeled as competing risk using the Aalen-Johansen estimator. Patients without events of interest were censored at the end of their in-trial observation period. Time from randomization to first cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke was analyzed using a Cox proportional hazards model with treatment as categorical fixed factor. The hazard ratio and confidence interval are adjusted for the group sequential design using the likelihood ratio ordering. HR: Hazard ratio; CI: confidence interval; CV: cardiovascular The treatment effect for the primary composite endpoint, its components, and other relevant endpoints in Study 1 are shown in Table 6 . Table 6. Treatment Effect for MACE and Other Events in Study 1 with WEGOVY Injection Table 6. Treatment Effect for MACE and Other Events in Study 1 with WEGOVY Injection Patients with events n (%) Patients with events n (%) Placebo N=8,801 WEGOVY Injection N=8,803 Hazard Ratio (95% CI) Primary composite endpoint Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke 701 (8%) 569 (6.5%) 0.8 (0.72; 0.9) Key secondary endpoints CV death 262 (3%) 223 (2.5%) 0.85 (0.71; 1.01) All-cause death 458 (5.2%) 375 (4.3%) 0.81 (0.71; 0.93) Other endpoints Fatal or non-fatal myocardial infarction 334 (3.8%) 243 (2.8%) 0.72 (0.61; 0.85) Fatal or non-fatal stroke 178 (2%) 160 (1.8%) 0.89 (0.72; 1.11) Hospitalization for heart failure or urgent heart failure visits 122 (1.4%) 97 (1.1%) 0.79 (0.6; 1.03) * p-value <0.001, one-sided p-value 1 Primary endpoint 2 Adjusted for group sequential design using the likelihood ratio ordering. 3 CV death was the first confirmatory secondary endpoint in the testing hierarchy and superiority was not confirmed. 4 Confirmatory secondary endpoint. Not statistically significant based on the prespecified testing hierarchy. 5 Not included in the prespecified testing hierarchy for controlling type-I error. 6 Effect on heart failure has not been established. NOTE: Time to first event was analyzed in a Cox proportional hazards model with treatment as factor. For patients with multiple events, only the first event contributed to the composite endpoint. Table 7. Mean Changes in Anthropometry and Cardiometabolic Parameters at Week 104 in Study 1 Table 7. Mean Changes in Anthropometry and Cardiometabolic Parameters at Week 104 in Study 1 PLACEBO PLACEBO WEGOVY Injection WEGOVY Injection Baseline Change from Baseline (LSMean) Baseline Change from Baseline (LSMean) Difference from Placebo (LSMean) Body Weight (kg) Body Weight (kg) 96.8 -0.9 96.5 -9.4 -8.5 Waist Circumference (cm) Waist Circumference (cm) 111.4 -1 111.3 -7.6 -6.5 Systolic Blood Pressure (mmHg) Systolic Blood Pressure (mmHg) 131 -0.5 131 -3.8 -3.3 Diastolic Blood Pressure (mmHg) Diastolic Blood Pressure (mmHg) 79 -0.5 79 -1 -0.5 Heart Rate Heart Rate 69 0.7 69 3.8 3.1 HbA 1c (%) HbA 1c (%) 5.8 0 5.8 -0.3 -0.3 Baseline Baseline % Change from Baseline (LSMean) Baseline % Change from Baseline (LSMean) Relative Difference from Placebo (%) (LSMean) Total Cholesterol (mg/dL) 156 156 -1.9 155.5 -4.6 -2.8 LDL Cholesterol (mg/dL) 78.5 78.5 -3.1 78.5 -5.3 -2.2 HDL Cholesterol (mg/dL) 44.2 44.2 0.6 44.1 4.9 4.2 Triglycerides (mg/dL) 139.5 139.5 -3.2 138.6 -18.3 -15.6 1 Parameters listed in the table were not included in the pre-specified hierarchical testing. 2 Responses were analyzed using an ANCOVA with treatment as fixed factor and baseline value as covariate. Before analysis, missing data were multiple imputed. The imputation model (linear regression) was done separately for each treatment arm and included baseline value as a covariate and was fitted to all subjects with a measurement regardless of treatment status at Week 104. 3 For body weight the ‘change from baseline’ and ‘difference to placebo’ the unit is percentage change from baseline. 4 Baseline value is the geometric mean. The reduction of MACE with WEGOVY injection was not impacted by age, sex, race, ethnicity, BMI at baseline, or level of renal function impairment. 14.2 Weight Reduction and Long-term Maintenance Studies in Adults with Obesity or Overweight Overview of Clinical Trials in Adults The efficacy of WEGOVY once weekly subcutaneous injection for weight reduction and long-term maintenance of body weight in conjunction with a reduced-calorie diet and increased physical activity were studied in three 68-week, randomized, double-blind, placebo-controlled trials; one 68-week, randomized, double-blind, placebo withdrawal trial; one 68-week, randomized, double-blind trial that investigated two different doses of WEGOVY injection versus placebo and two 72-week randomized, double-blind trials that investigated two different doses of WEGOVY injection versus placebo. In Studies 2 (NCT#03548935), 3 (NCT#03552757), and 4 (NCT#03611582), WEGOVY or matching placebo was escalated to 2.4 mg subcutaneous injection weekly during a 16-week period followed by 52 weeks on maintenance dose. In Study 5 (NCT#03548987), WEGOVY injection was escalated during a 20-week run-in period, and patients who reached a WEGOVY 2.4 mg subcutaneous injection weekly dosage after the run-in period were randomized to either continued treatment with WEGOVY injection or placebo for 48 weeks. In Study 6 (NCT#03811574), WEGOVY injection was escalated to 1.7 mg or 2.4 mg subcutaneous weekly dosages or placebo over 12 to 16 weeks followed by 52 weeks on either maintenance dose. In Study 8 (NCT#05646706) and Study 9 (NCT#05649137) WEGOVY injection was escalated to 2.4 mg or 7.2 mg subcutaneous weekly dosages or placebo over 20 weeks followed by 52 weeks on maintenance dose. The efficacy of WEGOVY 25 mg oral once daily tablet for weight reduction and long-term maintenance of body weight in conjunction with a reduced-calorie diet and increased physical activity was evaluated in a 64-week randomized, double-blind, placebo-controlled trial [Study 7 (NCT#05564117)]. WEGOVY tablet or matching placebo was escalated to a 25 mg tablet once daily during a 12-week period followed by 52-week maintenance period. In Studies 2, 3, 5, 7, 8 and 9, all patients received instruction for a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended to a minimum of 150 min/week) that began with the first dose of study medication or placebo and continued throughout the trial. In Study 4, patients received an initial 8-week low-calorie diet (total energy intake 1,000 to 1,200 kcal/day) followed by 60 weeks of a reduced-calorie diet (1200 to 1800 kcal/day) and increased physical activity (100 mins/week with gradual increase to 200 mins/week). Study 2 was a 68-week trial that enrolled 1,961 patients with obesity (BMI greater than or equal to 30 kg/m² ) or with overweight (BMI 27 to 29.9 kg/m² ) and at least one weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. Patients were randomized in a 2:1 ratio to either WEGOVY injection or placebo. At baseline, mean age was 46 years (range 18 to 86), 74% were female, 75% were White, 13% were Asian and 6% were Black or African American. A total of 12% were Hispanic or Latino ethnicity. Mean baseline body weight was 105.3 kg and mean BMI was 37.9 kg/m² . Study 3 was a 68-week trial that enrolled 807 patients with type 2 diabetes and BMI greater than or equal to 27 kg/m² . Patients included in the trial had HbA 1c 7-10% and were treated with either: diet and exercise alone or 1 to 3 oral anti‑diabetic drugs (metformin, sulfonylurea, glitazone or sodium-glucose co-transporter 2 inhibitor). Patients were randomized in a 1:1 ratio to receive either WEGOVY injection or placebo. At baseline, the mean age was 55 years (range 19 to 84), 51% were female, 62% were White, 26% were Asian and 8% were Black or African American. A total of 13% were Hispanic or Latino ethnicity. Mean baseline body weight was 99.8 kg and mean BMI was 35.7 kg/m² . Study 4 was a 68-week trial that enrolled 611 patients with obesity (BMI greater than or equal to 30 kg/m² ) or with overweight (BMI 27 to 29.9 kg/m² ) and at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. The patients were randomized in a 2:1 ratio to receive either WEGOVY injection or placebo. At baseline, the mean age was 46 years, 81% were female, 76% were White, 19% were Black or African American and 2% were Asian. A total of 20% were Hispanic or Latino ethnicity. Mean baseline body weight was 105.8 kg and mean BMI was 38 kg/m² . Study 5 was a 68-week trial that enrolled 902 patients with obesity (BMI greater than or equal to 30 kg/m² ) or with overweight (BMI 27 to 29.9 kg/m² ) and at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. Mean body weight at baseline for the 902 patients was 106.8 kg and mean BMI was 38.3 kg/m². All patients received WEGOVY injection during the run-in period of 20 weeks that included 16 weeks of dose escalation. Trial product was permanently discontinued before randomization in 99 of 902 patients (11%); the most common reason was adverse reactions (n=48, 5.3%); 803 patients reached WEGOVY 2.4 mg injection and were then randomized in a 2:1 ratio to either continue on WEGOVY injection or receive placebo. Among the 803 randomized patients, the mean age was 46 years, 79% were female, 84% were White, 13% were Black or African American, and 2% Asian. A total of 8% were Hispanic or Latino ethnicity. Mean body weight at randomization (Week 20) was 96.1 kg and mean BMI at randomization (Week 20) was 34.4 kg/m² . Study 6 was a 68-week trial that enrolled 401 East-Asian patients (Japan and South Korea) with BMI greater than or equal to 35 kg/m² and at least one weight-related comorbid condition or with BMI 27 to 34.9 kg/m² and at least two weight-related comorbid conditions. The patients were randomized 2:1:1 to receive subcutaneous injection of WEGOVY 2.4 mg, WEGOVY 1.7 mg, or placebo. At baseline, the mean age was 51 years, 63% were male, and all patients were Asian. Mean baseline body weight was 87.5 kg and mean BMI was 31.9 kg/m² . At baseline, 24.7% of patients had type 2 diabetes mellitus. Study 7 was a 64-week trial that enrolled 307 patients with obesity (BMI greater than or equal to 30 kg/m² ) or with overweight (BMI 27-29.9 kg/m² ) and at least one weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. Patients were randomized in a 2:1 ratio to either WEGOVY 25 mg tablet or placebo. At baseline, mean age was 48 years, 79% were women, 92% were White, 1% were Asian and 7% were Black or African American. A total of 7.8% were Hispanic or Latino ethnicity. Mean baseline body weight was 106 kg and mean BMI was 38 kg/m² . Study 8 was a 72-week trial that enrolled 1,407 patients with obesity (BMI greater than or equal to 30 kg/m² ), patients with type 2 diabetes mellitus were excluded. Patients were randomized in a 5:1:1 ratio to either WEGOVY 7.2 mg, WEGOVY 2.4 mg or placebo once weekly. At baseline, mean age was 47 years (range 18 to 80), 74% were female, 86% were White, 4% were Asian and 9% were Black or African American. A total of 5% were Hispanic or Latino ethnicity. Mean baseline body weight was 113 kg and mean BMI was 39.9 kg/m² . Study 9 was a 72-week trial that enrolled 512 patients with obesity and type 2 diabetes. Patients included in the trial had HbA 1c 7 to 10% and were treated with either: diet and exercise alone or 1 to 3 oral antidiabetic drugs (metformin, sulfonylurea, glitazone or sodium-glucose co-transporter 2 inhibitor). Patients were randomized in a 3:1:1 ratio to receive either WEGOVY 7.2 mg, WEGOVY 2.4 mg or placebo once weekly. At baseline, the mean age was 56 years (range 19 to 79), 52% were female, 84% were White, 6% were Asian and 9% were Black or African American. A total of 6% were Hispanic or Latino ethnicity. Mean baseline body weight was 110.1 kg and mean BMI was 38.6 kg/m² . Results In Studies 2, 3, and 4, 16% of WEGOVY injection-treated patients and 19% of the placebo-treated patients discontinued therapy. In these studies, 6.8% of WEGOVY injection-treated patients and 3.2% of placebo-treated patients discontinued their treatment due to an adverse reaction [see Adverse Reactions (6.1)] . In Study 5, the proportions of patients who discontinued study drug were 5.8% and 11.6% for WEGOVY injection and placebo, respectively. In Study 6, the proportions of patients who discontinued study drug were 7.9%, 6.5%, and 3% for WEGOVY 1.7 mg injection, WEGOVY 2.4 mg injection, and placebo, respectively. In Study 7, the proportions of patients who discontinued study drug were 18% and 25.5% for WEGOVY 25 mg tablet and placebo, respectively. Adverse reactions led to treatment discontinuation in 6.8% of patients treated with WEGOVY 25 mg tablet and 5.9% patients receiving placebo. In Study 8, 5.4% of patients treated with WEGOVY 7.2 mg and 1% patients treated with placebo permanently discontinued treatment as a result of adverse reactions. In Study 9, 5.5% of patients treated with WEGOVY 7.2 mg and 2% patients treated with placebo permanently discontinued treatment as a result of adverse reactions. For Studies 2, 3 and 4, the primary efficacy parameters were mean percent change in body weight and the percentages of patients achieving greater than or equal to 5% weight loss from baseline to Week 68. After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved 5%, 10% and 15% weight loss than those treated with placebo as shown in Table 8 . Table 8. Changes in Body Weight at Week 68 in Studies 2, 3, and 4 with WEGOVY 2.4 mg Injection Study 2 (Obesity or Overweight with Comorbidity) Study 2 (Obesity or Overweight with Comorbidity) Study 3 (Type 2 Diabetes with Obesity or Overweight) Study 3 (Type 2 Diabetes with Obesity or Overweight) Study 4 (Obesity or Overweight with Comorbidity Undergoing Intensive Lifestyle Therapy) Study 4 (Obesity or Overweight with Comorbidity Undergoing Intensive Lifestyle Therapy) Intention-to-Treat PLACEBO N=655 WEGOVY Injection N=1,306 PLACEBO N=403 WEGOVY Injection N=404 PLACEBO N=204 WEGOVY Injection N=407 Body Weight Baseline mean (kg) 105.2 105.4 100.5 99.9 103.7 106.9 % change from baseline (LSMean) -2.4 -14.9 -3.4 -9.6 -5.7 -16 % difference from placebo (LSMean) (95% CI) -12.4 (‑13.3; ‑11.6) -6.2 (-7.3; -5.2) -10.3 (-11.8; -8.7) % of Patients losing greater than or equal to 5% body weight 31.1 83.5 30.2 67.4 47.8 84.8 % difference from placebo (LSMean) (95% CI) 52.4 (48.1; 56.7) 37.2 (30.7; 43.8) 37 (28.9; 45.2) % of Patients losing greater than or equal to 10% body weight 12 66.1 10.2 44.5 27.1 73 % difference from placebo (LSMean) (95% CI) 54.1 (50.4; 57.9) 34.3 (28.4; 40.2) 45.9 (38; 53.7) % of Patients losing greater than or equal to 15% body weight 4.8 47.9 4.3 25.1 13.2 53.4 % difference from placebo (LSMean) (95% CI) 43.1 (39.8; 46.3) 20.7 (15.7; 25.8) 40.2 (33.1; 47.3) % of Patients losing greater than or equal to 20% body weight 1.7 30.2 2.3 12.8 3.5 33.9 % difference from placebo (LSMean) (95% CI) 28.6 (25,8; 31.3) 10.6 (6.4; 14.7) 30.4 (24.8; 36.1) LSMean = least squares mean; CI = confidence interval 1 The intent-to-treat population includes all randomized patients. In Study 2, at Week 68, the body weight was missing for 7.2% and 11.9% of patients randomized to WEGOVY injection and placebo, respectively. In Study 3, at Week 68, the body weight was missing for 4% and 6.7% of patients randomized to WEGOVY injection and placebo, respectively. In Study 4, at Week 68, the body weight was missing for 8.4% and 7.4% of patients randomized to WEGOVY injection and placebo, respectively. Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI). 2 Not included in the pre-specified hierarchical testing. * p<0.0001 (unadjusted 2-sided) for superiority. For Study 5, the primary efficacy parameter was mean percent change in body weight from randomization (Week 20) to Week 68. From randomization (week 20) to Week 68, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo ( Table 9 ). Because patients who discontinued WEGOVY injection during titration and those who did not reach the 2.4 mg weekly dose were not eligible for the randomized-treatment period, the results may not reflect the experience of patients in the general population who are first starting WEGOVY injection. Table 9. Changes in Body Weight at Week 68 in Study 5 (Obesity or Overweight with Comorbidity After 20-week Run-in) with WEGOVY 2.4 mg Injection Table 9. Changes in Body Weight at Week 68 in Study 5 (Obesity or Overweight with Comorbidity After 20-week Run-in) with WEGOVY 2.4 mg Injection WEGOVY Injection N=803 WEGOVY Injection N=803 Body Weight (only randomized patients) Mean at Week 0 (kg) 107.2 107.2 PLACEBO N=268 WEGOVY Injection N=535 Body Weight Mean at Week 20 (SD) (kg) 95.4 (22.7) 96.5 (22.5) % change from Week 20 at Week 68 (LSMean) 6.9 -7.9 % difference from placebo (LSMean) (95% CI) -14.8 (-16; -13.5) LSMean = least squares mean; CI = confidence interval 1 902 patients were enrolled at Week 0 with a mean baseline body weight of 106.8 kg. The intent-to-treat population includes all randomized patients. At Week 68, the body weight was missing for 2.8% and 6.7% of patients randomized to WEGOVY injection and placebo, respectively. Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI). * p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. For Study 6, the primary efficacy parameters were mean percent change in body weight and the percentage of patients achieving greater than or equal to 5% weight loss from baseline to Week 68. After 68 weeks, treatment with WEGOVY 1.7 mg and 2.4 mg injection resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved 5%, 10%, and 15% weight loss than those treated with placebo as shown in Table 10 . Table 10. Changes in Body Weight at Week 68 in Study 6 in East-Asian Patients with WEGOVY 1.7 and 2.4 mg Injection Table 10. Changes in Body Weight at Week 68 in Study 6 in East-Asian Patients with WEGOVY 1.7 and 2.4 mg Injection Study 6 (BMI ≥35 kg/m² with at Least One Comorbidity or BMI 27 – 34.9 kg/m² with at Least Two Comorbidities) Study 6 (BMI ≥35 kg/m² with at Least One Comorbidity or BMI 27 – 34.9 kg/m² with at Least Two Comorbidities) Study 6 (BMI ≥35 kg/m² with at Least One Comorbidity or BMI 27 – 34.9 kg/m² with at Least Two Comorbidities) Intention-to-treat PLACEBO N=101 WEGOVY 1.7 mg Injection N=101 WEGOVY 2.4 mg Injection N=199 Body Weight Baseline mean (kg) 90.2 86.1 86.9 % change from baseline (LSMean) -2.1 -9.6 -13.2 % difference from placebo (LSMean) (95% CI) -7.5 (-9.6; -5.4)* -11.1 (-12.9; -9.2)* % of Patients losing greater than or equal to 5% body weight 19.4 72.8 84 % difference from placebo (LSMean) (95% CI) 53.3 (41; 65.6)* 64.5 (54.8; 74.3)* % of Patients losing greater than or equal to 10% body weight 4.5 39.1 59.9 % difference from placebo (LSMean) (95% CI) 34.5 (23.9; 45.1)* 55.4 (47.3; 63.6)* % of Patients losing greater than or equal to 15% body weight 2.6 20.8 38.2 % difference from placebo (LSMean) (95% CI) 18.2 (9.8; 26.7)* 35.6 (27.9; 43.3)* LSMean = least squares mean; CI = confidence interval 1 The intent-to-treat population includes all randomized patients. At baseline, 24.7% of patients had type 2 diabetes mellitus. At Week 68, the body weight was missing for 3%, 3%, and 1% of patients randomized to WEGOVY 1.7 mg injection, WEGOVY 2.4 mg injection, and placebo, respectively. Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI). * p<0.0001 (unadjusted 2-sided) for superiority. For Study 7, the primary efficacy parameters were mean percent change in body weight and the percentages of patients achieving greater than or equal to 5% weight loss from baseline to Week 64. After 64 weeks, treatment with WEGOVY 25 mg tablets resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY 25 mg tablets achieved 5%, 10%, 15% and 20% weight loss than those treated with placebo as shown in Table 11 . Table 11. Changes in Body Weight at Week 64 in Study 7 with WEGOVY 25 mg Tablets Table 11. Changes in Body Weight at Week 64 in Study 7 with WEGOVY 25 mg Tablets Study 7 (Obesity or Overweight with Comorbidity) Study 7 (Obesity or Overweight with Comorbidity) Intention-to-Treat PLACEBO N = 102 WEGOVY 25 mg Tablet N = 205 Body Weight Baseline mean (kg) 104.8 106.4 % change from baseline (LSMean) -2.4 -13.6 % difference from placebo (LSMean) (95% CI) -11.2 [-13.6; -8.8] % of Patients losing greater than or equal to 5% body weight 31.3 76.3 % difference from placebo (LSMean) (95% CI) 45.1 [33.8; 56.3] % of Patients losing greater than or equal to 10% body weight 14.4 59.8 % difference from placebo (LSMean) (95% CI) 45.3 [35.5; 55.2] % of Patients losing greater than or equal to 15% body weight 5.5 47 % difference from placebo (LSMean) (95% CI) 41.5 [33.2; 49.8] % of Patients losing greater than or equal to 20% body weight 3.1 27.9 % difference from placebo (LSMean) (95% CI) 24.8 [17.7; 31.9] LSMean = least squares mean; CI = confidence interval 1 The intent-to-treat population includes all randomized patients. In Study 7, at Week 64, the body weight was missing for 6.3% and 11.8% of patients randomized to WEGOVY tablets and placebo, respectively. 2 p<0.0001 (unadjusted 2-sided) for superiority. 3 Model based estimates are based on an analysis of covariance (or logistic regression for the 5%, 10%, 15% or 20% achievement endpoints) including treatment as a factor and baseline value as a covariate. Missing data were multiple imputed from retrieved subjects of the same randomized treatment arm (RD-MI). The imputation model was a linear regression of the endpoint with gender as factor and baseline value of the endpoint, timing and the value of last available observation – on study (LAO-OS) of the endpoint as covariates, imputed by treatment status. For the 5%, 10%, 15% or 20% achievement endpoints, the missing body weight measurements were imputed before performing the logistic regression analyses. RD-MI: Retrieved Drop-outs Multiple Imputation For Studies 8 and 9, the primary efficacy parameters were mean percent change in body weight and the percentages of patients achieving greater than or equal to 5% weight loss from baseline to Week 72. After 72 weeks of treatment, WEGOVY 7.2 mg injection resulted in a statistically significant reduction in body weight compared with placebo in Studies 8 and 9 (see Table 12 and Figures 6 and 10 ). Table 12. Changes in Body Weight at Week 72 in Studies 8 and 9 with WEGOVY 7.2 mg Injection Table 12. Changes in Body Weight at Week 72 in Studies 8 and 9 with WEGOVY 7.2 mg Injection Study 8 (Patients with Obesity) Study 8 (Patients with Obesity) Study 8 (Patients with Obesity) Study 9 (Type 2 Diabetes with Obesity) Study 9 (Type 2 Diabetes with Obesity) Study 9 (Type 2 Diabetes with Obesity) Intention-to-Treat PLACEBO N=201 WEGOVY 2.4 mg Injection N=201 WEGOVY 7.2 mg Injection N=1005 PLACEBO N=102 WEGOVY 2.4 mg Injection N=103 WEGOVY 7.2 mg Injection N=307 Body Weight Baseline mean (kg) 112.4 116.5 112.4 112.1 107 110.5 % change from baseline (LSMean) -3.9 -15.5 -18.8 -3.8 -10.4 -13.2 % difference from placebo (LSMean) (95% CI) -14.9 [-16.2; -13.6] -9.4 [-11.0; -7.8] Difference (%) from 2.4 mg [95% CI] -3.3 [-4.9; -1.6] % of Patients losing greater than or equal to 5% body weight 38.3 86.6 88.7 34 74 83.7 % difference from placebo (LSMean) (95% CI) 50.4 [42.5; 58.3] 49.8 [39.6; 59.9] % of Patients losing greater than or equal to 10% body weight 20.3 72 79.8 11.2 49.5 60.7 % difference from placebo (LSMean) (95% CI) 59.5 [53.0; 66.0] 49.5 [41.2; 57.7] % of Patients losing greater than or equal to 15% body weight 7.5 52.3 63.8 6.9 27 39.8 % difference from placebo (LSMean) (95% CI) 56.4 [51.5; 61.2] 32.9 [25.5; 40.3] % of Patients losing greater than or equal to 20% body weight 2.8 32.3 45.5 2 13.5 20.6 % difference from placebo (LSMean) (95% CI) 42.7 [38.8; 46.6] 18.7 [13.4; 24.1] * p<0.0001 (unadjusted 2-sided) for superiority. ** This endpoint was not included in the hierarchy testing and is only for informative purposes. 1 The intent-to-treat population includes all randomized patients. In Study 8, at Week 72, the body weight was missing for 5.5%, 6.0% and 15.0% of patients randomized to WEGOVY 7.2 mg, WEGOVY 2.4 mg and placebo, respectively. In Study 9, at week 72, the body weight was missing for 5.2% and 6.9% of patients randomized to WEGOVY 7.2 mg and placebo, respectively. a Model based estimates are based on an analysis of covariance (or logistic regression for the 5%, 10%, 15% or 20% achievement endpoints) including treatment as a factor and baseline value as a covariate. Missing data were multiple imputed from retrieved subjects of the same randomized treatment arm (RD-MI) in Study 8 or all retrieved subjects regardless of treatment arm assignment in Study 9. The imputation model was a linear regression of the endpoint with gender as factor and baseline value of the endpoint, timing and the value of last available observation – on study (LAO-OS) of the endpoint as covariates, imputed by treatment status. For the 5%, 10%, 15% or 20% achievement endpoints, the missing body weight measurements were imputed before performing the logistic regression analyses. RD-MI: Retrieved Drop-outs Multiple Imputation A reduction in body weight was observed with WEGOVY irrespective of age, sex, race, ethnicity, BMI at baseline, body weight (kg) at baseline, and level of renal function impairment. The cumulative frequency distributions of change in body weight are shown in Figure 3 , Figure 4 , Figure 5 and Figure 6 for Studies 2, 3, 7 and 8. One way to interpret this figure is to select a change in body weight of interest on the horizontal axis and note the corresponding proportions of patients (vertical axis) in each treatment group who achieved at least that degree of weight loss. For example, note that the vertical line arising from ‑10% in Study 2 intersects the WEGOVY injection and placebo curves at approximately 66%, and 12%, respectively, which correspond to the values shown in Table 8 . Figure 3. Change in Body Weight (%) from Baseline to Week 68 (Study 2) with WEGOVY Injection Observed data from in-trial period including imputed data for missing observations (RD-MI). Figure 4. Change in Body Weight (%) from Baseline to Week 68 (Study 3) with WEGOVY Injection Observed data from in-trial period including imputed data for missing observations (RD-MI). Figure 5. Change in Body Weight (%) from Baseline to Week 64 (Study 7) with WEGOVY 25 mg Tablets Observed data from in-trial period including imputed data for missing observations (RD-MI). The missing observation was the patient-level average from the 1,000 imputed datasets. Figure 6. Change in Body Weight (%) from Baseline to Week 72 (Study 8) with WEGOVY 7.2 mg Injection Observed data from in-trial period including imputed data for missing observations (RD-MI). Missing observations were multiply (x1000) imputed from retrieved participants of the same randomized treatment arm and missing value was replaced by the average across imputations. The time courses of weight loss with WEGOVY injection and placebo from baseline through Week 68 are depicted in Figures 7 , 8 , and 9 , and through Week 72 in Figure 10 . Figure 7. Change from Baseline (%) in Body Weight (Study 2 on Left and Study 3 on Right) with WEGOVY Injection Observed values for patients completing each scheduled visit, and estimates with multiple imputations from retrieved dropouts (RD-MI). Figure 8. Change from Baseline (%) in Body Weight (Study 4 on Left and Study 5a on Right) with WEGOVY Injection Observed values for patients completing each scheduled visit, and estimates with multiple imputations from retrieved dropouts (RD-MI). a Change from Week 0 was not a primary endpoint in Study 5. Dotted line indicates time of randomization. Randomized patients (shown) do not include 99 patients that discontinued during the 20-week run-in period. Figure 9. Change in Body Weight (%) from Baseline to Week 68 (Study 6 in East-Asian Patients) with WEGOVY Injection Observed values for patients completing each scheduled visit and estimates with multiple imputations from retrieved dropouts (RD-MI). At baseline, 24.7% of patients had type 2 diabetes mellitus. Figure 10. Mean Change in Body Weight (%) from Baseline to Week 72 (WEGOVY 7.2 mg Injection– Study 8) Observed values for patients completing each scheduled visit, and estimates with multiple imputations from retrieved dropouts (RD-MI). Effect of WEGOVY Injection on Anthropometry and Cardiometabolic Parameters in Adults Changes in waist circumference and cardiometabolic parameters with WEGOVY injection are shown in Table 13 for Studies 2, 3, and 4; in Table 14 for Study 5; in Table 15 for Study 6; Table 16 for Study 7, and in Table 17 for Studies 8 and 9. Table 13. Changes in Anthropometry and Cardiometabolic Parameters at Week 68 in Studies 2, 3 and 4 with WEGOVY Injection Table 13. Changes in Anthropometry and Cardiometabolic Parameters at Week 68 in Studies 2, 3 and 4 with WEGOVY Injection Study 2 (Obesity or Overweight with Comorbidity) Study 2 (Obesity or Overweight with Comorbidity) Study 3 (Type 2 Diabetes with Obesity or Overweight) Study 3 (Type 2 Diabetes with Obesity or Overweight) Study 4 (Obesity or Overweight with Comorbidity Undergoing Intensive Lifestyle Therapy) Study 4 (Obesity or Overweight with Comorbidity Undergoing Intensive Lifestyle Therapy) Intention-to-Treat PLACEBO N=655 WEGOVY Injection N=1,306 PLACEBO N=403 WEGOVY Injection N=404 PLACEBO N=204 WEGOVY Injection N=407 Waist Circumference (cm) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 114.8 -4.1 114.6 -13.5 -9.4 115.5 -4.5 114.5 -9.4 -4.9 111.8 -6.3 113.6 -14.6 -8.3 Systolic Blood Pressure (mmHg) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 127 -1.1 126 -6.2 -5.1 130 -0.5 130 -3.9 -3.4 124 -1.6 124 -5.6 -3.9 Diastolic Blood Pressure (mmHg) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 80 -0.4 80 -2.8 -2.4 80 -0.9 80 -1.6 -0.7 81 -0.8 80 -3 -2.2 Heart Rate Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 72 -0.7 72 3.5 4.3 76 -0.2 75 2.5 2.7 71 2.1 71 3.1 1 HbA 1c (%) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 5.7 -0.2 5.7 -0.4 -0.3 8.1 -0.4 8.1 -1.6 -1.2 5.8 -0.3 5.7 -0.5 -0.2 Total Cholesterol (mg/dL) Baseline Percent Change from baseline (LSMean ) Relative difference from placebo (LSMean) 192.1 0.1 189.6 -3.3 -3.3 170.8 -0.5 170.8 -1.4 -0.9 188.7 2.1 185.4 -3.9 -5.8 LDL Cholesterol (mg/dL) Baseline Percent Change from baseline (LSMean ) Relative difference from placebo (LSMean) 112.5 1.3 110.3 -2.5 -3.8 90.1 0.1 90.1 0.5 0.4 111.8 2.6 107.7 -4.7 -7.1 HDL (mg/dL) Baseline Percent Change from baseline (LSMean ) Relative difference from placebo (LSMean) 49.5 1.4 49.4 5.2 3.8 43.8 4.1 44.7 6.9 2.7 50.9 5 51.6 6.5 1.5 Triglycerides (mg/dL) Baseline Percent Change from baseline (LSMean ) Relative difference from placebo (LSMean) 127.9 -7.3 126.2 -21.9 -15.8 159.5 -9.4 154.9 -22 -13.9 110.9 -6.5 107.9 -22.5 -17 Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI). 1 Model based estimates based on an analysis of covariance model including treatment (and stratification factors for Study 3 only) as a factor and baseline value as a covariate. 2 Not included in the pre-specified hierarchical testing (except HbA 1c for Study 3). 3 Model based estimates based on a mixed model for repeated measures including treatment (and stratification factors for Study 3 only) as a factor and baseline values as a covariate. 4 Baseline value is the geometric mean. Table 14. Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 5 (Obesity or Overweight with Comorbidity After 20-week Run-in) with WEGOVY Injection Table 14. Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 5 (Obesity or Overweight with Comorbidity After 20-week Run-in) with WEGOVY Injection PLACEBO N=268 PLACEBO N=268 WEGOVY Injection N=535 WEGOVY Injection N=535 Randomization (Week 20) Change from Randomization (Week 20) to Week 68 (LSMean) Randomization (Week 20) Change from Randomization (Week 20) to Week 68 (LSMean) Difference from Placebo (LSMean) Waist Circumference (cm) 104.7 3.3 105.5 -6.4 -9.7 Systolic Blood Pressure (mmHg) 121 4.4 121 0.5 -3.9 Diastolic Blood Pressure (mmHg) 78 0.9 78 0.3 -0.5 Heart Rate 76 -5.3 76 -2 3.3 HbA 1c (%) 5.4 0.1 5.4 -0.1 -0.2 Randomization (Week 20) % Change from Randomization (Week 20) (LSMean) Randomization (Week 20) % Change from Randomization (Week 20) (LSMean) Relative difference from Placebo (LSMean) Total Cholesterol (mg/dL) 175.1 11.4 175.9 4.9 -5.8 LDL Cholesterol (mg/dL) 109.1 7.6 108.7 1.1 -6.1 HDL Cholesterol (mg/dL) 43.6 17.8 44.5 18.2 0.3 Triglycerides (mg/dL) 95.3 14.8 98.1 -5.6 -17.8 Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI). 1 Model based estimates based on an analysis of covariance model including treatment as a factor and baseline value as a covariate. 2 Not included in the pre-specified hierarchical testing. 3 Model based estimates based on a mixed model for repeated measures including treatment as a factor and baseline values as a covariate. 4 Baseline value is the geometric mean. Table 15. Mean Changes in Anthropometry and Cardiometabolic Parameters at Week 68 in Study 6 in East-Asian Patients with WEGOVY Injection Table 15. Mean Changes in Anthropometry and Cardiometabolic Parameters at Week 68 in Study 6 in East-Asian Patients with WEGOVY Injection Study 6 (BMI ≥35 kg/m² with at least one comorbidity or BMI 27 to 34.9 kg/m² with at least two comorbidities) Study 6 (BMI ≥35 kg/m² with at least one comorbidity or BMI 27 to 34.9 kg/m² with at least two comorbidities) Study 6 (BMI ≥35 kg/m² with at least one comorbidity or BMI 27 to 34.9 kg/m² with at least two comorbidities) Intention-to-treat PLACEBO N=101 WEGOVY 1.7 mg Injection N=101 WEGOVY 2.4 mg Injection N=199 Waist circumference (cm) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 103.8 -1.8 101.4 -7.7 -5.9 103.8 -11 -9.3 Systolic blood pressure (mmHg) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 133 -5.3 135 -10.8 -5.4 133 -10.8 -5.5 Diastolic blood pressure (mmHg) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 86 -2.2 85 -4.6 -2.4 83 -5.3 -3.1 Heart Rate Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 73 2.4 73 4.4 2 73 6.3 3.9 HbA 1c (%) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 6.4 0 6.4 -0.9 -0.9 6.4 -0.9 -0.9 Total Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 203.1 0.8 203.3 -6.6 -7.3 197.2 -8.7 -9.4 LDL Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 123.3 -3.8 120.1 -10.1 -6.5 116.5 -14.6 -11.2 HDL Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 48.7 5.9 50.2 6.7 0.7 50.8 9.2 3.1 Triglyceride (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 134.2 5.5 138.8 -19.5 -23.7 127.1 -21.2 -25.3 Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI). At baseline, 24.7% of patients had type 2 diabetes mellitus. 1 Model based estimates based on an analysis of covariance model including treatment and type 2 diabetes status as factors and baseline value as a covariate. 2 Not included in the pre-specified hierarchical testing. 3 Model based estimates based on a mixed model for repeated measures including treatment and type 2 diabetes status as factors and baseline values as a covariate. 4 Baseline value is the geometric mean. Table 16. Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 7 with WEGOVY 25 mg Tablets (Obesity or Overweight with Comorbidity) Table 16. Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 7 with WEGOVY 25 mg Tablets (Obesity or Overweight with Comorbidity) Study 7 (Obesity or overweight with comorbidity) Study 7 (Obesity or overweight with comorbidity) Intention-to-treat PLACEBO N=102 WEGOVY Tablets 25 mg N=205 Waist circumference (cm) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 113.6 -2.8 114 -12.2 -9.4 Systolic blood pressure (mmHg) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 131 -5.4 131 -7 -1.6 Diastolic blood pressure (mmHg) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 83 -1.8 83 -2.8 -1 Heart Rate Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 74 2.4 72 2.7 0.4 HbA 1c (%) Baseline Change from baseline (LSMean ) Difference from placebo (LSMean) 5.7 -0.1 5.7 -0.3 -0.2 Total Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 190.5 -2.2 191.4 -3.3 -1.2 LDL Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 114.2 0.2 111.1 -2.9 -3.1 HDL Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 50.1 -1.1 49.6 3.3 4.5 Triglyceride (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 117.5 -9.1 115.9 -18.1 -9.9 1 Model based estimates are based on an analysis of covariance including treatment as a factor and baseline value as a covariate. Missing data were multiple imputed from retrieved subjects of the same randomized treatment arm (RD-MI). The imputation model was a linear regression of the endpoint with gender as factor and baseline value of the endpoint, timing and the value of last available observation – on study (LAO-OS) of the endpoint as covariates, imputed by treatment status. RD-MI: Retrieved Drop-outs Multiple Imputation 2 Not included in the pre-specified hierarchical testing. 3 Baseline value is the geometric mean. Table 17. Changes in Anthropometry and Cardiometabolic Parameters at Week 72 in Studies 8 and 9 (WEGOVY 7.2 mg Injection) Table 17. Changes in Anthropometry and Cardiometabolic Parameters at Week 72 in Studies 8 and 9 (WEGOVY 7.2 mg Injection) Study 8 (Patients with obesity) Study 8 (Patients with obesity) Study 8 (Patients with obesity) Study 9 (Type 2 diabetes with obesity) Study 9 (Type 2 diabetes with obesity) Study 9 (Type 2 diabetes with obesity) Intention-to-Treat PLACEBO N=201 WEGOVY 2.4 mg Injection N=201 WEGOVY 7.2 mg Injection N=1,005 PLACEBO N=102 WEGOVY 2.4 mg Injection N=103 WEGOVY 7.2 mg Injection N=307 Waist Circumference (cm) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean [95% CI]) 118.6 -5.6 - 120.3 -14.2 118.4 -17.5 -11.9 [-13.2; -10.6]* 123.9 -5.8 - 119.1 -10.7 121.8 -12.3 -6.6 [-9; -4.1]* Systolic Blood Pressure (mmHg) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 130 -4.8 - 129 -8.5 131 -10.1 -5.3 132 -3.5 - 134 -5.6 134 -7.5 -4 Diastolic Blood Pressure (mmHg) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 83 -1.8 - 83 -3 84 -4.5 -2.7 82 -2.9 83 -2.3 82 -3.1 -0.2 Heart Rate (beats/min) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean) 75 -0.6 76 0.3 75 0.5 1 77 -2.7 76 1 77 1.1 3.9 HbA 1c (%) Baseline Changes from baseline (LSMean ) Difference from placebo (LSMean [95% CI]) 5.7 0.0 5.6 -0.3 5.7 -0.3 -0.3 8.2 -0.2 8.1 -1.6 8 -1.7 -1.5 [-1.8; -1.2]* Total Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 193.4 -4.0 - 190.4 -3.6 193.6 -3.4 0.6 176.8 3.5 - 172.6 -1.4 175.2 0.1 -3.4 LDL Cholesterol (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 116.4 -4.8 - 114.4 -4.8 115.8 -3.5 1.3 93.5 6.7 - 93.8 2.7 91.5 10.5 3.8 HDL (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 48.9 -0.5 - 48.2 7.0 48.8 9.5 10.1 42.5 7.4 41.9 6 42.6 11.4 4.0 Triglycerides (mg/dL) Baseline Percent change from baseline (LSMean ) Relative difference from placebo (LSMean) 121.9 -0.9 - 121.6 -9.8 124.2 -16.4 -15.4 180.5 17.2 161.1 -14.8 175.5 -7.8 -25.0 * p<0.0001 (unadjusted 2-sided) for superiority. The difference or relative difference from placebo was comparison between Wegovy 7.2 mg and the placebo arms. 1 Model based estimates based on an analysis of covariance model including randomized treatment as factor and baseline value as a covariate Missing data were multiple imputed from retrieved subjects of the same randomized treatment arm (RD-MI) in Study 8 or all retrieved subjects regardless of treatment arm assignment in Study 9. The imputation model was a linear regression of the endpoint with gender as factor and baseline value of the endpoint, timing and the value of last available observation – on study (LAO-OS) of the endpoint as covariates, imputed by treatment status. RD-MI: Retrieved Drop-outs Multiple Imputation 2 Not included in the pre-specified hierarchical testing (except the comparison between placebo and Wegovy 7.2 mg in Study 8 and Study 9 for waist circumference and HbA 1c for Study 9). 3 Baseline value is the geometric mean. 14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to ≥95th percentile standardized for age and sex (Study 10) (NCT#04102189). After a 12-week lifestyle run-in period (including dietary recommendations and physical activity counseling), patients were randomized 2:1 to WEGOVY injection once weekly or placebo once weekly. WEGOVY injection or matching placebo was escalated to 2.4 mg or maximally tolerated dose during a 16-week period followed by 52 weeks on maintenance dose. Of WEGOVY injection-treated patients who completed the trial, 86.7% were on the 2.4 mg dosage at the end of the trial; for 5% of patients, 1.7 mg was the maximum tolerated dosage. The mean age was 15 years; 38% of patients were male; 79% were White, 8% were Black or African American, 2% were Asian, and 11% were of other or unknown race; and 11% were of Hispanic or Latino ethnicity. The mean baseline body weight was 108 kg, and mean BMI was 37 kg/m² . Results The proportions of patients who discontinued study drug were 10% for the WEGOVY injection-treated group and 10% for the placebo-treated group. The primary endpoint was percent change in BMI from baseline to Week 68. After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in percent BMI compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved ≥5% reduction in baseline BMI than those treated with placebo as shown in Table 18 . Table 18. Changes in Weight and BMI at Week 68 in Pediatric Patients with Obesity Aged 12 Years and Older in Study 10 with WEGOVY 2.4 mg Injection in Study 10 Table 18. Changes in Weight and BMI at Week 68 in Pediatric Patients with Obesity Aged 12 Years and Older in Study 10 with WEGOVY 2.4 mg Injection in Study 10 Intention-to-Treat PLACEBO N=67 WEGOVY 2.4 mg Injection N=134 BMI Baseline mean (kg/m² ) 35.7 37.7 % change from baseline in BMI (LSMean) 0.6 -16.1 % difference from placebo (LSMean) (95% CI) -16.7 (-20.3; -13.2)* % of Patients with greater than or equal to 5% reduction in baseline BMI 19.7 77.1 % difference from placebo (LSMean) 57.4 % of Patients with greater than or equal to 10% reduction in baseline BMI 7.7 65.1 % difference from placebo (LSMean) 57.5 % of Patients with greater than or equal to 15% reduction in baseline BMI 4 57.8 % difference from placebo (LSMean) 53.9 Body Weight Baseline mean (kg) 102.6 109.9 % change from baseline (LSMean) 2.7 -14.7 % difference from placebo (LSMean) -17.4 LSMean = least squares mean; CI = confidence interval a The intention-to-treat population includes all randomized patients. Missing data were imputed using available data according to value and timing of last available observation on treatment and endpoint’s baseline value from retrieved subjects (RD-MI). At Week 68, the BMI was missing for 2.2% and 7.5% of patients randomized to WEGOVY injection and placebo, respectively. b Parameters not included in the pre-specified hierarchical testing. * p<0.0001 (unadjusted 2-sided) for superiority. The time course of change in BMI with WEGOVY injection and placebo from baseline through Week 68 is depicted in Figure 11 . The cumulative frequency distribution of change in BMI is shown in Figure 12 . Figure 11. Change from Baseline (%) in BMI in Pediatric Patients with Obesity Aged 12 Years and Older in Study 10 with WEGOVY Injection Observed values for patients completing each scheduled visit, and estimates with multiple imputations from retrieved dropouts (RD-MI). Figure 12. Change in BMI (%) from Baseline to Week 68 in Pediatric Patients with Obesity Aged 12 Years and Older in Study 10 with WEGOVY Injection Observed data from in-trial period including imputed data for missing observations (RD-MI). Effect of WEGOVY Injection on Anthropometry and Cardiometabolic Parameters in Pediatric Patients with Obesity Aged 12 Years and Older Changes in waist circumference and cardiometabolic parameters with WEGOVY injection are shown in Table 19 for the study in pediatric patients aged 12 years and older. Table 19. Mean Changes in Anthropometry and Cardiometabolic Parameters in Pediatric Patients with Obesity Aged 12 Years and Older in Study 10 with WEGOVY Injection Table 19. Mean Changes in Anthropometry and Cardiometabolic Parameters in Pediatric Patients with Obesity Aged 12 Years and Older in Study 10 with WEGOVY Injection PLACEBO N=67 PLACEBO N=67 WEGOVY Injection N=134 WEGOVY Injection N=134 Baseline Change from Baseline (LSMean) Baseline Change from Baseline (LSMean) Difference from placebo (LSMean) Waist Circumference (cm) 107.3 -0.6 111.9 -12.7 -12.1 Systolic Blood Pressure (mmHg) 120 -0.8 120 -2.7 -1.9 Diastolic Blood Pressure (mmHg) 73 -0.8 73 -1.4 -0.6 Heart Rate 76 -2.3 79 1.2 3.5 HbA 1c (%) 5.4 -0.1 5.5 -0.4 -0.2 Baseline % Change from Baseline (LSMean) Baseline % Change from Baseline (LSMean) Relative difference from placebo (LSMean) Total Cholesterol (mg/dL) 160.1 -1.3 159.4 -8.3 -7.1 LDL Cholesterol (mg/dL) 91.7 -3.6 89.8 -9.9 -6.6 HDL Cholesterol (mg/dL) 43.3 3.2 43.7 8 4.7 Triglycerides (mg/dL) 108 2.6 111.3 -28.4 -30.2 1 Parameters listed in the table were not included in the pre-specified hierarchical testing. 2 Missing data were imputed using available data according to value and timing of last available observation on treatment and endpoint’s baseline value from retrieved subjects (RD-MI). Model based estimates based on an analysis of covariance model including treatment and stratification groups (gender, Tanner stage group) and the interaction between stratification groups as factors and baseline value as a covariate. 3 Model based estimates based on a mixed model for repeated measures including treatment as a factor and baseline value as a covariate all nested within visit. 4 For patients without type 2 diabetes at randomization (N=129 for WEGOVY injection-treated patients and N=64 for placebo-treated patients). 5 Baseline value is the geometric mean. 14.4 Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis with Moderate to Advanced Liver Fibrosis in Adults Treated with WEGOVY Injection Overview of Clinical Trial The efficacy of WEGOVY injection was evaluated based on an efficacy analysis at Week 72 in Study 11 (NCT#04822181), a 240-week, randomized, double-blind, placebo-controlled trial. Enrolled patients had a baseline or recent liver biopsy showing clinically significant MASLD (metabolic dysfunction-associated steatotic liver disease), defined as MASH with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) ≥4 with a score of 1 or more in steatosis, lobular inflammation, and hepatocyte ballooning. Efficacy determination was based on the effect of WEGOVY injection on resolution of steatohepatitis without worsening of liver fibrosis and on at least one stage improvement in liver fibrosis without worsening of steatohepatitis, on post-baseline liver biopsies collected at 72 weeks. The Week 72 analysis included 800 F2 and F3 (at eligibility) patients randomized 1:2 to receive placebo (n=266) or WEGOVY once weekly (n=534), in addition to standard of care for cardiometabolic comorbidities and healthy lifestyle counseling. WEGOVY injection or matching placebo was escalated to 2.4 mg once weekly during the initial 16 weeks of the treatment period. Dose escalation could be prolonged or patients could remain at a lower dose if 2.4 mg once weekly was not tolerable. Demographic and baseline characteristics were balanced between treatment and placebo groups. Overall, the median (Q1 to Q3) age of patients at baseline was 57 (49 to 65) years, 57% were female, 18% were Hispanic, 68% were White, 27% were Asian, and 0.6% were Black or African American. Median (Q1 to Q3) body mass index (BMI) was 34 (30 to 38) kg/m² and median (Q1 to Q3) body weight was 93 (79 to 110) kg. Baseline characteristics are presented in Table 20 . Table 20. Baseline Characteristics in Adults Patients with Noncirrhotic MASH with Stage 2 to Stage 3 Fibrosis in Study 11 Table 20. Baseline Characteristics in Adults Patients with Noncirrhotic MASH with Stage 2 to Stage 3 Fibrosis in Study 11 Characteristic Overall (N=800) Fibrosis stage, n (%) F2 F3 250 (31) 550 (69) Body Mass Index (BMI, kg/m² ), n (%) <25 25-30 30-35 ≥35 53 (7) 164 (21) 252 (32) 330 (41) Lean MASH, n (%) 22 (3) Type 2 Diabetes, n (%) 447 (56) Hypertension, n (%) 503 (63) Dyslipidemia, n (%) 198 (25) Statin use, n (%) 300 (38) Fibrosis Index Based on 4 Factors (FIB-4), Median (Q1, Q3) 1.6 (1.1, 2.3) Enhanced Liver Fibrosis (ELF), Median (Q1, Q3) 9.9 (9.3, 10.5) a Less than 5% missingness in the variable is omitted. b Lean MASH defined as BMI <25 kg/m² for non-Asian patients and BMI <23 kg/m² for Asian patients. Among the 79% of the patients with vibration-controlled transient elastography (VCTE) at baseline, median (Q1 to Q3) VCTE was 10.9 (8.6 to 15.5) kPa, which may not be representative of the entire study population. The 21% of patients with missing VCTE at baseline had higher percentages of being female and having baseline diabetes, hypertension, and dyslipidemia. Results Table 21 presents the Week 72 histopathology primary endpoint results comparing WEGOVY injection with placebo on: 1) the estimated percentage of patients with resolution of steatohepatitis and no worsening of liver fibrosis and 2) the estimated percentage of patients with at least one stage improvement in liver fibrosis and no worsening of steatohepatitis. The secondary endpoint results of the estimated percentage of patients with resolution of steatohepatitis and improvement in liver fibrosis at Week 72 are also presented. Two pathologists independently read the liver biopsies for each patient; a third pathologist performed adjudication if consensus could not be reached between the two pathologists. WEGOVY injection demonstrated improvement on these histopathology endpoints at Week 72 compared to placebo. Table 21. Efficacy Results at Week 72 in Adult Patients with Noncirrhotic MASH with Stage 2 or Stage 3 Fibrosis in Study 11 of WEGOVY Injection PLACEBO N=266 WEGOVY Injection N=534 Resolution of steatohepatitis and no worsening of liver fibrosis Resolution of steatohepatitis and no worsening of liver fibrosis Resolution of steatohepatitis and no worsening of liver fibrosis Response Rate (%) 34 63 Difference in response rate vs. placebo (95% CI) 29 (21, 36) Improvement in liver fibrosis and no worsening of steatohepatitis Improvement in liver fibrosis and no worsening of steatohepatitis Improvement in liver fibrosis and no worsening of steatohepatitis Response Rate (%) 22 37 Difference in response rate vs. placebo (95% CI) 14 (8, 21) Resolution of steatohepatitis and improvement in liver fibrosis Resolution of steatohepatitis and improvement in liver fibrosis Resolution of steatohepatitis and improvement in liver fibrosis Response Rate (%) 16 33 Difference in response rate vs. placebo (95% CI) 17 (10, 23) * Results were statistically significant. Endpoints were evaluated according to the MASH Clinical Research Network (CRN). Resolution of steatohepatitis is defined as a score of 0 to 1 for lobular inflammation, 0 for ballooning, and any value for steatosis. No worsening of steatohepatitis is defined as no increase from baseline in score for ballooning, lobular inflammation, or steatosis. Estimated using pooled Mantel-Haenszel (MH) estimates stratified by baseline type 2 diabetes status (presence or absence) and baseline fibrosis stage (F2 or F3) with missing data handled by reference-based multiple imputation and 95% confidence intervals (CIs) calculated using Rubin’s rule to pool Sato’s estimate of standard errors across the imputed datasets. Another secondary endpoint was the percent change in body weight from baseline to Week 72. Patients treated with WEGOVY injection (mean baseline body weight 95.4 kg) achieved an average of 10.5% weight loss from baseline at Week 72, and patients treated with placebo (mean baseline weight 97.6 kg) achieved an average of 2% weight loss from baseline at Week 72; treatment with WEGOVY injection resulted in an average of 8.5% greater weight loss from baseline compared to placebo (95% CI: 7.4% to 9.5%). Starting at Week 12 and through Week 72, there was a trend of greater reductions from baseline in average ALT and AST in the WEGOVY injection group as compared to the placebo group.

Other label records (4)

These may cover different packages or labelers. Older excerpts without full document identity are source links only.

  • Ozempic (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 30, 2026

  • WEGOVY (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Apr 23, 2024

  • Ozempic (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Nov 22, 2023

  • OZEMPIC (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Nov 17, 2023

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

7% (nejm.org/doi/full/10.1056/NEJMoa2032183) (7.0% vs 3.1% placebo · STEP 1 (2.4 mg, 68 wks, obesity))

Reported as 7.0% vs 3.1% placebo. The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

44.2% (nejm.org/doi/full/10.1056/NEJMoa2032183) (Nausea in the drug arm · STEP 1 (2.4 mg, 68 wks, obesity))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

Nausea (44%), diarrhea (32%), vomiting (25%), and constipation (23%) were the most common events, mostly mild-to-moderate and transient during dose escalation.

From STEP 1 (2.4 mg, 68 wks, obesity). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (nejm.org).

Safety signals

Beyond the US label

Regulators' safety notices beside the US label, each cited and dated. Where it matters, each says whether the label itself mentions it yet.

Before surgery: risk of pulmonary aspiration

In November 2024 the FDA added a class-wide warning to every GLP-1 label. Because these drugs slow stomach emptying, food can remain in the stomach before a procedure and be inhaled into the lungs (aspiration) during general anesthesia or deep sedation, even after normal fasting. Tell your care team you take a GLP-1 well before any planned surgery or sedation.

FDA (class-wide label update) (secure.medicalletter.org) · as of Nov 5, 2024

Eyes: rare risk of sudden vision loss (NAION)

In 2025 the EMA concluded that NAION (non-arteritic anterior ischemic optic neuropathy, a rare cause of sudden, usually painless vision loss in one eye) is a 'very rare' side effect of semaglutide (up to about 1 in 10,000 people), and the WHO issued a global alert. In February 2026 the UK's MHRA advised that semaglutide may be very rarely associated with NAION, citing a European review that found an approximately two-fold increase in relative risk in people with type 2 diabetes. In the US, the FDA's November 2026 requirement that every GLP-1 label warn of NAION, semaglutide's included, is listed separately. Seek prompt care for any sudden change in vision. None of the current US labels of Wegovy, Rybelsus/Ozempic tablets and Ozempic mentions NAION; every new revision is searched in full within a day of its publication.

MHRA / EMA (PRAC) / WHO (assets.publishing.service.gov.uk) · as of Feb 5, 2026

Eyes: FDA requires a warning about sudden vision loss (NAION)

On November 9, 2026 the FDA said it is "requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION" (non-arteritic anterior ischemic optic neuropathy), which it describes as "a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss." Its analysis of 126 randomized trials found 6.4 NAION cases per 100,000 person-years on a GLP-1, against 3.8 on placebo or another glucose-lowering medicine. Its list names every GLP-1 sold in the US, from Ozempic, Wegovy, Mounjaro and Zepbound to Foundayo. FDA's advice: "Patients should contact their health care professional right away if they have any of these symptoms." None of the current US labels of Byetta, Wegovy, Rybelsus/Ozempic tablets, Trulicity, Saxenda, Victoza, Mounjaro, Zepbound, Ozempic and Foundayo mentions NAION; every new revision is searched in full within a day of its publication.

FDA Drug Safety Communication, November 9, 2026 (fda.gov) · as of Nov 9, 2026

Mood: the FDA found no increased risk of suicidal thoughts

In January 2026 the FDA asked the makers of Wegovy, Saxenda and Zepbound to remove the warning about suicidal behavior and ideation from their labels, after a review of 91 placebo-controlled trials (107,910 patients) and a study of more than 2 million people's insurance claims found no increased risk. Wegovy's label shows the warning removed in February 2026. The FDA still advises telling your health care professional about new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.

FDA Drug Safety Communication (fda.gov) · as of Jan 13, 2026

Around the world

Semaglutide international price references

Published price snapshots, grouped by brand and country. Reporting years, doses, and price definitions differ, so these records cannot establish today’s price gap.

  • Australia · Ozempic~$87/mo (2023 list price) (healthsystemtracker.org) (PBS-subsidised patients pay far less out of pocket.)
  • Canada · Ozempic~C$258/mo (~$186); generic from ~C$89 (teletest.ca) (Brand cash price at major chains; generic semaglutide now from ~C$89.)
  • France · Ozempic~$83/mo (2023 list price) (healthsystemtracker.org) (Historical published price, not a current pharmacy quote.)
  • Germany · Ozempic~$103/mo (2023 list price) (healthsystemtracker.org) (~$103/mo (2023 list price))
  • Japan · Ozempic$169/mo (2023 list price) (healthsystemtracker.org) ($169/mo (2023 list price))
  • Sweden · Ozempic~$96/mo (2023 list price) (healthsystemtracker.org) (~$96/mo (2023 list price))
  • Switzerland · Ozempic~$144/mo (2023 list price) (healthsystemtracker.org) (~$144/mo (2023 list price))
  • United Kingdom · Ozempic~$93/mo (2023 list price) (healthsystemtracker.org) (Historical published price, not a current pharmacy quote.)
  • United States · Ozempic~$1,028/mo (therxindex.com) (Reported US WAC list price (28-day). Novo will cut it to $675 on Jan 1, 2027.)
  • Germany · Wegovy$328/mo (2023 list price) (healthsystemtracker.org) ($328/mo (2023 list price))
  • India · Wegovy₹5,660-16,400/mo by dose (~$60-173), Nov 2026 (pharmeasy.in) (Maximum retail price per pen (a month of weekly doses), 0.25 mg to 2.4 mg, after Novo Nordisk's November 2025 and April 2026 price cuts; selling prices can be lower. Generic semaglutide has been sold in India since the patent expired in March 2026.)
  • Netherlands · Wegovy$296/mo (2023 list price) (healthsystemtracker.org) ($296/mo (2023 list price))
  • United Kingdom · Wegovy£89.99-186/mo private by dose (~$121-251), Nov 2026 (medino.com) (Lowest private-pharmacy price per pen at each dose, 0.25 mg to 2.4 mg, across 25 UK providers checked Nov 2, 2026; NHS patients pay only the prescription charge where eligible.)
  • United States · Wegovy$1,349/mo (therxindex.com) (US WAC list price at maintenance dose. Novo will cut it to $675 on Jan 1, 2027 (a ~50% reduction).)

References include manufacturer list prices and reported pharmacy prices, not a single comparable measure of patient cost. Each amount links to its original record, or names the shop it was read at. Confirm current local pricing and coverage with a licensed pharmacy.

Studied together

Direct trial comparisons

Read the results for the exact products, doses, and participants studied.

Evidence

Clinical trials

806 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • Primary outcome: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

    Count of participants · Participants · From randomisation (week 0) up to 240 weeks

    Analysis population: FAS included all randomised participants. All participants were analyzed according to the treatment to which they were assigned at randomisation.

    Semaglutide
    569 Participants (clinicaltrials.gov/study/NCT03574597)

    Overall outcome: 8803 Participants (clinicaltrials.gov/study/NCT03574597) analyzed

    Placebo
    701 Participants (clinicaltrials.gov/study/NCT03574597)

    Overall outcome: 8801 Participants (clinicaltrials.gov/study/NCT03574597) analyzed

    Outcome definition & treatment groups

    Number of participants with first occurrence of composite outcome measure consisted of CV death (undetermined cause of death presumed CV death), non-fatal MI, or non-fatal stroke are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Semaglutide: Participants received semaglutide subcutaneously once weekly in a fixed-dose escalation manner, with dose increases every 4 weeks for up to week 16 (0.25 mg, 0.5 mg, 1.0 mg and 1.7 mg) followed by maintenance dose of 2.4 mg once weekly up to the end of treatment period.

    Placebo: Participants received placebo (matched to semaglutide) subcutaneously once weekly up to the end of treatment period.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Has results
    Primary outcome: Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke

    Count of participants · Participants · From randomisation (week 0) up to week 265

    Analysis population: FAS included all unique randomized participants who were grouped according to the treatment assigned at randomization.

    Oral Semaglutide
    579 Participants (clinicaltrials.gov/study/NCT03914326)

    Overall outcome: 4825 Participants (clinicaltrials.gov/study/NCT03914326) analyzed

    Placebo
    668 Participants (clinicaltrials.gov/study/NCT03914326)

    Overall outcome: 4825 Participants (clinicaltrials.gov/study/NCT03914326) analyzed

    Outcome definition & treatment groups

    Number of participants with first occurrence of EAC (event adjudication committee) confirmed major adverse cardiovascular event (MACE), a composite end-point. i.e., from time of randomization to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction and non-fatal stroke combined data during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.

    Oral Semaglutide: Participants were to receive once daily semaglutide tablets with a dose escalation every 4 weeks in doses 3 mg (week 0 to week 4), 7 mg (week 4 to week 8) until maintenance dose of 14 mg was reached and maintained till the end of treatment visit (up to week 260).

    Placebo: Participants were to receive once daily placebo matching oral semaglutide until end of the treatment visit (up to week 260).

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death

    Count of participants · Participants · From Week 0 up to Week 234

    Analysis population: FAS included all unique randomized participants who were grouped according to the treatment assigned at randomization.

    Semaglutide
    331 Participants (clinicaltrials.gov/study/NCT03819153)

    Overall outcome: 1767 Participants (clinicaltrials.gov/study/NCT03819153) analyzed

    Placebo
    410 Participants (clinicaltrials.gov/study/NCT03819153)

    Overall outcome: 1766 Participants (clinicaltrials.gov/study/NCT03819153) analyzed

    Outcome definition & treatment groups

    Number of participants with first composite renal event i.e., from time of randomization to first occurrence of an onset of persistent greater than or equal to (≥) 50 percent (%) reduction in estimated glomerular filtration rate (eGFR) (chronic kidney disease - epidemiology collaboration \[CKD-EPI\]), onset of persistent eGFR (CKD-EPI) \<15 milliliter per minute per 1.73 meter square (mL/min/1.73m\^2), initiation of chronic renal replacement therapy (dialysis or kidney transplantation), renal death, and cardiovascular (CV) death combined data were reported in this outcome measure.

    Semaglutide: Participants received a dose of semaglutide subcutaneously once weekly with dose escalation in every 4 weeks in doses 0.25 mg (weeks 0-3), 0.50 mg (weeks 4-7) until the maintenance dose of 1 mg was reached at week 8 and continued 1 mg dose along with standard of care until end of the study (week 238). Participants were followed up for 5 weeks after end of treatment.

    Placebo: Participants received placebo matching semaglutide subcutaneously once weekly along with standard of care until end of the study (week 238). Participants were followed up for 5 weeks after end of treatment.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke

    Number · percentage of subjects · Time from randomisation up to end of follow-up (scheduled at week 109)

    Analysis population: Full analysis set included all the randomised subjects. As specified in the protocol, the two semaglutide dose arms (semaglutide 0.5 mg + semaglutide 1.0 mg) and the two placebo dose arms (placebo 0.5 mg + placebo 1.0 mg) were pooled for the analysis of this endpoint.

    Semaglutide
    6.6 percentage of subjects (clinicaltrials.gov/study/NCT01720446)

    Overall outcome: 1648 Participants (clinicaltrials.gov/study/NCT01720446) analyzed

    Placebo
    8.9 percentage of subjects (clinicaltrials.gov/study/NCT01720446)

    Overall outcome: 1649 Participants (clinicaltrials.gov/study/NCT01720446) analyzed

    Outcome definition & treatment groups

    Percentage of subjects experiencing a first event of a major adverse cardiovascular event (MACE), defined as cardiovascular (CV) death, non-fatal myocardial infarction (MI), or non-fatal stroke.

    Semaglutide: Subjects received once-weekly dose of semaglutide 0.5 mg or 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment and the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

    Placebo: Subjects received once-weekly dose of placebo 0.5 mg or 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Placebo was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment and the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke

    Count of participants · Participants · Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.

    Analysis population: Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants.

    Oral Semaglutide
    61 Participants (clinicaltrials.gov/study/NCT02692716)

    Overall outcome: 1591 Participants (clinicaltrials.gov/study/NCT02692716) analyzed

    Placebo
    76 Participants (clinicaltrials.gov/study/NCT02692716)

    Overall outcome: 1592 Participants (clinicaltrials.gov/study/NCT02692716) analyzed

    Outcome definition & treatment groups

    Number of participants experiencing a first event of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.

    Oral Semaglutide: Participants were to take once-daily semaglutide tablets in a dose escalation manner for upto 82 weeks: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 9 to upto week 82.

    Placebo: Participants were to take oral semaglutide placebo tablets once-daily for a period of upto 82 weeks.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Glycated Haemoglobin (HbA1c)

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Change From Baseline in Glycated Haemoglobin (HbA1c)

    Mean · Percentage of HbA1c · Baseline (week 0), week 52

    Analysis population: Full analysis set included all randomized participants. Overall Number of Participants Analyzed = participants with available data for this outcome measure.

    Semaglutide
    -1.5 Percentage of HbA1c (clinicaltrials.gov/study/NCT03689374)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    Overall outcome: 795 Participants (clinicaltrials.gov/study/NCT03689374) analyzed

    Insulin Aspart
    -1.2 Percentage of HbA1c (clinicaltrials.gov/study/NCT03689374)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    Overall outcome: 783 Participants (clinicaltrials.gov/study/NCT03689374) analyzed

    Outcome definition & treatment groups

    Change from baseline in HbA1c at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).

    Semaglutide: Participants received metformin, IGlar U100 and semaglutide for 52 weeks in treatment period. Metformin dose was maintained at same level and frequency as optimized in run-in period unless safety concern related to background medication arose; IGlar U100 dose was adjusted in run-in period, increases in IGlar U100 dose was based on mean of 3 prebreakfast self-measured plasma glucose (SMPG) values obtained on day of visit/telephone contact and 2 days before contact and dose reduction of IGlar U100 was considered in accordance with approved local label to reduce risk of hypoglycaemia. Participants self-administered s.c. injection of semaglutide at an initiation dose of 0.25 mg once weekly, after 4 weeks dose was increased to 0.5 mg, and 1 mg after at least 4 weeks to further improve glycaemic control, at investigator's discretion. Dose reduction from 1 to 0.5 mg was allowed in case of safety concern/unacceptable intolerability. Participants were followed up for 5 weeks (week 57) for safety.

    Insulin Aspart: Participants received metformin, IGlar U100 and insulin aspart for 52 weeks in treatment period. Metformin dose was maintained at same level and frequency as optimized in run-in period unless safety concern related to background medication arose; IGlar U100 dose was adjusted in run-in period, increases in IGlar U100 dose was based on mean of 3 prebreakfast SMPG values obtained on day of visit/telephone contact and 2 days before contact and dose reduction of IGlar U100 was considered in accordance with approved local label to reduce risk of hypoglycaemia. Participants self-administered s.c. injection of insulin aspart at an initiation dose of 4 units three times daily, dose adjustments were considered twice weekly based on pre-prandial and bedtime SMPG from the preceding 3 days and the individualized goal according to investigator's discretion. Participants were followed up for 5 weeks (week 57) for safety.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in Body Weight (%)

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Change in Body Weight (%)

    Mean · Percentage point · Baseline (week 0) to week 68

    Analysis population: Overall number of participants analyzed = full analysis set (FAS) which comprised all randomized participants. Number Analyzed = number of participants with available data.

    In-trial observation period

    Semaglutide 2.4 mg
    -15.6 Percentage point (clinicaltrials.gov/study/NCT03548935)

    Standard Deviation: 10.1 (clinicaltrials.gov)

    This analysis: 1212 Participants (clinicaltrials.gov/study/NCT03548935) analyzed

    Placebo
    -2.8 Percentage point (clinicaltrials.gov/study/NCT03548935)

    Standard Deviation: 6.5 (clinicaltrials.gov)

    This analysis: 577 Participants (clinicaltrials.gov/study/NCT03548935) analyzed

    On-treatment observation period

    Semaglutide 2.4 mg
    -16.9 Percentage point (clinicaltrials.gov/study/NCT03548935)

    Standard Deviation: 9.4 (clinicaltrials.gov)

    This analysis: 1059 Participants (clinicaltrials.gov/study/NCT03548935) analyzed

    Placebo
    -3.1 Percentage point (clinicaltrials.gov/study/NCT03548935)

    Standard Deviation: 6.4 (clinicaltrials.gov)

    This analysis: 499 Participants (clinicaltrials.gov/study/NCT03548935) analyzed

    Outcome definition & treatment groups

    Change in body weight from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period: the uninterrupted time interval from date of randomization (week 0) to date of last contact with trial site (week 75). On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).

    Semaglutide 2.4 mg: Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg Semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing Semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg Semaglutide once weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced-calorie diet and increased physical activity.

    Placebo: Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg Semaglutide placebo administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing Semaglutide placebo 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg Semaglutide placebo after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced-calorie diet and increased physical activity.

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Least-squares mean · Percentage of HbA1c · Baseline, Week 40

    Analysis population: All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline HbA1c value, excluding patients who discontinued study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.

    10 mg Tirzepatide
    -2.37 Percentage of HbA1c (clinicaltrials.gov/study/NCT03987919)

    Standard Error: 0.048 (clinicaltrials.gov)

    Overall outcome: 459 Participants (clinicaltrials.gov/study/NCT03987919) analyzed

    15 mg Tirzepatide
    -2.46 Percentage of HbA1c (clinicaltrials.gov/study/NCT03987919)

    Standard Error: 0.048 (clinicaltrials.gov)

    Overall outcome: 464 Participants (clinicaltrials.gov/study/NCT03987919) analyzed

    1 mg Semaglutide
    -1.86 Percentage of HbA1c (clinicaltrials.gov/study/NCT03987919)

    Standard Error: 0.048 (clinicaltrials.gov)

    Overall outcome: 461 Participants (clinicaltrials.gov/study/NCT03987919) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

    10 mg Tirzepatide: 10 mg tirzepatide administered SC once a week.

    15 mg Tirzepatide: 15 mg tirzepatide administered SC once a week.

    1 mg Semaglutide: 1 mg semaglutide administered SC once a week.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in HbA1c: Week 26

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Change in HbA1c: Week 26

    Mean · Percentage of HbA1c · Week 0, week 26

    Analysis population: Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.

    In-trial

    Oral Semaglutide 3 mg
    -0.6 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 435 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    Oral Semaglutide 7 mg
    -1.1 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 1.1 (clinicaltrials.gov)

    This analysis: 438 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    Oral Semaglutide 14 mg
    -1.3 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 436 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    Sitagliptin 100 mg
    -0.8 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 0.9 (clinicaltrials.gov)

    This analysis: 446 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    On-treatment without rescue medication

    Oral Semaglutide 3 mg
    -0.6 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 391 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    Oral Semaglutide 7 mg
    -1.2 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 1.1 (clinicaltrials.gov)

    This analysis: 409 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    Oral Semaglutide 14 mg
    -1.4 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 398 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    Sitagliptin 100 mg
    -0.8 Percentage of HbA1c (clinicaltrials.gov/study/NCT02607865)

    Standard Deviation: 0.9 (clinicaltrials.gov)

    This analysis: 419 Participants (clinicaltrials.gov/study/NCT02607865) analyzed

    Outcome definition & treatment groups

    Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 26. The endpoint was evaluated based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.

    Oral Semaglutide 3 mg: Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.

    Oral Semaglutide 7 mg: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.

    Oral Semaglutide 14 mg: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.

    Sitagliptin 100 mg: Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]

    Selected primary outcome

    Results · Nov 14, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]

    Least-squares mean · Percentage of HbA1c · Baseline, Week 52

    Analysis population: All randomised participants who had evaluable data for this outcome. Data points obtained during the treatment period, defined as at or after baseline and up to the earliest date of discontinuation of study drug or initiation of additional antihyperglycemic medications (\>14 days of use).

    12 mg Orforglipron
    -1.91 Percentage of HbA1c (clinicaltrials.gov/study/NCT06045221)

    Standard Error: 0.058 (clinicaltrials.gov)

    Overall outcome: 326 Participants (clinicaltrials.gov/study/NCT06045221) analyzed

    36 mg Orforglipron
    -2.16 Percentage of HbA1c (clinicaltrials.gov/study/NCT06045221)

    Standard Error: 0.051 (clinicaltrials.gov)

    Overall outcome: 322 Participants (clinicaltrials.gov/study/NCT06045221) analyzed

    7 mg Semaglutide
    -1.11 Percentage of HbA1c (clinicaltrials.gov/study/NCT06045221)

    Standard Error: 0.063 (clinicaltrials.gov)

    Overall outcome: 325 Participants (clinicaltrials.gov/study/NCT06045221) analyzed

    14 mg Semaglutide
    -1.45 Percentage of HbA1c (clinicaltrials.gov/study/NCT06045221)

    Standard Error: 0.061 (clinicaltrials.gov)

    Overall outcome: 351 Participants (clinicaltrials.gov/study/NCT06045221) analyzed

    Outcome definition & treatment groups

    * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).

    12 mg Orforglipron: Participants initiated treatment with a 1 mg once-daily oral dose of orforglipron and increased the dose every 4 weeks until the targeted dose of 12 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    36 mg Orforglipron: Participants initiated treatment with a 1 mg once-daily oral dose of orforglipron and increased the dose every 4 weeks until the targeted dose of 36 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    7 mg Semaglutide: Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 7 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    14 mg Semaglutide: Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 14 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)

    Selected primary outcome

    Results · Oct 19, 2026 UTC

    Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)

    Mean · Percentage point of HbA1c · Baseline (week 0), week 52

    Analysis population: Full Analysis Set (FAS) which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure.

    Oral Semaglutide 14 mg
    -1.5 Percentage point of HbA1c (clinicaltrials.gov/study/NCT04707469)

    Standard Deviation: 1.3 (clinicaltrials.gov)

    Overall outcome: 497 Participants (clinicaltrials.gov/study/NCT04707469) analyzed

    Oral Semaglutide 25 mg
    -1.9 Percentage point of HbA1c (clinicaltrials.gov/study/NCT04707469)

    Standard Deviation: 1.3 (clinicaltrials.gov)

    Overall outcome: 475 Participants (clinicaltrials.gov/study/NCT04707469) analyzed

    Oral Semaglutide 50 mg
    -2.1 Percentage point of HbA1c (clinicaltrials.gov/study/NCT04707469)

    Standard Deviation: 1.4 (clinicaltrials.gov)

    Overall outcome: 492 Participants (clinicaltrials.gov/study/NCT04707469) analyzed

    Outcome definition & treatment groups

    Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.

    Oral Semaglutide 14 mg: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68.

    Oral Semaglutide 25 mg: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68.

    Oral Semaglutide 50 mg: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%)

    Selected primary outcome

    Results · Oct 23, 2026 UTC

    Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%)

    Mean · Percentage point of HbA1C · From baseline to week 26

    Analysis population: Full analysis set (FAS) included all randomized participants. Overall Number of Participants Analyzed: participants with available data for this outcome measure and Number Analyzed: number of participants with available data for each specified category.

    On-treatment observation period

    Oral Semaglutide 3 mg
    -0.8 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 321 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    Oral Semaglutide 7 mg
    -1.3 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 315 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    Oral Semaglutide 14 mg
    -1.6 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 298 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    Sitagliptin 100 mg
    -0.7 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 334 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    In-trial observation period

    Oral Semaglutide 3 mg
    -0.8 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 344 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    Oral Semaglutide 7 mg
    -1.3 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 340 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    Oral Semaglutide 14 mg
    -1.5 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 332 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    Sitagliptin 100 mg
    -0.7 Percentage point of HbA1C (clinicaltrials.gov/study/NCT04017832)

    Standard Deviation: 1.0 (clinicaltrials.gov)

    This analysis: 350 Participants (clinicaltrials.gov/study/NCT04017832) analyzed

    Outcome definition & treatment groups

    Change in HbA1c from baseline to week 26 in percentage (%) point of HbA1c is presented. The outcome data was evaluated based on the on-treatment without rescue medication observation period and in-trial observation period. On-treatment without rescue medication observation period: from date of first dose of trial product following randomization and the end date which was the first date of any of the following: the last dose of trial product plus 3 days or initiation of rescue medication. In-trial observation period: the time period where participants were considered to be in the trial, regardless of discontinuation of trial product or initiation of rescue medication.

    Oral Semaglutide 3 mg: Participants received semaglutide 3 mg tablet and placebo tablet matched to sitagliptin orally once daily for 26 weeks.

    Oral Semaglutide 7 mg: Participants received oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 0 to week 4 and 7 mg from week 5 to week 26. Participants also received placebo matched to sitagliptin 100 mg for 26 weeks.

    Oral Semaglutide 14 mg: Participants received oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 1 to week 4, 7 mg from week 5 to week 8 and 14 mg from week 9 to week 26. Participants also received placebo matched to sitagliptin 100 mg for 26 weeks.

    Sitagliptin 100 mg: Participants received oral sitagliptin 100 mg tablet and placebo tablet matched to oral semaglutide orally once daily for 26 weeks.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
FDA enforcement archive

Recall records

Enforcement records describe specific recalled products and lots. They do not establish the recall status of every product containing the ingredient. openFDA does not maintain current recall status after classification; read the FDA record and any manufacturer notice for details.

57 indexed product records, ordered by FDA report date. One recall event may include several products.

D-0018-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0019-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

SEMAGLUTIDE/CYANOCOBALAMIN 3/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0026-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0747-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-495-05

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0748-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202 NDC 71170-811-02

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0749-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202 NDC 71170-821-01

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
More indexed recall records (51)

D-0750-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-812-03

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0751-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-822-02

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0752-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-810-01

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0753-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-711-02

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0754-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202.NDC 71170-712-03

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0755-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-721-01

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0756-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-722-02

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0757-2026

Class IIFDA report: Aug 19, 2026

Recalling firm: Apollo Care, LLC

SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-724-04.

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0471-2026

Class IIFDA report: Apr 22, 2026

Recalling firm: PAYLESS COMPOUNDERS, LLC

Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0379-2026

Class IIFDA report: Mar 11, 2026

Recalling firm: Harbin Jixianglong Biotech Co., Ltd.

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China

Reason for recall

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0380-2026

Class IIFDA report: Mar 11, 2026

Recalling firm: Harbin Jixianglong Biotech Co., Ltd.

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China.

Reason for recall

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0392-2026

Class IIFDA report: Mar 11, 2026

Recalling firm: New Life Pharma LLC

Semaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-07.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0393-2026

Class IIFDA report: Mar 11, 2026

Recalling firm: New Life Pharma LLC

Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0244-2026

Class IIFDA report: Jan 7, 2026

Recalling firm: Novo Nordisk Inc.

Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4505-14

Reason for recall

Presence of Particulate Matter: Hair was found in a prefilled syringe

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0245-2026

Class IIFDA report: Jan 7, 2026

Recalling firm: Novo Nordisk Inc.

Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4501-14

Reason for recall

Presence of Particulate Matter: Hair was found in a prefilled syringe

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0114-2026

Class IIFDA report: Nov 5, 2025

Recalling firm: ProRx LLC

Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0115-2026

Class IIFDA report: Nov 5, 2025

Recalling firm: ProRx LLC

Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-04

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0116-2026

Class IIFDA report: Nov 5, 2025

Recalling firm: ProRx LLC

Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0117-2026

Class IIFDA report: Nov 5, 2025

Recalling firm: ProRx LLC

Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0118-2026

Class IIFDA report: Nov 5, 2025

Recalling firm: ProRx LLC

Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-06

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0119-2026

Class IIFDA report: Nov 5, 2025

Recalling firm: ProRx LLC

Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0083-2026

Class IIFDA report: Oct 15, 2025

Recalling firm: GenoGenix LLC

Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0091-2026

Class IIFDA report: Oct 15, 2025

Recalling firm: GenoGenix LLC

Semaglutide for Injection, a) 20 mg b) 20 mg/mL, 10 mL Multi-Dose Vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Synergy Wellness, 20 mg, 10mL vial lyophilized.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0606-2025

Class IIFDA report: Sep 10, 2025

Recalling firm: Boothwyn Pharmacy LLC

Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy

Reason for recall

Subpotent Drug

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0608-2025

Class IIFDA report: Sep 10, 2025

Recalling firm: Boothwyn Pharmacy LLC

Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy

Reason for recall

Subpotent Drug

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0609-2025

Class IIFDA report: Sep 10, 2025

Recalling firm: Boothwyn Pharmacy LLC

Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy

Reason for recall

Subpotent Drug

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0553-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0561-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0562-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0563-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0564-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0565-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0479-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0480-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0481-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Semaglutide/Cyanocobalamin Injectable, 5mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0393-2025

Class IIFDA report: May 7, 2025

Recalling firm: Cardinal Health Inc.

Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14.

Reason for recall

Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0650-2024

Class IIFDA report: Sep 11, 2024

Recalling firm: ProRx LLC

Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0652-2024

Class IIFDA report: Sep 11, 2024

Recalling firm: ProRx LLC

SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0653-2024

Class IIFDA report: Sep 11, 2024

Recalling firm: ProRx LLC

SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0654-2024

Class IIFDA report: Sep 11, 2024

Recalling firm: ProRx LLC

Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-1105-2023

Class IIFDA report: Aug 30, 2023

Recalling firm: TMC Acquisitions LLC dba Tailor Made Compounding

Semaglutide/Cyanocobalamin 2mg/0.4mg/mL, 1mLvials, Tailor Made Compounding.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0538-2023

Class IIFDA report: Apr 26, 2023

Recalling firm: Pharmacy Plus, Inc. dba Vital Care Compounder

C-Semaglutide 5mg/mL injection, 0.5mL vials, Rx only, Vital Care Compounder 115 South 40th Ave, Suite A Hattiesburg, MS 39402

Reason for recall

Lack of assurance of sterility.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0236-2023

Class IIFDA report: Feb 1, 2023

Recalling firm: Pharmacy Innovations

SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 2MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 4MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 5.4MG/ML (0.5ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

Reason for recall

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0053-2023

Class IIFDA report: Nov 9, 2022

Recalling firm: Pharmacy Plus, Inc. dba Vital Care Compounder

SEMAGLUTIDE INJECTION 5MG/ML (0.25MG/0.05ML) SOLN, various amounts in unit dose vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402

Reason for recall

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-1519-2022

Class IIFDA report: Sep 21, 2022

Recalling firm: Carolina Infusion

Semaglutide/Cyanocobalamin 5/2 MG/ML Injectable, 0.2 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-1520-2022

Class IIFDA report: Sep 21, 2022

Recalling firm: Carolina Infusion

Semaglutide/Cyanocobalamin 10/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-1521-2022

Class IIFDA report: Sep 21, 2022

Recalling firm: Carolina Infusion

Semaglutide/Cyanocobalamin 24/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-1224-2022

Class IIFDA report: Jul 20, 2022

Recalling firm: TMC Acquisition LLC dba Tailor Made Compounding

Semaglutide/Cyanocobalamin 2mg/0.4mg/ml, 1mL-vial, Refrigerate, Tailor Made Compounding

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-1225-2022

Class IIFDA report: Jul 20, 2022

Recalling firm: TMC Acquisition LLC dba Tailor Made Compounding

Semaglutide/Cyanocobalamin 5mg/0.2mg/ml, 2ml-vial, Refrigerate, Tailor Made Compounding

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0536-2021

Class IIFDA report: Jun 2, 2021

Recalling firm: Cardinal Health Inc.

Rybelsus (semaglutide) Tablets 7 mg Once daily Each tablet contains 7 mg semaglutide 30 tablets 3 blister packs. Each pack contains 10 tablets. Rx only NDC 0169-4307-13 Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark

Reason for recall

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0617-2021

Class IIFDA report: Apr 21, 2021

Recalling firm: Novo Nordisk Inc

OZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, Sample. Not for Resale, Rx only, Novo Nordisk Inc, Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, NDC 0169-4132-90 (Pen), NDC 0169-4132-97 (Kit)

Reason for recall

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

Browse the FDA enforcement archive (accessdata.fda.gov) · Source coverage & limitations (open.fda.gov)

Compounded semaglutide is not an FDA-approved product and is not reviewed by the FDA for safety, effectiveness, or quality. The FDA declared the semaglutide shortage resolved in February 2025, which ended the exemption that let pharmacies make copies of the approved drug in bulk. FDA (fda.gov) (FDA: policies for compounders as the GLP-1 supply stabilizes) Compounded semaglutide prices from every seller we track.
Related

Related GLP-1s to compare

Updated automatically

What changed for Semaglutide

  • PricePrice no longer listed: semaglutide via primma wellness at primmawellness (was Product price not verified)
  • PriceNew price listed: TrumpRx, Ozempic pill via TrumpRx (pharmacy coupon), ~$149 per 30 tablets (read on trumprx.gov)
  • PriceNew price listed: TrumpRx, Wegovy pill via TrumpRx (pharmacy coupon), ~$149 per 30 tablets (read on trumprx.gov)
  • PriceNew price listed: SkinnyRx, Wegovy pill via SkinnyRx, from $248/mo (read on skinnyrx.com)
  • PriceNew price listed: Shed, Oral semaglutide liposomal tablets via Shed, from $299/mo (read on tryshed.com)
  • PriceNew price listed: Shed, Semaglutide lozenges via Shed, from $199/mo (read on tryshed.com)
  • PriceNew price listed: Shed, Semaglutide liquid drops via Shed, from $229/mo (read on tryshed.com)
  • PriceNew price listed: Nucific, Ozempic via Nucific, from $1,498/mo (read on nucific.com)

Written from each source's own record as it changes. Every change on GLPcompare

ClinicalTrials.gov

What Semaglutide is studied for

Registered trials of this medicine by condition. A trial shows a question being asked, not that the answer is yes.

From PubMed

Latest Semaglutide trials and reviews

  • Disordered Eating Attitudes and Behaviors in Individuals With BMI &gt; 27 kg/m&lt;sup&gt;2&lt;/sup&gt; Treated by Semaglutide: A 60-Week Randomized Placebo-Controlled Trial (pubmed.ncbi.nlm.nih.gov/43035836)

    Randomized trial · Int J Eat Disord · Nov 15, 2026 · Allison KC et al.

  • Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review (pubmed.ncbi.nlm.nih.gov/43034163)

    Systematic review · BMC Oral Health · Nov 14, 2026 · Muknickas D et al.

  • Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial (pubmed.ncbi.nlm.nih.gov/43033821)

    Randomized trial · Lancet Diabetes Endocrinol · Nov 14, 2026 · Wharton S et al.

  • First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43013292)

    Randomized trial · JAMA Cardiol · Nov 11, 2026 · Marx N et al.

  • Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial (pubmed.ncbi.nlm.nih.gov/43014326)

    Randomized trial · Lancet · Nov 11, 2026 · Mosenzon O et al.

  • Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial (pubmed.ncbi.nlm.nih.gov/43000472)

    Randomized trial · Nat Med · Nov 8, 2026 · Borlaug BA et al.

  • Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT-1 Randomized Controlled Trial (pubmed.ncbi.nlm.nih.gov/43000189)

    Randomized trial · Diabetes Obes Metab · Nov 8, 2026 · Morioka T et al.

  • The effect of subcutaneous semaglutide injection on blood pressure: a systematic review and meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/42987980)

    Meta-analysis · Diabetes Res Clin Pract · Nov 5, 2026 · Ahmadi N et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about Semaglutide

What is the brand name of semaglutide?
Semaglutide is sold in the US as Ozempic, Wegovy, Wegovy HD, and Rybelsus. A compounded version has no brand name and is not FDA-approved.
Is Semaglutide in shortage?
No shortage is listed in the latest complete FDA check. The FDA does list discontinuation notices for specific presentations. Last complete check: Nov 17, 2026. Confirm local stock with your pharmacy. Source (accessdata.fda.gov)
Is there a generic semaglutide?
Not yet. FDA tentatively approved a generic of Ozempic from Apotex on Apr 7, 2026, and FDA says a product with a tentative approval is not an approved drug product, so it cannot be sold. No. FDA has not approved a generic of Wegovy. No. FDA has not approved a generic of Rybelsus. Source
How much does Semaglutide cost per month?
Among the sourced FDA-approved offers in our catalog, a tracked starting quote is $149/30 days for Wegovy pill via Amazon Pharmacy via Amazon Pharmacy. $149 per 30 days at this quoted rate. without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 30-day supply The quote at the cited trial dose is $349/28 days for Wegovy pen via Amazon Pharmacy at 2.4 mg via Amazon Pharmacy. without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01) Amazon fills a prescription you already have and delivers in all 50 states. Its $199 for 0.25 mg "Includes $100.00 off with manufacturer coupon if eligible": Novo Nordisk's coupon, which its terms limit to a new patient's first two 28-day fills, filled by Dec 31, 2026. FDA-approved product. 28-day supply Starting and trial-dose quotes may cover different products. These are self-pay offers, not insurance estimates or a guarantee of eligibility. Source (pharmacy.amazon.com)
How much weight can you lose on Semaglutide?
In its pivotal trial (STEP 1), Semaglutide at 2.4 mg weekly (Wegovy) showed a mean body-weight change of -14.9% at 68 wks. This is a trial average; individual results vary. Source (nejm.org)
What is Semaglutide approved for?
Approved uses across Semaglutide products include type 2 diabetes, chronic weight management, cardiovascular risk reduction, chronic kidney disease in type 2 diabetes and mash with liver fibrosis. Indications differ by brand and formulation; this does not mean every product is approved for every use. See the product-specific prescribing information above.